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ABSTRACT
Proliferation of a human carcinoma cell line (RPMI-2650) was found 
to be density dependent in culture In a double-layer agar clonal 
assay, no growth was observed below a critical "cut-off" density 
unless autologous feeder cells were present Medium conditioned by 
RPMI-2650 cells could substitute for the physical presence of 
feeder cells, thus opening the way to biochemical analysis of the 
nature of the feeder and density dependence effects RPMI-2650 
conditioned medium (CM) was shown, using specific cell culture 
bioassays, to contain TGF-a (transforming growth factor-a)-like, 
TGF-B-like and autostimulatory activities, as well as EGF 
(Epidermal growth factor) receptor binding activity Following 
large-scale production of CM m  roller and suspension culture, 
these activities were fractionated using ultrafiltration, gel 
filtration m  acetic acid and HPLC HPLC separated TGF-a and TGF-B 
activities, but autostimulatory activity was lost RPMI-2650 cells 
had lower EGF receptor levels than'3 other human carcinoma cell 
lines examined (A431, T-47D, SCC-9) EGF receptor levels m  some 
of these lines were shown to be regulated by steroid hormones The 
results presented here indicate that the autostimulatory activity 
may consist of at least two components, one of high molecular 
weight (> 30 kDa) and another of low molecular weight (< 1 kDa), 
and may be distinct from previously-described TGFs
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SECTIO N 1
INTRODUCTION
1 .  INTRODUCTION
1.1 Growth Factors
Growth factors, defined as polypeptides that stimulate cell 
proliferations, are major growth regulatory molecules for cells in 
culture and probably also for cells in vivo. They stimulate cell 
proliferation by binding to specific high-affinity cell membrane 
receptors (Rosengurt, 1986). There is some recent evidence for 
specific nuclear binding sites, but this is controversial (Burwen 
and Jones, 1987). Growth factors have been purified from a variety 
of sources including platelets and tissues of adult and embryonic 
origin. Some growth factors are thought to be released by most 
cells in culture (Shields, R., 1978). Non-transformed cells show 
an absolute requirement for growth factors for proliferation in 
culture and generally more than one growth factor is required 
(Pledger and Stiles, 1979). Under usual culture conditions, growth 
factors are more readily depleted than other media components and 
this becomes rate limiting for proliferation (Barnes and Sato, 
1980); (Tsao et al., 1982). A loss of, or a decreased requirement 
for, specific growth factors is a common feature of neoplastically 
transformed cells and may lead to a selective growth advantage 
which might be expected to be a cardinal feature of cancer cells 
(Temin, 1966; Paul et al., 1971). Membrane receptors for growth 
factors are ubiquitous with most cells having receptors for more 
than one growth factor (Wrann et al., 1980; Bowen-Pope et al.,
1983) .
Recent work with transforming growth factors, platelet derived 
growth factor and oncogenes, has produced some insight into the 
mechanisms through which alterations in growth factor-receptor- 
response pathways could lead to a growth advantage, as found in 
neoplastically transformed cells. The use of defined growth 
factors and serum-free methods have been of great use here (Barnes 
and Sato, 1980). Many oncogene products are similar to growth 
factor receptors in that they have transmembrane and tyrosine 
kinase domains (Hunter, 1984). See Section 1.11. Other aspects of 
the post receptor-growth factor stimulated pathway are also 
mimiced and lead to growth stimulation (Kelly £t al., 1983).
Study of the molecular mechanism(s) of growth factor action has 
just begun The excitement and attention focused on cellular 
oncogenes m  recent years is now turning toward growth factors, not 
only as they concern the control of normal cell growth but also the 
involvement of growth factor-initiated pathways m  the etiology of 
cancer
1 2  1 Epidermal growth factor
Epidermal growth factor was first described by Cohen, 1962, as a 
peptide which would stimulate precocious eyelid opening and tooth 
eruption m  newborn mice and it was purified on this basis, its 
ability to stimulate the growth of cultured cells was recognised 
later (Carpenter and Cohen, 1975, Hollenberg and Cautrecasas,
1973) The active molecule was termed epidermal growth factor due
to its capacity to induce cell proliferation m  the basal cells of 
the skin (Cohen, 1962) First purified from male mouse 
submaxillary glands (Cohen, 1962) and later from human urine as
urogastrone (Gregory, 1975, Cohen and Carpenter, 1975), mature EGF
is a 6 kDa single polypeptide chain of 53 amino acids displaying 3 
internal disulfide bonds (Taylor et al , 1972) (Fig 1 shows the 
ammo acid sequences of growth factors related to EGF)
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Fig I I A)  Amino acid sequences of 
growth factors related to EGF The 
sequences of the individual poly­
peptides are taken from references 
cited in the text and are shown in 
comparison with the sequence of 
mouse EGF (B) Representation of 
stnctly conserved amino acid resi­
dues m the EGF family of growth 
factors and the portioning of disul­
fide bonds as derived from data on 
the mouse-derived EGF [6]
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EGF and TGF ot, a related polypeptide (Derynck et al , 1984) , are 
produced as large precursors In the case of EGF, the protein 
precursor is approximately 130 kDa m  size and contains seven 
EGF-like sequences m  addition to that for authentic EGF (Gray et 
al , 1983) The available data suggests that EGF (Zabel et al ,
1985) and TGF a (Brissenden et al , 1985) are products of unlinked 
genes that are independently regulated EGF is found m  almost all 
body fluids under normal physiological conditions, but its site of 
synthesis is uncertain in most species No organ m  any species 
examined contains levels of EGF approaching that found in the mouse 
submaxillary gland
Examination of a group of EGF-like growth factors like plasminogen 
activator and fibronectm (Banayi et al , 1983, Doolittle et al ,
1984) show that strict sequence conservation in this group is not 
evident, with the marked exception of the positioning of the 
cystine residues The precursors of each of these small EGF-like 
growth factors have a common but unexpected terminus, a hydrophobic 
sequence suggestive of the 'stop transfer' or membrane anchoring 
sequence of membrane proteins Based on the occurence of this 
sequence m  the precursor molecules, it has been proposed that the 
growth factor precursors may exist as integral membrane proteins on 
the surface of cells It is thought that proteolytic activity at 
the cell surface may give rise to free growth factor, or that 
growth factors may interact with the membrane receptors while m  
the precursor form Rail et al , 1985, has further proposed that 
m  the case of the large EGF precursor, which is produced but not 
degraded to lower molecular weight products m  the proximal tubule 
cells of the kidney, might also function as a receptor for an 
unidentified ligand
Radioimmune (Dailey et al , 1978) and radioreceptor (Carpenter et 
al , 1975) assays have been developed for measuring EGF 
concentration m  extracts the latter assay detects TGF a as 
equivalent to native EGF Not only do EGF and TGF a recognise the 
same cellular receptor, they are apparently equally effective on a 
mole-for-mole basis m  most systems TGF a is produced by a
variety of transformed cells (Roberts et al , 1983) and is found
m  acid extracts of tumours (Roberts et al , 1980) and m  foetal 
samples (Proper et al , 1982) It may be the case that EGF is the
adult form of the embryonic growth factor TGF 0,
EGF is mitogenic for a variety of cultured mesenchymal and 
epithelial cells, its mitogenic activity is strongly potentiated by 
insulin (Rose et al , 1975, Shipley et al , 1984) EGF also acts 
m  synergism with PDGF on BALB/c - 3T3 cells (Leof et al , 1983) 
Aspects of differentiation are also induced following EGF treatment 
m  certain cell culture models and in vivo (Oka et al , 1983, 
Weissman et al , 1983)
Elder et al , 1978, showed, using a fluorescent double-antibody 
technique, that hEGF was found in the duct cells of the human 
submandibular salivary glands and m  cells of Brunner's glands of 
the duodenum, but not in many other cell types tested A recent 
observation by Sato et al , 1985, has found an adenocarcinoma of 
the human salivary gland which expresses hEGF and TGF 3
1 2  2 EGF Receptor
A plasma membrane receptor for EGF was identified m  the mid 1970s 
Early reports showed that cultured cells responded to the mitogenic 
signal provided by EGF and that radiolabelled EGF bound m  a 
specific, saturable manner and with high affinity for the surface 
of these responsive cells (Carpenter et al , 1979) The only 
cells in which EGF receptors have not been demonstrated either in 
vivo or in vitro, are those of the hemopoietic system
A key element m  elucidating the biochemistry of the EGF receptor 
was the discovery m  1977 that a cell line, designated A-431, over­
expresses the EGF receptor (Fabricant et al , 1977) Most cell 
types express lO^-lO^ receptor molecules/cell (Todaro et al ,
1976), while A-431 cells express 2 5 x 10^/cell (Haigler et al , 
1978) This over-expression of the EGF receptor suggests that it 
may have a role in the malignant growth of squamous cell carcinomas 
as suggested by Cowley et al , 1986
EGF was demonstrated to activate a protein kinase in vitro m  1978 
(Carpenter e_t al , 1978) and m  1980 the EGF receptor was found to 
co-purify with the growth factor-dependent kinase activity (Cohen 
et al , 1980) The protein kinase activity was subsequently 
identified as specific for tyrosine residues (Ushiro and Cohen, 
1980) Several lines of biochemical and immunologic evidence 
suggested that the kinase activity was intrinsic to the receptor
molecule and not part of a separate effector system (Cohen et al , 
1982, Cohen et al , 1980) The cloning and sequencing of the EGF 
receptor provided the final evidence that the receptor molecule did 
indeed possess an intrinsic enzymatic activity, one which might 
serve as an effector system (Gray et al , 1983)
The EGF receptor is an integral 170 kDa membrane protein exhibiting 
an extracellular binding domain that serves to bind the ligand, a 
transmembrane region, and an intracellular domain facing the 
cytoplasm, exhibiting the tyrosine kinase function and binding 
sites for ATP and the phosphorylation substrates (Cohen et al ,
1982) In response to EGF, the receptor is capable of 
autophosphorylation on tyrosine residues (Ushiro and Cohen, 1980)
Receptor protein purified from A-431 cells was used for sequencing 
by Downward et al , 1984, who found that a high level of homology 
existed between the EGF receptor (170, kDa) and the v-erb B 
oncogene product (74 kDa) The external part of v -erb-B protein 
is too small to accommodate a ligand binding site, but the internal 
domains of both the EGF receptor and the v-erb-B protein contain 
highy homologous sequences and resemble the sequences described for 
other tyrosine kinases (Downward et al , 1984) The function of 
the EGF -dependent protein kinase and the v-erb-B kinase 
activities m  the control of cell proliferation remain to be 
resolved
1 3 Platelet-Derived Growth Factor
Platelet derived growth factor (PDGF) is a serum protein that is 
released mainly from the alpha granules of platelets into serum 
during the clotting process (Stiles, 1983) PDGF is a potent 
mitogen for connective tissue (smooth muscle cells, fibroblasts and 
glial cells) and for those cell types possessing receptors for its 
binding (Ross and Vogel, 1978) Polypeptide growth factors (Deuel 
and Huang, 1983), m  general, appear to have specific target cells 
and tissues Many cells m  culture are serum dependent and 
require, among other factors, PDGF (Ross et al , 1974, Kohler and 
Lipton, 1974).
PDGF from human platelets is a cationic glycoprotein of 
approximately 30 kDa (Antomades, 1981, Deuel et al , 1981,
Raines, 1982) Each human platelet contains about 1000 molecules 
of PDGF (Stiles, 1983) PDGF is released during clot formation and 
human clotted blood serum contains 15-20 ng ml*^ of PDGF 
Reduction of disulfide bonds destroys its mitogenic activity and 
generates multiple species of 14 to 17 kDa Sequence analysis 
shows two distinct but related sequences (Antomades and 
Hunkapeller, 1983, Waterfield et al , 1983), suggesting that PDGF 
from human platelets is a heterodimer of two chains, these are 
termed A and B (Johnsson et al , 1984) Porcine PDGF appears to 
consist of B-B homodimers (Stroobant and Waterfield, 1984), while 
human PDGF produced by osteosarcoma cells consists of A-A 
homodimers (Heldin et al , 1986)
Receptors for PDGF are found on a variety of mesenchymal cells 
(Bowen-Pope and Ross, 1982, Heldin, 1981) as well as human 
placental cytotrophoblasts (Goustin et al , 1975) The 
cytotrophoblasts are part of the human placenta and are the most 
invasive and proliferative normal cells known, the expression of 
PDGF receptors m  this tissue may help account for their 
"pseudomalignant" phenotype (Beaconsfield et al , 1980)
Stimulation of cells with PDGF induces an autophosphorylation of a 
185 kDa protein (Ek and Heldin, 1982) which turns out to be the 
PDGF receptor (Williams et al , 1984) An antibody to 
phosphotyrosine has been used m  the purification of the receptor 
from BALB/c-3T3 cells, purified receptors inserted into liposomes 
reconstitute the growth factor binding characteristics of native
A
receptor (Daniel et al , 1985)
Table 1 shows the variety of cells capable of secreting PDGF and 
also its possible biological roles (Ross et al , 1986)
Abnormal cell proliferation and its control are primary problems m  
a number of diseases, including neoplasia and atherosclerosis In 
many instances, the basis for this cell proliferation, whether 
normal or abnormal, most likely lies m  the response of the cells 
to a group of polypeptide hormones or growth factors which may act 
singly or m  concert to stimulate the proliferation of particular 
populations of cells Each growth factor appears to have specific 
target cells and tissues
The v-sis gene product of simian sarcoma virus (SSV) is nearly 
identical to the B-chain of human PDGF and the active v-sis 
product is probably a B-B dimer (Doolittle et al , 1983, Heldin et 
al , 1983) SSV was the first acute transforming retrovirus to be 
isolated from a primate Injection of SSV into laboratory test 
animals induces tumours, but only in those tissues which express 
the PDGF receptor (Leal et al , 1985) SSV mediates cell 
transformation by the production of a PDGF like molecule (Gazit et 
al , 1984) Since all known effects of PDGF are mediated via its 
interaction with its receptor, it is reasonable to propose that 
transformation of cells by SSV involves the binding of v-sis 
encoded PDGF-like proteins with the PDGF receptors of the cell, 
thereby activating those processes responsive to PDGF
T a b l e  1 : C e l l s  C a p a b l e  o f  S e c r e t i n g  P D G F - l i k e  M o l e c u l e s
Cell Type
Circulating Cells 
Platelet
Monocyte/macrophage
Resident Cells 
Megakaryocyt e
Endothelium
Smooth muscle from: 
Rat pup
Adult rat
First trimester 
human placental 
extracts
Agent Inducing 
PDGF Secretion
Thrombin, collagen,
ADP, adherence
Endotoxin, concanavalin A, 
TPA, foreign agents, 
adherence
Thrombin, collagen 
ADP, adherence
Culture, thrombin, 
factor Xa, injury 
(endotoxin and phorbois)
"Development"
Balloon catheter injury 
culture
"Development"
Other Growth Factor 
Produced
+ (FGF, EGF, TGF-3, 
+(FGF, IL-1, ?)
+ (?)
+ (IL-1, ?)
+ (IGF-1, ?)
+ (? )
+ (?)
Anatomical 
Considerat ions
Possible Biological 
Ro les
9-11 days m  the 
circulation
Can reside m  tissue 
for months
Bone marrow
Permeability barrier 
between circulating 
blood cells and under­
lying cells
Rat aorta
Rat carotid (neomti- 
raa), rat aortic media
Cytotrophoblasts of 
the placental 
cytotrophoblastic 
shell
Wound healing; 
atherosclerosis
Wound healing; 
atherosclerosis; fibrotic 
disorders of lung, liver, 
and kidneys; inflammation 
arthritis
Abundant m  some forms oft 
myelofibrosis
Wound healing; 
athersclerosis
Development, growth
Atherosclerosis; wound 
healing
Development, growth
T a b l e  1 : C e l l s  C a p a b l e  o f  S e c r e t i n g  P D G F - l i k e  M o l e c u l e s  ( c o n t * d )
Cell Type
Transformed Cells
Cells transformed 
by SSV
Activation of c-sis 
during trans­
formation
PDGF-responsive cells
PDGF-nonresponsive 
Cells
Agent Inducing 
PDGF Secretion
SSV
Wide variety of trans­
forming agents
Other Growth Factors 
Produced
+ (?)
+ (TGF-a, ?)
+ (TGF-a, ?)
Anatomical 
Considérât ions
Possible Biological 
Roles
Multiple subcutaneous Neoplasia 
fibrosarcomas, astrocy­
tomas (intracranial)
Principally blastomas 
and sarcomas
Autocrine stimulation 
in atherosclerosis, 
neoplasia
Erythroleukamic cells, Paracrine stimulation
bladder carcinoma, 
hepatoma
in myelofibrosis, 
desmoplasia
Abbreviations PDGF - platelet-derived growth factor; FGF - fibroblast growth factor; EGF - epidermal growth factor; 
TGF - transforming growth factor; IL-1 - interleukin-1 ; IGF - insulmlike growth factor; SSV - simian 
sarcoma virus; TPA - 12-0-tetradecanolyphorbo1-1 3-acetate.
Ref : (Ross et al., 1986)
1 4  1 Transforming growth factors
Transforming growth factors are hormonally active polypeptides that 
induce phenotypic transformation in certain normal cells in vitro 
Two types of transforming growth factors, TGF-a and TGF-3 , from 
both humans (Todaro et al , 1980) and rodents (De Larco and 
Todaro, 1978, Moses et al , 1981; Roberts et al , 1980, Todaro and 
De Larco, 1978, Twardzik et al , 1982) have recently been 
purified, characterized, chemically synthesized and cloned With 
the identification of cellular receptors for TGF-a and TGF-3 , we 
now have more approaches available to address their mode of action 
and their role m  normal and malignant cell proliferation
TGFs cause the reversible appearance of many characteristics of the 
neoplastically transformed phenotype m  cells that normally grow m  
an anchorage-dependent manner (connective tissue and epithelial 
cells) (Moses et al , 1981, Todaro et al , 1980) The phenotypic 
alterations induced by TGFs include morphologic transformation of 
cells m  monolayer and an induction of multiple rounds of cell 
division m  cells suspended m  semi-solid medium (Todaro et al , 
1980, Todaro et al , 1981)
1 4  2 Transforming Growth Factor-q
TGF-a is related to epidermal growth factor (EGF) and binds to the 
EGF receptor, ( m  contrast to TGF-3 , which is a structurally 
unrelated protein with a distinct receptor) The initial 
observation that led to the identification of TGF-0t was that some 
retrovirally transformed fibroblasts displayed a strongly reduced 
number of EGF binding sites at their surface (Todaro et al ,
1976) Later it was shown that these cells release an EGF-like 
factor that is able to bind to EGF receptors, which then become 
unavailable for binding of an externally added ligand This EGF 
receptor binding factor was first isolated from murine-sarcoma- 
virus-transformed fibroblast cultures and was first called sarcoma 
growth factor (SGF) (De Larco and Todaro, 1978) It was then 
thought that SGFs (or TGFs as they are now known), were involved m  
neoplastic cell growth Further investigation of a variety of cell 
sources showed that this factor was made by many more transformed
cells but not by adult normal cells m  culture (Todaro et al ,
1980, Roberts ej: al , 1980)
Following extensive biochemical purification and characterization, 
it was found that sarcoma growth factor was composed of two 
structurally unrelated peptides, TGF-a and - 6 Purified TGF-a 
alone m  serum-containing medium only weakly stimulates soft agar 
colony formation (Anzano et al , 1983) The apparent colony 
stimulating ability of sarcoma growth factor was presumably due to 
the interaction of TGF-a and TGF- 6 on NRK indicator cells
TGFs-ahave been detected m  culture supernatants and extracts from 
several transformed rodent and human cells (De Larco and Todaro, 
1978, Marquardt et al , 1983) These TGFs-a, which all bind to 
the EGF receptor, display upon gel filtration a heterogeneity m  
apparent molecular weights ranging from a 6 kDa species secreted by 
several tumour cell lines (Marquardt et al , 1983) to the 34 kDa 
TGF-a species detected m  the urine of cancer patients The low 
molecular weight TGF-a species has been purified to homogeneity 
from several cell sources (Massague, 1983) Subsequent a m m o  acid 
sequencing led to the establishment of the complete a m m o  acid 
sequence of the 50-ammo-acid-long rat TGF-a (Marquardt et al ,
1984) These data on the structure of TGF-a have now been 
confirmed and extended by cDNA analysis The sequence of a human 
TGF-a cDNA derived from a renal cell carcinoma cDNA library 
indicates that the 50-ammo-acid TGF-a is synthesized as a larger 
precursor (Derynck et al , 1984), as has now been shown by the 
sequence analysis of rat TGF-a cDNAs (Lee et al , 1985) To 
generate the 50-ammo-acid TGF-a, proteolytic cleavage of the 
160-ammo-acid precursor must occur at both the a m m o  and carboxy 
terminus between an alanine residue and valine dipeptide Fig 2 
shows the hypothetical TGF-a precursor model
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Fig. 2 Depiction of a hypothetical model of the TGF-a 
precursor as a transmembrane protein. The NH^- 
terminal signal sequence is shown as already 
cleaved from the precursor. The 50-ammo-acid 
TGF-a with its three proposed cystine (C) - 
disulfide bridges is shown as a heavy fane line, 
flanked by the proteolytic cleavage sites (arrows). 
The boxed transmembrane region is flanked at each 
side by two basic a m m o  acids (KK and RK) . The 
carboxy-termmal cytoplasmic domain shown below 
the membrane is rich in cystines (C).
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The protease cleavage protein required is extremely specific and 
may not be produced by all cells This could then result in the 
continuous anchorage of the TGF-a precursor m  the membrane and the 
absence of TGF-a m  the medium The rat and human TGF-a precursors 
show strong homology followed by a long hydrophobic transmembrane 
region (Derynck et al , 1984) It is m  the C-terminal regions 
that the rat (Lee et al , 1984) and human TGF-a precursors are 
virtually identical, which reflects an evolutionary conservation of 
this sequence and suggests an as yet unknown biological function 
One gene has been shown to code for TGF-a (Derynck et al , 1984)
The larger TGF-a species as found by several researchers (Marquardt 
and Todaro, 1982) are now known to be N-glycosylated and are 
derived from the same precursor as the smaller 50-ammo- acid form 
(Brmgman et al , 1987)
1 4  3 Relationship of TGF-a to other Growth factors
TGF-a and EGF have very similar sequence homology (Derynck et al ,
1984) 6 cystines found m  human TGF-a and EGF have corresponding
sites Rat TGF-a and EGF also have significant homology Since 
TGF-a and EGF are so similar, it is likely that the three disulfide 
bonds found in EGF are also found m  TGF-a The third cystine loop 
contains the most significant homology between TGF-a and EGF and
it is suggested that this region is important for binding to the 
EGF receptor (Nestor et al , 1985)
Vaccinia virus encodes a polypeptide precursor of 140-ammo-acids 
with a sequence very similar to TGF-a and EGF This vaccinia virus 
growth factor competes for EGF receptors as shown by Stroobant et 
al , (1985)
The initial observation that TGF-a was found m  the medium of 
various virally or chemically transformed cells (Todaro et al ,
1985), led to the belief that TGF-a was a key molecule m  the 
malignant transformation of cells TGF-a could not be detected m  
medium from normal cells m  vitro and is not known to be made m  
normal fully developed tissues However, due to the limited number 
of obsrvations reported, it cannot be concluded that TGF-a has no 
role m  the physiology of normal adult cells TGF-a is synthesized 
m  early foetal development (Lee et al , 1985), which may indicate 
that TGF-a may function as an embryonic form of the EGF family
The expression of TGF-a gene at a later stage of growth may occur 
m  the process of malignant transformation and tumour development
In in vitro cell growth, it has been shown that anchorage 
independent growth of NRK cells was due to the combined effect of 
TGF-a and TGF-3 (Anzano et al , 1983) It has been postulated 
that during the transformation process, TGFs exert their action via 
an autocrine mechanism in which they help sustain the transformed 
character of the same cells which produced them ( S p o m  and Todaro,
1980) This hypothesis would also explain the reduced number of 
EGF binding sites available to externally-added ligand m  
retrovirally transformed cells (Todaro et al , 1976)
It has not yet been reported whether constitutive expression of 
TGF-a is sufficient to induce malignant transformation via an 
autocrine mechanism Even though TGF-a expression is quite common 
m  solid tumours and tumour cell lines, it is still debatable if 
the autocrine mechanisms of transformation by TGF-a or by any 
growth factors will induce or contribute to the development of 
human malignancies in vivo
The delay m  studying the biological activities of TGF-a was due to 
very low levels produced by cells The determination of the 
complete sequence of the 50-ammo-acid rat TGF-a (Marquardt et 
al , 1984), has enabled the direct synthesis of larger amounts of 
rat TGF-a by solid phase techniques (Tam et al , 1984) The 
isolation of a human TGF-0t cDNA has also led to the synthesis and 
purification of relatively large amounts of human TGF-a from 
genetically engineered Escherichia coli (Derynck et al , 1984, 
Rosenthal et al , 1986)
TGF-a can be quantified by radioreceptor assay m  which TGF-a 
competes with for bincLlng sites on a mole per mole
basis TGF-a also binds to a 60 kDa membrane component but studies 
have shown that TGF-a binding to this site does not mediate the 
transformed phenotype (Carpenter et al , 1983) EGF and TGF-a 
exhibit very similar binding to the EGF receptor (Massague, 1983)
On binding to the EGF receptor TGF-a activates a receptor 
associated kinase m  the same manner as EGF (Pike et al, 1982)
The greater availability of TGF-a m  the past few years has allowed 
comparison of TGF-a to EGF Although they behave almost 
identically m  many systems, but m  other cases (as found m  bone 
resorption and angiogenesis), TGF-a is far more potent than EGF 
See Table 2 for details of TGF-a- (EGF-like) activity
Table 2
Activity Refs
Soft agar colony formation NRK (Derynck et al , 1984)
Precocious eyelid opening m  new 
born mice (Smith et al , 1985)
Accelerate tooth eruption, retard 
growth rate inhibit hair growth (Tam, 1985)
Promote calcium release from foetal (Stern et al , 1985 and 
Rat long bones (Ibbotson et al , 1986)
Induction of angiogenesis (Schreibner et al , 1986)
It is unclear how both TGF-a and EGF, which bind to the same 
receptor, can trigger differential responses It is thought that 
EGF receptors with high and low affinities respond with different 
results when binding to TGF-a or EGF Alternatively, there may be 
differences on internalization of the receptor-ligand complex or 
different cell types may respond differently to either TGF-a or 
EGF Further research into the functions of TGF-a is necessary 
before it can be fully evaluated
1.4.4 Transforming growth factor-B
In spite of its name, transforming growth factor-B is very- 
different to TGF-ct in molecular composition, biological response 
elicited and membrane receptor binding. TGF-a or EGF must be 
present along with TGF-B to support the formation of soft agar 
colonies of normal rat kidney fibroblasts (Roberts et al., 1981). 
TGF-3 alone can induce anchorage-independent growth of mouse embryo 
fibroblasts (AKR-2B) (Moses et al., 1984; Tucker et al., 1983). 
TGF-B activity is generally assayed by its ability to stimulate 
soft agar colonies of a clone of NRK-(49F) in the presence of EGF 
(Roberts et al., 1981). In contrast to these mitogenic effects on 
some fibroblast systems, TGF-B appears to have a negative growth 
modulatory role in various other cell systems, particularly normal 
epithelial cells and several types of malignant cells (Tucker et 
al., 1984; Roberts et al., 1985; Moses et al., 1985; Heimark et 
al., 1986).
Initially, TGF-Oi and TGF-B were co-purified (see section 1.4) until 
further investigation by HPLC showed that TGF activity on NRK .was 
due to two molecules (Childs et al., 1982; Roberts et al., 1982; 
Tucker et al., 1983).
TGF-B is a fundamental regulatory molecule widely distributed in 
different tissues (Goustin et al., 1986; Sporn and Roberts, 1985) 
and has been purified to homogeneity from four sources; bovine 
kidney (Roberts et al., 1983); human placenta (Frolik et al.,
1983) ; human platelets (Assoian et al., 1983) and feline sarcoma 
virus transformed rat cells (Massague, 1984). These sources reveal 
a 25 kDa disulfide-linked homodimeric molecule. Previous reports 
have shown that TGF-B from porcine platelets also contain another 
form of TGF-B with much the same structure and functions as the 
original TGF-B- Specific receptors have been found for each type 
which may be a means of modulating the cells response to TGF-B 
(Cheifetz et al., 1987). TGF-B has numerous regulatory actions on 
a variety of cell types and virtually all have a specific high 
affinity receptor for this peptide (Frolik et al., 1984; Tucker et 
al., 1984; Fanger et al., 1986). The molecular mechanism of 
action of TGF-B is at present unknown.
TGF-3 is derived from a large precursor molecule and on reduction,
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the TGF- g dimer yields two identical chains of 112 amino acids 
(Derynck et al., 1985). TGF- Bis highly stable to acid and heat. 
Derynck et al., 1985 have cloned the gene for TGF-3 from a human 
genomic library and from cDNA libraries derived from human term 
placenta and from the human fibrosarcoma line HT-1080. Murine 
TGF- 8 has also been cloned and the cDNA sequence determined. The 
high degree of cDNA sequence homology found between human and 
murine TGF- 6 coding region suggests that most regions of the TGF-B 
molecule are necessary for biological activity and that TGF-B 
probably plays an essential role in normal growth and development 
(Derynck et al., 1986).
It has recently been appreciated that TGF- 6 is prototypic of a 
family of homologous polypeptides that control the development of 
tissues in organisms ranging from humans to Drosophila. This 
family includes various inhibins and activins, which regulate the 
ability of cultured pituitary cells to release follicle stimulating 
hormone (Mason et al., 1985; Ling et al., 1986); the Mullerian 
inhibiting substance, which inhibits development of the Mullerian 
duct in mammalian male embryos (Cate et al., 1986) and the 
transcript of the decapentaplegic gene complex (DPP-C), which is 
critical for the development of Drosophila (Padgett et al. , 1987). 
The bioactive domains of these polypeptides share about 25-35% 
amino acid sequence identity with TGF-g, including conservation of 
at least seven of the nine cystines. Biological and polypeptide 
analyses have shown that cartilage inducing factor-A (CIF-A)
(Zeydin et al., 1986) is TGF-g.
Three structurally distinct cell surface glycoproteins have been 
identified that specifically bind TGF-g with affinity constants in 
the pico molar range. These receptors are found to be ubiquitous 
like the TGF-g molecule (Tucker et al., 1984) and the receptor 
number per cell is between 10,000 and 40,000 (Frolick et al.,
1984). TGF-g from different species bind to the receptors equally 
well, suggesting that these growth factor-receptor systems are 
highly conserved. It was proposed and shown that this family of 
TGF-g receptors might interact wth a family of TGF-g related 
polypeptides in a situation similar to that found in the receptors 
for other families of hormonally active agents (Cheifetz et al., 
1987). The TGF-g receptor is unlike those of EGF or PDGF in that, 
so far, no kinase or other enzymatic activities have been found.
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TGF-B enhances the ligand-binding affinity of the EGF receptors of 
NRK cells (Assoian et al , 1984) and the activation of the 
EGF-receptor appears to be essential for the action of TGF-B m  
these cells (Inman and Colowick, 1985) The need for insulin-like 
growth factors m  TGF-g-induced cell transformation has also been 
proposed (Massague et al , 1985)
It has been shown that various combinations of growth factors can 
stimulate the formation of soft agar colonies (Van Zolen et al ,
1986) and not as was originally thought that transforming growth 
factors were the sole stimulators However, TGF-B m  certain 
systems can stimulate soft agar colonies of various mouse and rat 
fibroblasts and also secondary cultures of human foreskin 
fibroblasts (Moses et al , 1981, Roberts et al , 1981, Moses et 
al , 1985). The general effects of TGF-B are multifunctional as 
shown m  Table 3 Generally, in the case of cell growth and 
inhibition, it is thought that TGF-B is primarily an inhibitor 
(Shipley et al , 1985; Holley et al , 1983), the mechanism(s) of 
which are largely unknown and that stimulation of fibroblastic 
cells is mediated by the induction of c-sis followed by the 
autocrine stimulation of PDGF-like sis-protein and DNA synthesis 
(Leof et al , 1986) Lawrence et al , 1984 have shown that many 
cell types release TGF- in an inactive form This inactive form 
seems to be of a higher molecular weight, which is activated on 
cleavage from a binding protein e g by acid treatment The 
mechanism of activation is unknown
Chemically transformed cells gain increased sensitivity to TGF-B 
with regard to stimulation of growth m  soft agar (Moses et al ,
1985) It was proposed that on transformation, a newly activated 
H-ras gene could enhance autocrine stimulation by TGF-B or could be 
involved m  the transduction of the TGF-B signal This would 
explain how these transformed cells become more responsive to 
endogenously produced TGF-B without an increase m  cellular 
receptor number (Leof et al , 1986)
Epithelial cells are normally inhibited m  the presence of TGF-B 
It is thought that these cells activate TGF-B found m  an inactive 
state m  serum which then inhibits the cells m  an autocrine 
manner The loss of the ability to activate TGF-B m  cells that
1 9
T a b l e  3
B i o l o g i c a l  E f f e c t s  o f  T G F -ß R e f s
1 Inhibits the growth of most normal, 
especially epithelial cells and 
several malignant cells
Moses et al , 1985 
Roberts et al , 1985 
Shipley et al , 1986
2 Mitogenic for mesenchymal cells Moses et al , 1981 
Roberts et al , 1981 
Shipley et al , 1985
3 Stimulates anchorage independent 
growth of non-malignant fibroblasts
Moses et al , 1981 
Roberts et al , 1981
4 Inhibits adipogénie differentiation Ignotz et al., 1985 
of 3T3 cells
5 Stimulates terminal differentiation Masui et al , 1986 
of bronchial epithelial cells
6 Wound Healing Roberts et al , 1986
7 Regulates the plasminogen activator 
activity of cultured cells, induces 
endothelial type plasminogen activator 
inhibitors
Laiho et al , 1986
8 Enhances the production of connective Roberts et al , 1986 
tissue and components
9 Acts as a modifier of different Kehrl, et al , 1986 
immunological responses
are normally inhibited could lead to their growth advantage (Moses 
et al , 1985, Shipley et al , 1986)
TGF- 8 could play a major role m  many disease states involving
fibroblastic proliferation and collagen deposition as indicated by 
its ability to enhance wound healing (Sporn et al,, 1983) and its 
general stimulatory effect on connective tissue (Roberts et al ,
1986) m  building up the extracellular matrix (Ignotz and Massague,
1986) Atherosclerosis is one of the main diseases in which TGF-B 
could play an important role (Ross, 1986)
Another effect of TGF-8 is m  bone resorption although TGF-a is a 
far more potent factor m  the cause of hypercalcemia found m  some 
cancers (Ibbotson et al , 1983, Mundy et al , 1984)
TGF-g is a growth regulatory polypeptide with stimulatory and
inhibitory activity on a variety of cell types Further 
characterization of this molecule will greatly expand our concept 
of normal and malignant cell control
1 4  5 Other Transforming growth factors
Other transforming growth factors which can stimulate the 
transformed phenotype are also known TGF-a2 is an acid labile 
factor that stimulates the growth m  soft agar of BALB/c-3T3 cells 
(Hirai et al , 1983) This growth factor has been purified and an 
amino acid composition has been determined (Yamnoka et al , 1984)
An epithelial tissue derived autocrine growth factor from the 
carcinoma cell line SW13, has also been described (Halper et al ,
1983) Vaccinia Virus-infected cells have been found to release a 
transforming growth factor functionally related to the known 
transforming and epidermal growth factors (Twardzik et al , 1985, 
Stroobant et al , 1985) An acid-sensitive factor from human 
platelet sonicate has been found to promote soft agar colony 
formation of human metastatic melanoma cells (Sipes et al , 1985)
An autostimulatory melanoma mitogen (melanoma growth-stimulatory 
activity, MGSA) has also been described by Richmond et al , 1985 
The variety of transforming growth factors appears to be greater 
than at first thought Further characterization will determine the 
basic mechanism behind transformation and the relationship of all 
these transforming growth factors
1 5 I n s u l i n - l i k e  g r o w t h  f a c t o r s  ( I G F - I  a n d  I G F - I I )
The insulin-like growth factors (somatomedins) refer to a family of 
closely related mitogenic polypeptides There are two main groups 
based on their isolectnc points The basic group (IGF-I) with 
isoelectric point above 7 5 and the acid-neutral group with
isoelectric point below 7 5 (IGF-II) IGF-I corresponds to human
somatomedin C (Klapper et al , 1983), and IGF-II corresponds to 
human somatomedin A and rat multiplication stimulating activity 
(Marquardt & Todaro, 1981) Somatomedin C is the term most often 
used m  the literature Somatomedin C is produced in response to
circulating growth hormone, and is one of the important growth
factors found in serum and plasma (Svoboda et al , 1980) It is 
active in stimulating a large number of cultured cells (Van Wyk et 
al , 1981) Excessive concentrations of insulin (above lOOmM) can 
replace the IGF requirement m  defined media through cross-reaction 
with ubiquitous IGF-I receptors (Van Wyk et a l  , 1975)
Somatomedins apparently circulate m  plasma non-covalently bound to 
a specific carrier protein (Furlanetto, 1980) It is generally 
thought that somatomedins function m  an autocrine fashion (Temin 
et al , 1982), BRL-3A cells, however, which secrete large amounts 
of IGF-II into the medium (Dulack & Temin, 1973) do not need IGF-II 
for stimulation (Nissley et al , 1977) Evidence is accumulating 
that the stimulation of foetal mouse growth by somatomedin C is m  
an autocrine or paracrine mode (D'Ercole et al , 1984)
Purification of Somatomedin C (IGF-I) from human serum has shown a 
single chain of 70 a m m o  acids with 3 internal disulfide bonds 
This factor has also been sequenced (Rmderknecht & Humbel, 1978) 
The genes for both human IGF-I and IGF-II have been cloned (Bell 
et al , 1984) Recombinant somatomedin C, which is almost 
identical to human somatomedin C except for one a m m o  acid change, 
is commercially available The human IGF-II gene is found very 
near the human insulin gene (Bell et al , 1985) Both of the 7 
kDa IGFs are processed from larger precursors (Bell et al , 1984), 
and it is thought that IGF-I may be an adult somatomedin with 
IGF-II the embryonic counterpart (Adams et al , 1983) Although 
IGF-I and IGF-II have their own receptors, some cross-reactivity is 
found at higher growth factor concentrations (Massague & Czech,
1982) Cell receptors for IGF-I (type 1 receptors) show homology 
to the insulin receptor This is a heterotetrameric 450 kDa
complex consisting of two transmembrane 8 subunits (98-kDa each), 
each disulfide bonded to one a-subunit (130 - kDa each) (Pilch et 
al., 1980). The a subunits provide the insulin (or IGF) binding 
sites (Pilch et al, 1979) and the 8 subunit posesses the ATPase 
and tyrosine kinase activities (Van Oberghen et al., 1983) . Much 
is now known of the insulin receptor. Homology exists between the 
extracellular domain of the human EGF receptor and the a*region of 
the insulin receptor. The 8 domain however, has homology with the 
oncogenes, in particular the ros oncogene (Ullrich et al., 1985). 
These homologies strongly suggest that one or more of these 
oncogenes may encode growth factor receptors. The second type of 
IGF receptors, Type II, are far more simple. They are a 250 kDa 
component which may be single chain (Kasuga et al., 1981), and 
they may not undergo ligand-induced down regulation (Massague,
1985).
1.6.1 Interleukin 2
Treatment of human peripheral blood T-cells with the lectin Con A, 
causes the release of soluble factors that stimulate the 
proliferation of activated T-cells (Smith 1984; Morgan et al.,
1976). This antigen triggered factor called T cell growth factor 
or interleukin 2, supported the longterm in vitro culture of 
clonal populations of normal cytotoxic T-lymphocytes (Morgan et 
al, 1976). Tanaguchi and co-workers (1983) successfully isolated 
the first cDNA clone that codes for IL-2. The sequence shows a 
peptide of 153 amino acids that is cleaved to form the mature 133- 
residue secreted sialoglycoprotein displaying one internal 
disulfide bond (Robb et al., 1983).
The human gene for IL-2 spans about 8 kilobases and consists of 4 
exons (Holbrook et al., 1984). A cDNA-encoding mouse IL-2 has 
been cloned which exhibits 76% homology at the amino acid level to 
human IL-2. The mouse cDNA for IL-2 has a reading frame sufficient 
to encode a protein of 169 residues (Kashima et al., 1985). The 
tumour cell line JURKAT has been used in much of the work with 
IL-2. Treatment of this cell line with Con A induces an IL-2 
transcript of 1.5 kilobases (Taniguchi al., 1983). The lectin 
phytohemagglutinin stimulates a 30-fold induction of IL-2 
transcription in normal human lymphocytes (Efrat and Kaempfer,
1984). However, the immunosuppressive drug cyclosporn A has been
shown to deactivate the IL-2 gene m  phytohemagglutinin induced 
JURKAT cells (Kronke et al , 1984) These observations may 
suggest a possible role for the activation of the IL-2 gene during 
T-cell activation
Cell surface receptors for IL-2 have been purified from both normal 
and transformed lymphocytes (Urdal et al , 1984) The receptors 
from normal lymphocytes are 55 kDa and from transformed 
lymphocytes, 60 kDa The reason for the difference in size is not 
fully known. The receptor is apparently quite different from those 
of other known growth factors Cloning and sequencing analysis of 
IL-2 receptor cDNA show only a 33 kDa receptor reading frame with a 
very short cytoplasmic region. Another functional receptor cDNA 
sequence may yet be cloned which will contain the full 55 kDa 
reading frame In the 33 kDa protein, the cytoplasmic domain has 
one serine and one threonine which can be phosphorylated An 
alternative receptor species is found m  the HuT-102 B2 (human T- 
cell leukaemia Virus 1 transformed) cells These cells encode an 
almost normal IL-2 receptor except for a 72 a m m o  acid deletion 
near the IL-2 binding domain (Leonard et al , 1985) The 
significance of this truncated receptor species is not clear IL-2 
receptor structure and genetic regulation are still not fully 
understood despite extensive cloning and purification
Functional receptors for IL-2 are not found on resting T-cells 
(Robb et al , 1981), the action of Con A or antigen m  T-cell 
proliferation thus involves the induction not only of IL-2 
production by the T-helper cells, but also of IL-2 receptors on 
T-killer cells, a two step process (Larsson and Coutmho, 1979)
The control of IL-2 receptor presentation m  the immune response 
is, in this way, a key control of normal T-cell proliferation
Future work on the biology of IL-2 will help m  the understanding 
of eukaryotic gene regulation, cell growth and differentiation, the 
regulation of the immune response, immunodeficiency and leukaemia
1 6  2 Interleukin-1
Interleukin-1 (previously called lymphocyte activating factor or 
LAF) is released by macrophages and possibly by dendritic cells, 
and acts on B rather than T lymphocytes IL-1 is membrane
associated but is also secreted from the cells IL-1, however, is 
as yet poorly characterized and will not be discussed further here
1 7 Fibroblast growth factor (Heparin-bmding growth factors)
Bovine neural tissue extracts contain growth factors mitogenic for 
cultured fibroblasts and vascular endothelial cells (Gospodarowicz 
et al , 1976) Other sources as recorded by Gospodarowicz include 
bovine pituitary (Gospodarowicz, 1975), and bovine brain 
(Gospodarowicz et al , 1978), the molecular characterization of 
these factors has not been possible until recently It was claimed 
at one time that FGF was derived from brain myelin protein 
fragments (Westall et al , 1978), but later this was shown to be 
incorrect (Thomas et al., 1980) These neural extracts contain 
several factors which are given the name FGF, they are all 
apparently s m g l e - c h a m  proteins m  the 14-18 kDa size Other 
members of the FGF family include the factors described as 
endothelial cell growth factor, heparin binding growth factor 
(Klagsbrun, 1986) and chondrosarcoma factor ( S h m g  et al , 1984) 
Proteins that are apparently acidic and basic m  the neural 
extracts show similar features (Thomas et al , 1980, Lemmon & 
Bradshaw, 1983, Lemmon et al , 1982) Several factors have now 
been purified to apparent homogeneity, an acidic form of FGF from 
bovine brain (Thomas et al , 1984), and a cationic form from 
bovine pituitary (Bohlen et al , 1984) have been isolated by 
multistep procedures and an NH2- terminal sequence was reported 
for the cationic form (Gospodarowicz et al., 1984) Both factors 
have a molecular weight of 16,000
Several factors that have properties similar to those of FGF have 
been recently purified by heparin affinity chromatography An 18 
kDa endothelial growth factor from chondrosarcoma was the first to 
be purified by this technique ( S h m g  et al , 1984) It was shown 
that the cationic brain FGF can be purified by this technique and 
are identical (Gospodarowicz et al , 1985) An 18 kDa pituitary 
form of the heparm-binding growth factor has also been observed m  
preparations from bovine pituitary (Shipley et al , 1985) and 
hypothalamus (Lobb and Fett, 1984). It has been reported that 
multiple forms of FGF activity can be isolated by heparin binding 
affinity, including both the cationic and anionic FGFs from b r a m  
(Klagsbrun & Shmg, 1985) An a m m o  acid composition for both
forms has been reported (Lobb & Fett, 1984) and the acidic form of 
the molecule isolated by this technique has the same molecular 
weight and amino acid composition as the molecule isolated by the 
multistep procedure (Thomas et al., 1984). The complete sequence 
of bovine pituitary basic FGF is now available (Esch et al.,
1985); the sequence describes a molecule of 146 amino acids (16.4 
kDa). This sequence agrees with the partial sequence obtained for 
bovine basic FGF obtained from other tissues, including brain, 
adrenal gland, retina, corpus luteum, and kidney (Esch et al.,
1985). Since this sequence differs substantially with that 
reported for the bovine brain acidic form (Thomas et al., 1985), 
there are probably at least two genes encoding FGFs corresponding 
to the acidic and basic FGFs. There is, however, antigenic and 
sequence relatedness between these two gene products (Esch et al.,
1985). A slight amount of homology exists between acidic FGF and 
interleukin 1 (Thomas et al., 1985). The factor described as 
endothelial cell growth factor is related to the FGF family. 
Purified endothelial cell GF has been radio-iodinated for use in a 
radioreceptor assay, allowing the estimation of dissociation 
constant (200-800 pM) and receptor number per cell (20,000-40,000) 
(Schreiber et al., 1983).
A radioreceptor assay for FGF might allow for a survey of the 
distribution of FGF content and FGF production by various tissues; 
no such survey has yet been carried out. The significance of an 
endothelial cell growth factor concentrated in brain or pituitary 
is as yet unclear. The possible scenario of FGF as an endocrine 
growth factor would stand in contrast to patterns of other GFs as 
locally produced and locally acting paracrine or autocrine growth 
factors. The production of a FGF by chondrosarcoma is more in 
keeping with the general scheme, if one imagines a paracrine role 
for this growth factor in the stimulation of tumour angiogenesis, 
as has been suggested (Folkman, 1983) .
1.8 Nerve growth factor (NGF)
Nerve growth factor has been known for some time; however, its role 
as a factor for the maintenance and differentiation of sensory and 
sympathetic neurons argues against its inclusion in a strict list 
of growth factors in many ways. Indeed, in the most recent 
research, evidence indicates that NGF may play a role in cultured
rat adrenal chromaffin cells (Lillien & Claud, 1985) NGF was 
first detected as a factor released by transplanted tumours 
(Levi-Montalemi & Hamburger, 1951) , it was first purified from 
snake venom (Cohen, 1959), and then from mouse submaxillary gland 
(Cohen, 1980) NGF isolated from submaxillary glands is found m  a 
7S complex, containing three protein subspecies termed a, 8 and y 
(Bradshaw, 1978) NGF activity resides in the 8 species, a 
26 kDa dimer of two identical NGF chains (118 a m m o  acids per 
chain) which has been sequenced (Angeletti & Bradshaw, 1971) 
Sequencing of mouse and human cDNA clones suggests that NGF is 
synthesized as a much larger precursor (Scott et al , 1983), pro 
NGF is apparently a dimer of 307 residues per chain, with native 
NGF encoded in residues 188-305 of the precursor
NGF receptors are present on a variety of normal, sympathetic and 
sensory neurons as well as normal and neoplastic chromaffin cells 
The rat phaechromocytoma cell line, PC-12 has been used extensively 
in studies concerning NGF PC-12 cells respond to NGF treatment by 
an inhibition of proliferation and a stimulation of diffentiation 
(Green & Tischler, 1976) The mechanisms controlling this response 
are at present unknown Cross-linking ligand studies have been 
used to help define the PC-12 receptor It is a single chain 
protein of 130 kDa, a smaller receptor of 100 kDa, has also been 
found This is possibly a degradation product (Massague et al ,
1981) The receptor m  A875 melanoma cells has been partially 
purified by affinity chromatography, again a 98 kDa species is 
present, although larger species of 138 and 190 kDa are present 
(Puma et al , 1983) It is not known how these multiple NGF 
receptor species correspond to the two receptor species defined by 
their apparent*' dissociation constants of 2 pM and 2 nM (Landreth 
and Shooter, 1980, Costnni and Bradshaw, 1979) Recently, six 
cDNA clones representing mRNAs induced m  PC-12 cells by NGF have 
been isolated, one of the clones, VGF 8a, encodes a 90 kDa protein, 
the mRNA of which is induced more that 50 fold by NGF (Levi et 
al , 1985)
1 9 Colony stimulating factors (CSF-1, CSF-2 and Multi-CSF)
The soft agar colony assay developed by Metcalf & Johnson m  1977 
has led to the identification of a number of factors, called CSFs, 
that regulate the growth and differentiation of hematopoietic
precursor cells. As is the case with other tissue growth factors, 
CSFs are synthesized at a large number of sites in the body and are 
active in the low pM level. These factors include CSF-1 [formerly 
called macrophage CSF (Stanley and Heard, 1977)]; CSF-2 
[granulocyte-macrophage CSF (Burgess et al., 1977)]; and 
granulocyte CSF factor (Nicola et al., 1983) called interleukin 3, 
(IL-3), is active in stimulating colonies of mixed cell type (Ihle 
et al., 1983) and has been given the name multi-CSF. This factor 
is referred to by different names in the literature as a result of 
its stimulatory effect on various cell types. The activity of IL-3 
(multi-CSF) includes the promotion of growth and differentiation of 
granulocytes, macrophages and multipotential stem cells as well as 
colony formation from early erythroid, esoinophilic, megakaryocytic 
and mast cell progenitors (Iscove et al., 1982).
IL-3 was described and purified on the basis of its ability to 
induce an enzyme (20a*hydroxysteroid dehydrogenase) in mouse spleen 
T-lymphocytes (Ihle et al., 1981). This method of purification 
differs greatly to the methods used for other GFs which are usually 
purified on the basis of a cell growth bio-assay. Multi-CSF has 
been purified and partially sequenced (Ihle et al., 1983) ; cDNA 
clones corresponding to both human and mouse multi-CSF have been 
isolated (Yokota et al., 1981; Dunn et al., 1985).
CSF-1 has been purified to homogeneity from mouse L-cells (Stanley 
and Heard, 1977) and human urine (Das and Stanley, 1982) and radio­
receptor and radio-immune assays have been developed (Stanley,
1983; Stanley and Gilbert, 1981). Native CSF-1 from mouse L-cells 
is a 65-80 kDa sialoglycoprotein of two (possibly identical) chains 
linked by disulfide bonds (Das & Stanley, 1982). The human gene 
encoding CSF-1 has now been cloned (Kawasaki et al., 1985); 
sequence analysis of the cDNA clone indicates a pre-pro-CSF-1 of 
252 residues with a 32 residue leader peptide. Further proteolytic 
processing reduces the pro-CSF-1 peptide to a 20 kDa form. 
Incubation of bovine marrow adherent cells with either CSF-1 or 
multi-CSF will induce up regulation of the number of CSF-1 
receptors (Bartelmez and Stanley, 1985). Recent reports indicate 
that the C-fms proto-oncogene ia closely related co the receptor 
for CSF-1 (Sherr et al., 1985) . This protein is a 170 kDa 
transmembrane glycoprotein with tyrosine kinase activity 
(Rettenmier et al., 1985a; Rettenmier et al., 1985b). The c-fms
gene is found on the human chromosome 5 (Heisterkamp et al ,
1983), and a deletion m  the long arm of this chromosome is 
associated with a syndrome m  which patients are predisposed to 
certain types of cancer such as myeloid leukaemia (Sokal et al , 
1975)
The macrophage-granulocyte factor, (CSF-2), is a glycoprotein that 
has been purified from endotoxin-treated mouse lung (Metcalf,
1985) The factor has now been cloned from three species, mouse, 
gibbon ape, and humans A mature protein of 127 residues (14 kDa) 
is produced by the human and gibbon ape (Wong et al , 1987) and 
there is 54% a m m o  acid homology between mouse and human CSF-2 
(Wong et al , 1985, Cantrell et al , 1985) CSF-2 are widely 
produced in the body and probably play an important role in 
resistance to infections
Hematopoiesis, the production of white and red blood cells which 
are short-lived, is carried out on a complex and enormous scale 
(There are 100 times more cells in the bone marrow of an adult than 
there are people in the world) All blood cells originate from a 
small common population of multipotential stem cells that is formed 
during one short interval during early embryonic life which 
maintains hematopoiesis by an extensive capacity for self
i
generation Dearrangement of this complex process of blood cell 
formation does occur and results m  a range of medically important 
diseases from anaemia to leukaemia However, the hematopoietic 
system usually functions with remarkable fidelity as a consequence 
of regulation by an overlapping system of control mechanisms 
including control by CSFs
1 10 Bomb e s m
Bombesm is a 14-ammo acid peptide, produced and released by most 
human small cell lung cancers (Moody et: al , 1981, Sorenson et 
al , 1982, Erismann, et al , 1982) B o m b e s m  was initially 
isolated from the skin of the frog (Anastasi et al , 1971)
Bombesm-like immunoreactivity m  mammals has been located m a m l y  
m  the brain, lung and intestine (Walsh et al , 1978, Moody et al, 
1978 Wharton et al , 1978) A mammalian analogue of B o m b e s m  has 
now been isolated from the p r o c m e  gastrointestinal tract (McDonald 
et al , 1978), and the cDNA cloned from a human pulmonary
carcinoid tumor (Spmdel et al , 1984) Bombesin and its analogue 
GRP bind to the same cellular receptors (Moody et al, 1983)
Bombesin is a potent mitogen for 3T3 cells (Rosengurt and 
Sinnett-Smith, 1983) and can stimulate clonal growth of small cell 
lung cancer cells in serum free medium (Carney et al , 1981)
Monoclonal antibodies specific for the C-terminal region of 
bombesin not only inhibit the binding of bombesin to its receptor, 
but also inhibit markedly both the clonal growth of small-cell lung 
cancer cell lines in vitro and the growth of xenografts of these 
cells in nude mice (Cuttitta et al , 1985) Both Bombesin and its 
analogue GRP are both readily found in foetal and newborn lung and 
significant levels are absent in adult lung This suggests that 
these growth factors may have an important role m  foetal lung 
function and perhaps development (Cutz et al , 1981) Lung from 
infants with respiratory distress syndrome show a marked reduction 
m  Bombesin-like immunoreactivity-positive cells (Ghatei et al ,
1983) Carney et al , (1987) have shown most recently that 
several small cell lung cancers lines express high affinity 
receptors for Bombesin or GRP These cells secrete and respond 
m  a very selective manner to the regulatory peptide, but only in 
a serum-free defined medium
1 11 Oncogenes
Almost all oncogenes are altered versions of normal cellular genes, 
and their products are presumed to work at least in part by 
mimicing the products of the cellular genes from which they arose 
"Proto-oncogene" is a term used to describe a gene which shares 
sequences with any of the 20 or so known viral one genes or genes 
which have the potential to give rise to cancer cells (Duesberg,
1985) Many, if not all, oncogenes are now perceived as functional 
components of a mitogenic cascade which is normally controlled by 
growth factors
Ushiro and Cohen (1980) showed that the receptor for EGF was 
associated with protein tyrosyl kinase activity It was previously 
known that the transforming proteins encoded by certain 
retroviruses are associated with a tyrosine specific protein 
kinase Gradually, it was discovered that other growth factor
receptors like insulin (Kasuga et al , 1982) somatomedin c (Jacobs 
et al , 1984) and PDGF (Ek and Heiman, 1982) were also associated 
with tyrosine-specific protein kinase activity By 1983, the full 
extent of the overlap between oncogenes and growth factors became 
apparent (Doolittle et al , 1983, Waterfield et al , 1983)
There are three sites m  a growth control pathway at which 
oncogenic proteins can intervene to deliver a growth stimulus
Firstly, the protein itself might mimic a growth factor The 
interaction of such a protein with a suitable receptor could 
stimulate cell growth m  an autocrine fashion Secondly, the 
oncogenic protein might imitate an occupied growth factor receptor 
and thus provide a mitogenic signal m  the absence of exogenous 
growth factors Thirdly, the oncogenic protein might act on an 
intracellular growth control pathway, uncoupling it from the need 
for an exogenous stimulus Oncogenic proteins have been found to 
interact with all of the above three sites of a growth control 
pathway
The protein product of the v-sis oncogene of simian sarcoma virus 
(SSV) and PDGF share strong homology (Waterfield et al, 1983, 
Doolittle £t al , 1983) It is the PDGF B chain which is closely 
related to the COOH-terminal of the v-sis protein They also 
share a functional similarity in that the v-sis protein can 
compete with PDGF for binding to PDGF receptors (Wang and Williams,
1984) All the data available is consistent with the hypothesis 
that the mature v-sis gene product enters the cellular pathway and 
interacts with the PDGF receptor to cause the unrestricted growth 
of SSV-transformed cells m  an autocrine fashion To date, no 
other oncogenic protein is known to be secreted
The EGF receptor purified from the human tumor cell line A-431, 
shows an almost perfect match with the predicted product of the 
v-erb-B oncogene of the avian erythroblastosis virus (AEV)
(Downward et al , 1984)
Sequence homology has shown that it seems extremely likely that the 
v-erb-B gene was derived from the chicken EGF receptor gene (Lin 
et al , 1984) The EGF receptor is the best characterized growth 
factor receptor (Buhrow et al , 1982) About a 250 a m m o  acid
stretch of the internal domain of the EGF receptor has a striking 
homology with the catalytic domain of the src gene family of 
protein tyrosine kinases; this is in keeping with the known enzymic 
activity of the receptor. The v-erb-B gene product and the EGF 
receptor show 90% similarity. The v-erb-B protein appears to be a 
truncated form of the EGF receptor, which lacks most of the 
external EGF binding domain (Ullrich et al., 1984).
Several types of human tumor show abnormalities in the EGF receptor 
expression. Many squamous cell carcinomas and gliomas have very 
high concentrations of EGF receptor protein. In some cases this is 
apparently a result of amplification of the entire EGF receptor 
gene. Whether the altered expression of EGF receptor played a part 
in the tumorigenesis in these cases is unclear. Other growth 
factor receptors and oncogene products may interact but 
insufficient work has been done to date to say for certain what 
these are.
The third type of oncogene product is one that intervenes in a 
cellular growth control pathway at a post receptor stage. There 
are several of these oncogenes (CF Table 4.) The family of src 
oncogene all encode proteins with protein tyrosine kinase activity. 
These enzymes might phosphorylate proteins which are normally 
targets for the growth factor-activated receptor protein tyrosine 
kinase and thus provide a continuous intracellular mitogenic 
stimulus. The family of ras oncogenes may transduce signals from 
cell surface receptors by regulating adenylate cyclase and thus 
cAmp levels. The c-myc (Persson et al., 1984) and c-fos (Curran 
et al, 1984) genes, which are thought to code for DNA binding 
proteins, (Abrams et al., 1982) are quickly induced upon PDGF 
treatment of resting fibroblasts. Since these proteins are located 
in the nucleus, they may play a role in regulating expression of 
other genes, which are necessary for the mitogenic response (Muller 
et al.. 1984; Duesbery, 1985). The presence of these various 
families argues well for the theory of multistage carcinogenesis 
where activiation of more than one gene is necessary to initiate 
cancer (Balmain, 1985).
Most of the known growth factors are found to be involved in growth 
pathways where oncogene transcripts can occur and lead to growth 
stimulation (Thomas et al. , 1982; Kelly et al, 1983; Muller et 
al., 1984) .
T a b l e  4 : A m p l i f i c a t i o n  o f  p o s t r e c e p t o r  s i g n a l l i n g ,  c a u s e d  b y  o n c o g e n e s ,  m  p a t h w a y s  m e d i a t e d  b y  g r o w t h  f a c t o r s .
Oncogene Effect
myc Reduced cellular requirement for PDGF
Enhanced cellular sensitivity to EGF
ras Regulation of adenyl cyclase
Amplification of EGF signalling
src Enhanced cellular sensitivity to EGF and
insulin
Reference
Kelly et _al., (1983)
Armelin et al., (1984) 
Roberts ejt al. , (1985)
Hurley et al., (1984) 
McGrath e_t al., (1984)
Kamata and Feramisco, (1984)
Balk et al., (1982)
Ref. (Sporn and Roberts, 1985)
1 . 1 2  G r o w t h  i n h i b i t o r s
The growth and division of normal cells is usually well regulated 
by the action of various endogenous stimulators and inhibitors.
One of the basic challenges in the study of growth control is to 
determine the biochemical nature and sites of action of agents that 
can shift cells from one state to another.
Endogenous inhibitors of cell proliferation have been purified from 
several sources, including normal tissues (Assoian et al., 1983; 
McMahon et al., 1982) and conditioned medium from epithelial 
(Holley et al., 1980) and fibroblast cell lines (Hsu & Wang,
1986). Some growth factors in some instances are also inhibitory; 
transforming growth factor-8 is one such growth factor. It is 
also closely related to the BSC-1 growth inhibitor purified from 
the African green monkey kidney epithelial cells (Tucker et al.,
1984). The BSC-1 growth inhibitor has a native size of 25 kDa and 
yields a polypeptide of 12 kDa after reduction, its action is 
apparently autocrine (Tucker et al., 1984; Holley et al, 1983).
TGF-8 and BSC-1 growth inhibitor have the same biological 
activities in that they can stimulate the growth of AKR-2B cells in 
soft agar, inhibit DNA synthesis in monolayer AKR-2B, BSC-1 and 
CCL-64 (mink lung) cells, and bind to TGF-B specific receptors on 
the cell surface.
An inhibitor of hepatocyte proliferation has been purified from rat 
liver (McMahon et al., 1982). This protein reversibly inhibits 
the proliferation of non-malignant rat liver cells, but exerts no 
effect on the proliferation of hepatoma cells.
Different inhibitory factors have been fractionated from 
3T3-cell-conditioned medium, in the 13, 11 (Steck et al., 1982) 
and 45 kDa range (Harel et al., 1983). Secondary cultures of 
mouse embryo fibroblasts produce growth inhibitors of between 12-15 
kDa (Wells and Malluci, 1983). This factor is designated FGR-s 
(13k), for fibroblast growth regulator secreted or shed in a 
soluble form. It is not cytotoxic and its effects on target cells 
are reversible. More recently, Harel et al., 1985, have shown 
that dense cultures of 3T3 cells secrete both inhibitory and 
stimulatory autocrine factors of different molecular weights. The 
inhibitory factor found here is 45 kDa.
A growth inhibitor for Erlich ascites mammary carcinoma cells in 
vitro has been purified from bovine mammary gland The active 
preparation consists mainly of a single peptide (13 kDa) The 
inhibitory protein is found mainly m  lactatmg bovine mammary 
glands (Bohmer et al , 1985, Bohmer et al , 1984) The growth 
inhibitory effect on Ehrlich ascites mammary cells could be 
abolished by EGF and insulin
Other growth inhibitors are also known, like a glycopeptide 
preparation from bovine cerebral cortex cells that inhibits protein 
synthesis and cell growth of normal but not transformed cells 
(Kinders and Johnson, 1982) of 18 kDa, a heparin-like molecule, 
produced by cultured endothelial cells (Castellot et al , 1981)
EGF too, has inhibitory effects on squamous call carcinoma cells m  
culture, but not on primary cultures of human epidermal 
keratinocytes and dermal fibroblasts which it stimulated (Kamata 
et al , 1986)
Most of the work on growth inhibitors has been m  tissue culture 
systems and the activity of these factors needs to be examined in 
vivo before their physiological importance or practical 
application can be evaluated
1.13 Autocrine Growth Factors
The relatively autonomous nature of malignant cells has been known 
for years; that is, they generally require fewer exogenous growth 
factors for optimal growth and multiplication than do their normal 
counterparts (Holly, 1975). To explain this phenomenon, it was 
suggested that cells could become malignant by the endogenous 
production of polypeptide growth factors acting on their producer 
cells via functional receptors, allowing phenotypic response to the 
peptide by the same cell that produces it (Todaro & De Larco,
1978). This process has been termed 'autocrine secretion'.
endocrine PARACRINE A U TO C R IN E
Fig. 3 : Diagrammatic representation of autocrine, paracrine
and endocrine secretion. Regulatory chemical messengers 
such as growth factors are shown in latent form within the 
cell. The thickened, semicircular regions of the cell 
membrane represent receptor sites. (Sporn and Todaro, 1980)
Thus the ability of cancer cells to produce and respond to their 
own growth factors has become a central concept linking oncogene 
and growth factor research. Oncogenes confer growth factor 
autonomy on cells not only by coding directly for autocrine 
peptide growth factors or their receptors, but also by amplifying 
the mitogenic signals generated by a growth factor at its receptor 
(Waterfield e_t al. , 1983; Doolittle e_t a_l. , 1983; Downward et al. ,
1984) .
The first peptides identified as participating m  the autocrine 
pathway are the EGF related TGF-ct growth factors There is a lot 
of data to indicate that human cancer cells produce and release 
TGF-a and have functional receptors for this peptide (Todaro et 
al , 1980, Marquardt and Todaro, 1982, Richmond et al , 1983)
Other peptide growth factors that function via an autocrine 
mechanism m  cancer cells include peptides related to 
platelet-derived growth factor (Huang et al , 1984), bombesin 
(Cuttitta et al , 1985) and TGF-S (Anzano et al , 1985). The 
autocrine mode of growth action however, is not limited to cancer 
cells Arterial smooth muscle cells from very young mouse or rat 
but not from the adult, secrete significant amounts of PDGF-like 
peptides into their extracellular medium (Seifert et al , 1984)
TGF-3 and PDGF are both stored m  circulating platelets, and are 
two of the most active factors regulating both anchorage- 
independent and anchorage-dependent growth of mesenchymal cells 
(Assoian et al , 1983) The kinetics of TGF-3 monolayer 
mitogenicity m  AKR-2B cells (Mouse embryo derived - normal 
fibroblasts) are delayed relative to stimulation with serum or 
other purified growth factors (Shipley et al , 1984) Leof et 
al , 1986, suggests that the monolayer mitogenic action of TGF-3 
on AKR-2B cells may be mediated to a large extent through induction 
of c-sis and PDGF autocrine activity Since most epithelial cells 
are unresponsive to TGF- 3 (Moses et al , 1985), and most lack PDGF 
receptors (Goustin et al , 1985), the lack of stimulation of 
epithelial cells by TGF- 3 may thus be explained Autocrine 
mechanisms for self stimulation may be of critical importance 
during the repair of tissue injury (Walker et al , 1984), as m  
wound healing and during the explosive growth of the early embryo 
(Seifert et al , 1984) only the inappropriate expression of an 
autocrine peptide may be pathological
The most recent version of the autocrine hypothesis includes the 
concept that malignant transformation may be the result not only of 
excessive production, expression and action of positive autocrine 
growth factors, but also the failure of cells to synthesize, 
express or respond to specific negative growth factors they 
normally release to control their own growth TGF-B is a 
bi-functional factor which can stimulate or inhibit cell growth
(Moses et al , 1985) The set of conditions m  a cell determining 
whether the addition of TGF-S is positive or negative for growth is 
complex and cannot always be explained by differences in cell type, 
growth conditions or the concentrations of TGF-B (Roberts et al ,
1985) The loss of negative growth control may result from a 
biochemical lesion m  either the growth inhibitor, its receptor or 
the post receptor signalling pathway (See Section 1 10)
The autocrine hypothesis is therapeutically optimistic, as it 
allows the possibility of restoring growth control to cancer cells 
by replacement of a deleted or defective growth inhibitor
1 . 1 4  B a c k g r o u n d  a n d  p u r p o s e  o f  t h e  w o r k  d e s c r i b e d  i n  t h i s
thesis.
The autocrine hypothesis just described has important implications 
for our understanding of the nature of cancer. It may also have 
practical implications for the technology of culturing human cells.
Routine methods for the culture of human tumor cells would be very 
valuable. For example, individual patients' tumor cells could be 
examined, following surgery, for properties such as response to 
particular chemotherapeutic agents, growth rate, antigen profile 
etc. Assessment of such properties for individual patients could 
help in providing more rational post-operative treatment of 
metastatic tumour deposits. Routine culture methods could also 
provide a wider range of established cell lines, which might 
provide experimental material more relevant to most human cancers 
than those lines currently available. Primary culture of tumor 
cells however, currently meets with limited success, (Dobrynin, 
1963; Giard et al., 1973), and establishment of permanent cell 
lines is a rare event; this is in contrast to the sad fact that 
many of the tumours concerned grow progressively in the patient.
The failure of many human tumors to grow progressively in vitro 
could be due to one or more factors, for example :
(i) Inadequate nutritional/hormonal environment rn vitro;
(ii) Lack of a perfusion system in culture means build-up of 
waste, e.g. ammonia, lactate, CO2 , depletion of 
nutrients and periodic pH/temperature/nutritional 
shock when the cultures are fed;
(iii) Lack of interaction with other cell types and 
intercellular matrix in vitro.
(iv) Possible selection against tumour cells by aspects of 
the in vitro environment, e.g. subculturing methods.
Another possibility, which forms the basis for the investigations 
described here, is that progressive tumour growth may in some cases 
be dependent on substances produced in an autocrine fashion by the 
tumour cells (Sporn & Roberts, 1985). Such substances might be 
present at high local concentrations inside the tumor in vivo, but
may be diluted below effective levels in cultures of low cell 
density, as is usually the case i n  primary cultures
In 1979, Martin Clynes (unpublished observation) demonstrated that 
the human carcinoma line RPMI 2650 showed a marked density 
dependence i e , cell growth, as measured by colony forming 
efficiencies, was virtually eliminated below a certain critical 
cell density or "cut-off point" This observation suggested that 
an autocrine factor might be involved, and further support for this 
idea was provided by the same group m  1982 when McManus and 
Clynes, (1984) showed that feeder layers of RPMI 2650 growing m  
monolayer on the bottom of the culture dish markedly lowered the 
cut-off point of RPMI 2650 cells suspended m  agar above the 
feeders This also showed that direct cell contact was not 
important in this feeder system
The purpose of the work described m  this thesis, was to confirm 
these preliminary experiments, to develop an assay for detection of 
the feeder effect m  cell-free feeder-conditioned medium, to 
attempt to purify and characterize the putative autocrine 
substance(s) and to determine if it/they were identical to any of 
the known growth factors, in particular the transforming growth 
factors TGF-a and TGF-8 The possibility that the feeder effect 
was due to an in vitro artifact, such as removal of toxic 
materials from the medium, had also to be considered

SECTION 2
MATERIALS AND METHODS
I
2 Materials and Methods
It is essential to use ultrapure water in cell culture The water 
used for preparation of all growth media and reagents, was passed 
through a millipore Milli-Q ultrapure water system This system 
consisted of a reverse osmosis system, which, with two prefilters 
removed ionic and non-ionic solutes, and a further purification 
stage with two-ion exchange filters, a carbon filter and a 0 22pm  
cellulose acetate filter The resulting water was of reagent grade 
and was regularly monitored by an on-line conducting meter (10-18 
megohms/cm, was the acceptable resistivity)
2 2 Glassware
All items of glassware which came into contact with tissue culture 
medium and cells were put through a strict washing -and rinsing 
cycle
Glassware containing waste medium from cells was autoclaved and 
rinsed with tap water Glassware and bottle caps were soaked 
separately m  a non-toxic detergent, RBS-25, at 0 2% (v/v) m  warm 
water 1-2 hours later, bottles were scrubbed out by hand and 
rinsed m  tap water Three rinses in reverse-osmosis purified 
water were then followed by a final rinse m  ultrapure water All 
glassware was dried and autoclaved ready for use
2 3 Sterilization
Water, glassware and solutions of temperature resistant chemicals 
(e g PBS A) were sterilized by autoclavmg at 120°C for 20 m m s
Temperature labile chemicals, (e g enzymes, hormones, growth 
factors) were filter sterilized through 0 22jjm sterile disposable 
filters (Millipore Millex-GV, for low protein binding) Growth 
medium and supplements were sterile on receipt
2 1 Ultrapure Water ^
Growth media were made up as shown m  Table 2 1 Before use, all 
media were sterility tested 10-15mls of medium was dispensed into 
sterile universals and incubated at 37°C for 3 days. This 
procedure was found adequate to detect for most forms of 
contamination Antibiotics were not used during routine cell 
culture 1ml Penicillin/Streptomycin (Gibco 043-05140 H) per 
lOOmls of growth medium was used for all large scale animal cell 
culture (See Section 2 11)
Conditioned medium (CM) is medium m  which cells have been growing 
for 24-48 hours Initially medium used for conditioning contained 
5% foetal calf serum However, for subsequent purification of 
factors secreted by the conditioning cells, it was necessary to use 
serum-free medium Cells were generally grown m  25cm2 flasks 
for 3-4 days until about 90% confluent at which stage waste medium 
was removed and cells were extensively rinsed with PBS at 37°C 
Serum-free medium was then added and conditioned for 24 or 48 hour 
periods at which time it was collected and centrifuged at 4000 rpm 
for 15 m m s  and stored at 4°C Subsequent batches of serum-free 
conditioned medium were also collected from these cultures for up 
to 6 days or until the cells began to detach See relevant 
sections for production of CM by large scale methods
2 5 1 Cell Lines
All cell culture work was carried out m  a Class II downflow 
recirculating laminar flow cabinet (Microflow), with strict aseptic 
technique See Table 2 2 for details of cells cultivated
Cell lines were grown in 25cm^ flasks (Cell Cult 32025) or 
75cm2 flasks (Costar 3075) m  the recommended medium See Table 
2 1 for details of medium and supplements Cells were fed every 
two to three days, or when a change m  pH was observed (colour 
change of phenol red indicator m  the medium) On reaching 
confluency, cells were subcultured
2 4 Growth Medium and Conditioned Medium (CM)
s
Table 2 1. . Growth Medium and Supplements
I0X Media Stock Media
Supply
Source
Sterile
Ultrapure
Water
**1M Hepes
Sigma
H-9136
7.5% NaHC03
BDH
30151
2mM
L-glutamine 
I Gibco 
043-05030
MEM
Vitamins
(100X)
Gibco
15F-3162
Sodium
Pyruvate
100mM
Gibco
043-1360
•k-k AMEM 
NEAA 
(100X) 
Gibco 
043-01140
Foetal 
calf serum 
Gibco 
021-6010
MEM - Minimum 
essentiaL Eagle's 
medium
Gibco
042-02501 450 mis 10 mis 11 mis 5 mis - - 5 mis 25 mis
DME - Dulbecco's 
Modified Eagle's 
Medium
Gibco
042-02501 450 mis 10 mis 11.5 mis 5 mis - - - 25 mis
SLM - Earl's 
Balanced Salt 
Solution
Gibco
042-4050 450 mis - 17.5 mis 10 mis 1 1 mis 5.5 mis 22 mis 25 mis
RPMI-1640 Gibco 
042-2511 450 mis 10 mis 11 mis 5 mis - - 5 mis 25 mis
For details of chemicals and solutions from Gibco, refer to Catalogue or write to Gibco Ltd., Unit 4, Cowley Mill 
Trading Estate, Londonbridge Way, Uxbridge, UB8 2YG, Middlesex, England. Tel. (0895) 36355.
> A
Hepes : 4-(2-hydroxyethyl) -1-piperazmeethanesulfonic acid
\ /v
NEAA . Non essential ammo acids
Note : AIL media were brought to pH 7.4-7.6 at room temperature with 1.5N NaOH or 1.5N HC1
Penicillin/Streptomycin (Gibco 043-05140H) Penicillin 10,000 IU/ml streptomycin 10,000 UG/ml was not added 
to growth medium for general cell culturing. P/S was used m  Agar assays and large scale cell culture at 
ImL per 100 mis medium
2 5 2 Sub-culture of Cell Lines
Animal cells grow attached to the bottom of culture vessels, 
immersed m  growth medium and supplemented with 5-10% foetal calf 
serum Upon reaching confluency, cells were enzymatically 
detached using 0 25% Trypsin (Gibco 043-05090) m  PBS* (Oxoid BR 
14a) All solutions were pre-warmed to 37°C
Method
Waste medium was removed from the cells which were then rinsed with 
PBS or trypsin (for every lOmls of growth medium, 2mls of PBS or 
trypsin solution was used) 2mls of 0 25% trypsin was then added 
and incubated with the cells for 10-15 m m s  at 37°C Once a 
single-cell suspension was obtained, growth medium containing 
foetal calf serum (foetal calf serum contains a trypsin inhibitor) 
was added to the trypsin in a 1 1 25 ratio of trypsin growth 
medium
The cell suspension was then transferred to a sterile universal 
( S t e n l m  128A) and centrifuged at 900 rpm for 5 m m s  The cell 
pellet was then resuspended m  5mls growth medium and a cell count 
obtained (See Section below) Cells were then diluted to 10^ or
10^ per ml of growth medium lOmls of cell suspension was added
to 25cm^ flasks amd 20mls to 75cm2 flasks Cells were then 
incubated at 37°C
PBS type A, which is calcium and magnesium free
2 5 3 Cell Counting
A sample of single cell suspension was applied with a pasteur
pipette to a Waber haemocytometer pipette (improved Neubawer) so 
that it was held m  the counting area between the slide and a cover
slip A series of gridded lines were observed at 100 X by
microscope (Fig 2 1) All those cells found m  the 16 squares of
the 4 corner grids were counted Cells found lying on any two of
the 4 outer lines were also counted and the total was estimated
(X) The average number of cells in the 4 corner grids was then
estimated and multiplied by 10^ ( X I O ^ )  This gives number of 
cells per ml of solution
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Adjustments for non-viable cells was determined by a dye exclusion 
test where a 1/5 dilution of trypan blue (Gibco 525) to cell 
suspension was prepared Those cells which take up the blue dye 
are non-viable] The area enclosed below the cover slip and the 16 
squares is 0 lnmr^
CORNEA
SQUWE
(ENLARGEMENT)
- y -
& —r
r ig .  2.1 Diagram of standard Haemocytometer gridded area.
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Table 2 2 .Cell Lines
Cell Line Source Chief Use
RPMI-2650 ATCC (CCL 30)
AProduction of CM. 
Clonopenic/feeder 
assay
Autostimulatory assay 
Large scale 
cultivation.
NRK Ian Pragnall 
Beatson Institute 
for Cancer Research 
Glasgow
TGF assay 
Mycoplasma test
NRK-49F Ian Pragnall TGF-3 assay
AKR-2B Ian Pragnall TGF-ß assay
663 + N Ian Pragnall TGF-a production
A4 31 ATCC CRL-1555 ^'’i-EGF Radioreceptor 
assay
T47D Dr. Denis Headon, 
Dept, of Biochem 
U.C.G , Galway
125I-EGF Radioreceptor 
Assay
CM - Conditioned Medium
Details of Cell Type Growth 
Medium 
(+5% FCS)
Reference
Human squamous 
epithelial cell 
carcinoma of the 
nasal septum.
Very small cells 
which grow in dense 
clusters
Normal rat kidney 
fibroblasts
Clone of NRK
Normal embryo fibro­
blast of the mouse
Myeloproliterative 
sarcoma virus trans­
formed NRK cells
Vulval carcinoma 
(human)
Breast carcinoma 
(human)
MEM
DME
DME
DME
DME
SLM
DME
RPMI-1640
(Moorhead, 1965)
(Moor & Sandberg, 1963)
(Koury & Pragnall, 1982)
(Haigler et al., 1978)
2 6 1 Long term storage of Animal Cells
New cell stocks received from the ATCC* (American Type Culture 
Collection) or other sources, were immediately grown up and then 
frozen m  liquid nitrogen for long term storage Only those cells 
which were m  subconfluent exponential growth phase were suitable 
for long term storage A cell suspension of at least 2 x 10^/ml 
of growth medium was required 1ml of a 10% (v/v) solution of DMSO 
(BDH 282166) m  growth medium was added to 1ml of cell suspension 
m  a slow dropwise manner with continual mixing 1ml of this 
mixture was transferred by pipette to sterile cyrotubes (Sterilm 
35001) The cells were then slowly frozen m  the vapour phase of 
liquid nitrogen for 3 hours, then stored in liquid nitrogen storage 
container until required
2 6 2 Recovery of Frozen Cell Stocks
The required vials of cell stocks were removed from the liquid 
nitrogen storage container and quickly thawed at 37°C Once 
thawed, the cell suspension was transferred to a sterile universal 
with 5mls of growth medium and centrifuged at 900 rpm for 5 m m s  
The cells were centrifuged to remove the cryo-protective agent DMSO 
which may be toxic to the cells The cell pellet was resuspended 
m  5mls of growth medium and transferred to a 25cm^'flask The 
cells were incubated at 37°C for 24 hours Waste medium was then 
replaced with lOmls of fresh growth medium 
* American Type Culture Collection, 12301 Parklawn Drive,
Rockville, Maryland 20852
2 7 Monolayer Assays
Monolayer assays were set up to determine the colony forming 
efficiencies of various cell lines Monolayer assays were also 
used to test different batches of serum
Serial dilutions of single cell suspensions were prepared m  growth 
medium with 1% or 5% foetal calf serum A range of cell 
concentrations from 50 to 10^ cells per plate were usually set 
up Assays were set up in 30mm plates (Cell Cult 31030) with 3mls 
of growth medium and incubated at 37°C and 5% CO2 , 95% air for 
up to 10 days The assays were then stained and colony counts were
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estimated manually or by image analysis (CF Section 2.24.1). The 
colonies were stained using the Leishmanns staining method. See 
following method.
Note : 35mm plates were also used (Corning 25000)
2.8 Leishmann's Stain (BDH-34042)
Monolayer assays were stained as follows. Waste medium was removed 
and cells were gently rinsed in PBS. 1ml of Leishmanns stain (0.3% 
in absolute methanol, filtered through Watmann filter paper No. 1 
before use) was added to 30mm plates and left for 5 mins. 1ml of 
distilled water was added for a further 5 mins. This was then 
removed from the cells which were rinsed well in distilled water 
and then dried. Colony counting was carried out manually or by 
image analysis (CF Section 2.24.1).
2.9 Mycoplasma detection
Unlike contamination by bacteria or fungi, mycoplasma contamination 
of cells is not obvious. Cells which become infected continue to 
grow, but their growth rate slows and they appear granular. They 
can remain like this for some weeks and finally the cells die. 
Routine mycoplasma examination of cell lines was carried out by a 
fluorescent staining method, specific for DNA (Chen, 1977). The 
method used was greatly modified from those in the literature. 
Initially, each cell line was stained up for mycoplasma, but we 
found a variation in background between the cell lines. This 
variation in background may have been due to cell damage caused 
during fixation. We found that NRK cells were very suitable for 
the fixation proceedure used.
Method
Mycoplasma-free stocks of NRK cells were grown overnight on sterile 
cover slips in 1ml of medium at 10^ cells ml"-*-, at 37°C and 
in an atmosphere of 5% CO2 . 2mls of growth medium from cell 
lines to be tested and 2mls of growth medium from control 
(mycoplasma-free NRK) cell line were then added to individual cover 
slips. These cover slips were then incubated for a further 4-5 
days at 37°C and 5% CO2 .
4 8
Fixing and Staining of Cells
The cells on the cover slips were gently rinsed m  PBS A Cells 
were then fixed to the coverslips by immersion m  acetone methanol 
at a ratio of 1 1, at -20°C, and left for 6 m m s  The coverslips 
were removed and thoroughly rinsed m  PBS Hoechst 33258, (Sigma) 
at 0 05 g m l " i n  PBS was added to the cells, so that they were 
completely covered, and left for 10 m m s  in a light-proof sealed 
container at room temperature Excess stain was removed by rinsing 
m  water The coverslip was mounted and sealed onto a glass slide 
(with the cells between the two glass surfaces)
The cells were then observed under oil immersion using 405nm 
light Definite pm-points of fluorescence m  the cell cytoplasm 
indicated the presence of mycoplasma contamination Contaminated 
stocks were disposed of and fresh cultures grown up from stock
2 10 Growth Factor Assays
2 10 1 RPMI-2650 Feeder Assay
It was possible to set up two populations of RPMI-2650 cells m  a 
double layer agar assay system One population of cells was grown 
m  monolayer on the base of the plate (feeder layer), while the 
second population was suspended m  the upper layer of the double 
layer of agar
Method
Feeder layer
Single cell suspensions of RPMI-2650 cells were seeded onto 30mm 
plates (Cell Cult 31030) m  3mls of growth medium with 5% FCS In 
a typical experiment, 6 replicates of the following cell 
concentrations were set up and allowed to attach overnight at 
37°C m  5% C02
[0, 102 , 103, 5 x 103 , 104 , 5 x 104 , 105 , 5 x 105]
The following day, waste medium was removed from the cells just 
prior to the addition of a specially prepared agar growth medium 
mixture
Preparation of agar growth medium and cells for the upper layer
A buffered 2X medium as follows and lOOmls of 1 4% agar (Bacto 
Difco) were prepared m  advance
Buffered 2X medium - MEM [10X] 20 Omls
Sterile ultrapure H2O 76 Omls
ImM HEPES 4 Omls
7 5% NaHC03 2 2mls
1 5N NaOH/1 5N HCl(to ph 7 4) 2 Omls
The agar was melted and transferred to a water bath at 41°C*
The agar growth medium (AGM) was prepared as follows
AGM Buffered 2X medium 52 Omis
FCS
Penicillin/Streptomycin
L-Glutamme
20 Omis
1 Omis
1 Omis
Growth medium 16 Omis
The agar and AGM solutions were allowed to equilibrate to 41°C, 
then 50mls of 1 4% agar was mixed with 90 mis of AGM. 2mls of this 
mixture was quickly added onto each plate of RPMI-2650 feeder 
layers and allowed to set at room temperature (waste medium should 
be removed) The remaining AGM + Agar was returned to the water 
bath at 41°C
A single cell suspension of RPMI-2650 cells was then prepared at 9 
x 104 cells per ml m  growth medium Dilution m  AGM + Agar in a 
ratio of 1 25 mis of cells 2 5mls of AGM + agar gave 3 x 104 
cells per ml 1ml of this mixture was quickly added to the 
required plate Triplets were set up for each feeder cell 
concentration with or without cells in the upper layer
The plates were allowed to set at room temperature for about 10 
m m s  Small dishes of water were included with each assay to 
prevent drying out of agar, the assay was then carefully covered 
with tin foil and incubated at 37°C and 5% CO2 for up to 14 
days Colonies greater than 50 m in diameter were counted and the 
average colony forming efficiencies estimated (CF Section 2 24 2)
* The temperature of AGM is very important At 41°C, the agar 
remains liquid and will not scald the cells when they come m  
contact with one another
See Fig 2 2 for diagrammatic representation of Feeder Assay 
System
See Plate 1 and 2 for photographs of RPMI-2650 cells m  monolayer 
and m  agar
S1
Fig. 2.2 : RPMI Feeder Assay
30mm plate
f
Monolayer of RPMI-2650 incubated 
at 37°C and 5% C02 overnight.
Waste medium was removed
2mls of Agar growth medium + Agar at 
41°C was added and allowed to set at 
room temperature
1ml of AGM + Agar with the required " 
concentration of RPMI-2650 cells at 
41°C was then added to the pre-set base 
layer
Plates were then incubated at 37°C 
and 5% C02 . Colonies >50jjm were counted 
after 10 days.
Plate 1 : RPMI-2650 cells subconfluent culture in 
monolayer Ph 1 (150X) magnification.
Plate 2 : RPMI-2650 anchorage-independent growth in agar 
Ph 1 (150X) magnification.
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2.10.2 Transforming Growth Factor Assay (TGF)
This assay was set up on the basis that if TGFs are present they 
will induce non-transformed cells to form colonies while suspended 
in a semi-solid matrix like agar (De Larco and Todaro, 1978). A 
series of experiments using various normal fibroblast indicator 
cell lines and several optimization experiments were set up during 
the development of the TGF assay. The following protocol is the 
optimized version of the TGF assay routinely used in this thesis.
Method
50mls of 1.548% Agar (Bacto Difco) was melted and brought to 
44°C. It was then mixed with the following agar medium mixture 
also at 44°C.
Buffered 2X medium 50..0 mis
FCS 10.,0 mis
ImM HEPES 2,.0 mis
Penicillin/Streptomycin 1,.0 ml
L-Glutamine 1..0 ml
7.5% NaHC03 1,.0 ml
Growth Medium 14 .0 mis
(Buffered 2X medium used here is similar to that used in Section 
2.10.1 except that it is made up with DME [10X] instead of MEM 
[10X]). The agar and AGM was mixed well and 1.5mls was quickly 
transferred to 30mm plates. The remaining AGM and agar was 
returned to the water bath at 41°C and the plates were allowed to 
set at room temperature.
0.6mls of test samples and controls were then added to sterile 
universals. A single cell suspension of NRK cells at [6.6X] the 
final concentration per plate was prepared (4 x 104 cells/ml of 
growth medium). This gave a final concentration of 6 x 103 cells 
per plate. 0.15ml of 4 x 104 cells per ml was added to 0.6ml of 
sample in the sterile universal. 0.75 mis of AGM + agar was 
quickly added to the sample and cells. These were mixed well and 
the total volume of 1.5mls was transferred to the pre-set base 
layer. Growth medium was set up as a control. Small trays of 
water were added to each assay which was then covered with tin foil
and incubated at 37°C and 5% CC>2 for up to 8 days Colonies 
greater than 50wn were then counted and the colony forming 
efficiency determined (CF Section 2 24 2)
Note Samples were usually set up in triplicate as follows 
2mls of test sample (CM/control)
0 5ml cells 
2 5mls AGM + agar
These were mixed well and 1 5mls was quickly added to each 
of three plates where the base layer was already set It 
is important to use a suitably tested batch of serum m  the
lTGF assay See Plate 3 and 4* for photographs of NRK m  
agar and monolayer culture
2 10 3 TGF-B assay
A modification of the TGF assay was developed which was used to 
determine the presence of TGF-B m  samples The indicator cell 
line used here was NRK-49F It was used at a concentration of 2 x 
104 cells/plate (i e 1 3 x 10^/ml stock concentration) The 
formation of large colonies in the presence of 2ng/ml EGF after 
9-10 days incubation at 37°C and 5% CO2 indicated the presence 
of TGF- B like growth factor(s) Colonies > 50>Jm in diameter were ? 
counted and the colony forming efficiency determined (CF Section 
2 23 2) See Plate 5 for photograph of NRK-49F in monolayer 
culture
2 10 4 RPMI-2650 Autocrine Assay
RPMI-2650 autocrine assay follows a similar protocol to that for 
TGF and TGF-B assays However, 3 x 104 cells per 30mm plate (2 x 
10^ cells/ml growth medium, stock) were used The assay was 
incubated at 37°C and 5% CO2 for up to 10 days at which time 
colonies > 50jjm m  diameter were counted as m  Section 2 24 2
2 11 Large Scale Cell Culture
Growth factor(s) secreted by RPMI-2650 cells were found at very low 
levels m  CM tested m  the autostimulatory and TGF assays For the 
purpose of purification and characterization of these growth
factor(s), we found it necessary to produce large volumes of CM 
The following methods were examined
2 11 1 Roller bottle
Bellco roller bottles with an internal surface area of 670cm2 
were washed dried and autoclaved and brought to 37°C before use 
Roller bottles were first rinsed with about lOmls of growth medium 
then seeded with 100-120mls of growth medium with 5% foetal calf 
serum and 1ml of penicillin/streptomycin (P/S) and 5 x 10^ cells 
ml'l of the required cell type The roller bottle head space was 
gassed with a steady flow of 5% CO2 Air, gas mixture for up to 10 
seconds The roller bottle was then transferred to a Bellco roller 
bottle apparatus at an initial speed of 0 25 rpm for 24 hours and 
then increased to 0 75 rpm To achieve a satisfactory 
well-dispersed monolayer, it was essential to bring roller bottle 
and medium to 37°C before use
These conditions yielded an 85-95% confluent monolayer after 3 
days, at which time the culture was set up for collection of CM
Preparation of CM
Waste medium was removed and the cells rinsed twice with 50mls of 
PBS (at 37°C) lOOmls of medium, without foetal calf serum, with 
lml P/S, at 37°C was added and conditioned by the cells for 24 
hours The medium was then collected, centrifuged at 4000 rpm for 
15 mins and stored at 4°C 5 subsequent 24-hour batches of CM
were usually collected, at which time the cells were beginning to 
detach The remaining cells were trypsmized as described m  
Section- 2 5 2, to remove them before autoclavmg and washing of the 
roller bottle could be carried out prior to subsequent use
2 11 2 Suspension Culture
1 litre and 500ml suspension culture vessels were used (Techne, 
Cambridge, U K )  These employed glass enclosed magnetic bars 
suspended from the lid of the vessel, this system prevents grinding 
of the cells on the bottom of the vessel See Fig 2 3 for diagram 
of suspension vessel
Method
Culture vessel and magnetic stirrer were washed and dried (see 
Section 2 2) The glass surfaces which would come m  contact with 
the cells were siliconised to prevent cell adherence Sigmacote 
(Sigma SL-2) was added to the vessel and swirled around, until all 
internal surfaces and stirrer were fully coated The excess 
solution was poured off (and stored for subsequent runs) The 
vessel was dried, rinsed 3 times in ultrapure water, dried and 
autoclaved Before use, the vessel was rinsed in growth medium and 
brought to 37°C
100-120mls of MEM with 5% foetal calf serum and 1ml P/S with 5 x 
105 RPMI-2650 cells was added to the 500ml vessel or 200mls of 
the above to the 1 1 vessel The head space was gassed with a 
steady flow of 5% CO2 Air, gas mixture for up to 10 seconds The 
cells were stirred at 30 rpm at 37°C on a Techne stirrer base 
(MCS-1044) It was necessary to feed the suspension cultures every 
2 days by replacing half the growth medium as follows The vessel 
was removed from the stirrer base and the cells allowed to settle 
by gravity It was then possible to remove 50% waste medium from 
above the cells with a sterile pipette The same volume of growth 
medium with 5% foetal calf serum and P/S was then added
Cell counting and CM collection
A 2ml homogeneous sample of cells was carefully removed from the 
suspension culture vessel and centrifuged at 900 rpm for 5 m m s  
Waste medium was removed and 5mls of 0 25% Trypsin was added to the 
cell pellet This was incubated at 37°C until a single cell 
suspension was obtained The cells were then counted on a 
haemocytometer, see Section 2 5 3 This method of counting was 
found to give consistently accurate results
After 5 or 6 days m  culture, the suspension culture yielded >
Q10° cells from a 500ml vessel or twice this concentration from a 
1 1 vessel At this stage, the culture was ready for the 
collection of CM The vessel was transferred to the laminar flow 
cabinet where the cell clumps settled on the bottom of the vessel 
Waste medium was carefully removed by a pipette until about 20mls 
remained Care was taken not to disturb the cells The cells were
then transferred to a universal The vessel was rinsed twice with 
15mls PBS which was also transferred to a universal The cells 
were pelleted at 900 rpm for 4 m m s  The cell pellets were pooled 
and rinsed twice m  15mls PBS This helped remove most traces of 
foetal calf serum The cell pellet was finally resuspended m  
lOOmls MEM for a 500ml vessel or 200mls MEM for a 1 litre vessel, 
without serum, with 1ml P/S per lOOmls growth medium at 37°C CM 
batches were collected at 24 hour or 48 hour intervals for up to 8 
days See Plate 6 and 7 for photographs of RPMI-2650 m  suspension 
culture
Fig. 2.3 * Suspension Culture Vessel
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2 11 3 Microcarrier Culture
The culture of anchorage dependent cells on dextran beads allows a 
high ratio of cells to medium to be achieved This system consists 
of a spinner vessel with a stirrer, as m  suspension cultures, and 
small beads kept m  suspension by gentle stirring This system was 
set up on a trial basis, using 500ml spinner vessels CM was 
collected from RPMI-2650 cells grown on a variety of microcarrier 
beads available on the market
(Pharmacia II 32125) 
( " KF 35315)
( " HL 24905)
(KC Biological)
Method
Cytodex 1 
Cytodex 2 
Cytodex 3 
Geli-bead
0 3g of each microcarrier was hydrated m  30mls of PBS for 3 hours 
The beads were washed once with 30mls of PBS and autoclaved The 
PBS was then replaced with 30mls of growth medium with 5% foetal 
calf serum at 37°C This was then transferred to the suspension 
vessel A 10ml single cell suspension of RPMI-2650 cells at 6 x 
10^ per ml m  growth medium at 37°C was then added to the beads 
m  the suspension vessel The head space was gassed with a steady 
flow of 5% CO2 air for up to 10 seconds The culture vessels was 
then placed on a stirrer base with intermittent stirring at 37°C 
(30 seconds at 40 rpm every 4 1/2 mms) This allowed the cells to 
attach evenly to the beads Intermittent stirring was continued 
for 3 hours, at which time the volume of medium was brought to 
lOOmls and the culture turned to continuous stirring at 30 rpm 
(The speed at which the beads were stirred was that speed at which 
the beads remained m  suspension without clumping) A small sample 
of beads was removed daily to examine the extent of cell growth
Note All glassware surfaces which came m  contact with the cells 
and beads were siliconised (as already described for suspension 
cultures)
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CM Collection
When all the beads were about 90% confluent, they were allowed to 
settle m  the culture vessel About 80mls of waste medium was 
gently removed with a sterile pipette The beads were then 
transferred to a universal and the vessel was rinsed twice with 
15mls PBS which was also transferred to a universal The beads 
were gently pelleted at 800 rpm for 4 m m s , and all pellets were 
pooled The beads were rinsed twice with 15mls PBS The pellet 
was then resuspended m  lOOmls growth medium without serum with 1ml 
P/S, at 37°C This was then transferred to the culture vessel 
and stirred at 30 rpm at 37°C CM was collected at 24 hr and 48 
hr intervals for up to 7 days (An accurate method for cell 
counting was not determined) See Plate 8 and 9 for photographs of 
RPMI-2650 cells m  microcarrier culture
Plate 3 : NRK anchorage-independent-growth in agar 
(TGF assay) Ph 1 150X magnification.
6 1
Plate 4 : NRK monolayer culture.
Ph. 1. (150X) magnification.
Plate 5 : NRK-49F monolayer culture.
Ph. 1. (150X) magnification.
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6 : Growth of RPMI-2650 cells in suspension culture
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Plate 7 : Large RPMI-2650 colony in suspension culture :-
0.55-0.6mm diameter. Ph. 1. (150X) magnification.
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Plate 8 : Growth of RPMI-2650 cells in microcarrier 
culture (Cytodex 3) - 3 hrs Ph.1. (150X) 
magnification.
Plate 9 : RPMI-2650 cells in microcarrier culture (Cytodex 3) 
24 hrs. Ph. 2. (300X) magnification.
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2 12 Ultrafiltration
{
Concentration of large volumes of CM was carried out by 
ultrafiltration The stirred cell method was used (Amicon No 8499 
- 400ml capacity chamber) Standard procedures were used m  setting 
up the ultrafiltration cell Various molecular-weight cut-off 
membranes were used
YM 30 (Amicon) 30,000 cut-off
YM 10 (Amicon) 10,000 cut-off
YM 5 (Amicon) 5,000 cut-off
YM 2 (Amicon) 1,000 cut-off
Method
CM batches were ultrafiltered through a YM 2 membrane until a [10X] 
concentrate was obtained The retentate and samples of filtrate 
and unconcentrated CM were then filter-sterilized and assayed for 
autocrine and TGF activity The 1000 retentate, IR, was used for 
most purification procedures
Ultrafiltration of RPMI-2650 CM through a series of membranes of 
various molecular-weight cut-offs was used to help determine the 
relative size of the autocrine and TGF activity molecule(s)
Method
Each of 4 batches of 130mls of CM was ultrafiltered through one of 
the 4 membranes [10 X] retentâtes were obtained Samples of 
retentâtes and filtrates were collected A fifth batch of CM was 
processed as follows
The YM 30 filtrate was passed through YM 10 from which a [10 X] 
retentate was collected The YM 10 filtrate was then passed 
through YM 5 and a [10 X] retentate was collected The YM 5 
filtrate was finally passed through YM 2 until a [10 X] retentate 
was obtained
All of the above retentâtes and filtrates were centrifuged at 4000 
rpm for 15 m m s  and filter sterilized Samples were then stored at 
4°C and subsequently assayed for TGF, TGF 6 and autocrine
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activity, and for protein content
The following abbreviated versions of ultrafiltered CM fractions 
have been used m  experimental detail
Conditioned Medium - CM
30.000 retentate - 30 R
30.000 filtrate - 30 F
10.000 - 3000 retentate - 10 - 30R
10.000 retentate - 10 R
10.000 filtrate - 10 F
5.000 - 10,000 retentate* - 5 - 10 R
5.000 rententate* - 5 R
5.000 filtrate - 5 F
1.000 - 5,000 retentate - 1 - 5 R
1.000 retentate - I R
1.000 filtrate - 1 F
Note All retentâtes were ultrafiltered to 10 X, unless otherwise 
stated
It was found that the protein content of 5 R retentate was 
lower than the protein content of 30 R, 5 R and 1 R retentâtes 
This indicated that this particular batch of YM 5 membranes may 
have been leaky to proteins
2 13 Dialtrafiltration
Before fractionation of CM by column chromatography could be 
carried out, it was necessary to make the CM up m  1M acetic acid, 
the elution buffer for Bio-Gel P-60 and P-30 This was generally 
achieved by dialysis against 1% acetic acid to reduce the salt 
content, followed by lyophilization The sample was then dissolved 
m  1M acetic acid This was a lengthy process The time involved 
in dialysis was reduced by dialtrafiltenng the CM
Method
A 10ml sample of [>50 X] CM was brought to lOOmls with 1% acetic 
acid The sample was ultrafiltered to lOmls through YM 2 The 
10ml retentate was again brought to lOOmls with 1% acetic acid and 
ultrafiltered. This process was repeated up to 4 times The final 
10ml retentate was then lyophilized and reconstituted in 1ml 1M 
acetic acid The sample was centrifuged at 4000 rpm for 15 m m s  
to remove acid insoluble protein and fractionated by column 
chromatography
2 14 Dialysis
lOmls samples of concentrated CM was extensively dialysed against 
10 volumes of 1% acetic acid A low molecular weight, benzoylated, 
1,200 cut-off tubing was used (Sigma D7884)
Before use, the required length of tubing was boiled for about 4 
m m s  m  lOmM EDTA It was then washed m  distilled water 
Dialysis was carried out at 4°C The acetic acid was changed 
twice daily for 3 days
CM was then removed and centrifuged at 400 rpm for 15 m m s  to 
remove insoluble protein and lyophilized The protein was then 
reconstituted m  the required buffer For column chromatography 
1M acetic acid was used, for HPLC 0 1% TFA and for all bioassays
I O Cand ■L/1-,1-EGF radioreceptor assay, growth medium
2 15 Lyophilization
Lyophilization of CM at various stages of purification was carried 
out, using a 4 5 L Consol freeze dryer (Virtis) Samples were 
routinely frozen to -30°C overnight The freeze drying cycle was 
then commenced and generally lasted for 36 hours
A solvent trap, based on liquid nitrogen, removed harmful solvents 
from the vacuum before they reached the pump All HPLC fractions 
contained a mixture of TFA and acetonitnle and were freeze dried 
using the liquid nitrogen solvent trap
2 16 Bio-Rad Protein Microasay
0 2ml dye reagent concentrate (Bio-Rad 500-0006) was added to 0 8ml 
of standards and appropriate dilutions of samples with either MEM 
or 1M acetic acid in clean Eppendorfs Reagent and samples were 
then mixed thoroughly
A standard curve using BSA (Sigma A7031) 1- 25 g ml'-*- of working 
buffer was prepared for each assay Absorbance at OD595 was read 
for all standards and samples. Readings were taken after 5 mins 
and before 60 mins Protein concentration of samples were read 
from the standard curve
2 17 1 Acid Stability
Samples of CM were brought to pH 3 6 with 1 5N HC1 and left for 1 
hour at 37°C They were then brought to pH 7 5 with 1 5N NaOH 
Acid unstable protein was removed by centrifugation at 4000 rpm 
for 15 m m s
2 17 2 Dilutions
Samples of CM were diluted as required with growth medium without 
foetal calf serum Samples of CM concentrated to [10X] by ultra­
filtration were filter sterilized and diluted to [X] before 
assaying as required
2.18 Column Chromatography
Fractionation of RPMI-2650 and 663+N CM was carried out by column 
chromatography using Bio-Gel P-60, 100-200 mesh (Bio-Rad 150 1640) 
and Bio-Gel P-30, 100-200 mesh (Bio-Rad 150 1340) gel bed. This 
procedure gave an approximate molecular weight of the growth 
factor(s) present in CM. 1.5 x 90cm columns were set up according 
to standard requirements using a downward flow system, equilibrated 
with 1M acetic acid at room temperature. Bio-Gel P-60 was run at 
5mls per hour and Bio-Gel P-30 was run at approximately lOmls per 
hour, fractions of 8mls were collected on a fraction collector (LKB 
2070 Ultrorack II). A steady flow of buffer was maintained by use 
of a peristaltic pump (Pharmacia P-l). The void volumes were 
determined using Blue Dextran (Sigma 0-5751) and the column 
calibrated with the following molecular weight markers : BSA (Sigma 
A-8531) 66kDa; Carbonic anhydrase (Sigma C-5024) 29kDa; Cytochrome 
C (Sigma C-7150) 12.4kDa; and Bovine aprotinin (Sigma A-3886) 
6.5kDa. (See Fig. 2.4 for standard curve).
Sample preparation
CM from RPMI-2650 or 663+N cells was concentrated by 
ultrafiltering through a YM 2 (1000 cut-off) membrane. [500 X] 
samples were prepared from RPMI-2650 CM and [200 X] samples were 
prepared from 663+N CM. Samples were then extensively dialysed 
against 1% acetic acid, lyophilized and reconstituted in 1M acetic 
acid. The sample was then centrifuged at high speed to remove 
particulate and insoluble protein before being applied to the 
column.
Note : The concentration factor of CM samples differed for most 
column runs.
Fraction analysis
Up to 30 fractions (8 mis) were collected. 0.8ml samples were 
removed for protein analysis using the Bio-Rad Microassay (Section 
2.16). All remaining fractions were then lyophilized and 
reconstituted in 3mls growth medium - FCS. The fractions were 
serially filter-sterilized through a Millex-GV filter and assayed 
for TGF, TGF-6 and autocrine activity.
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Fig. 2.4 Bio-Gel P 30 calibration curve
Average fraction vol = 7.83 mis 
Void volume = 52 mis
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Analysis of the fractions in the 12^1-EGF radioreceptor assay was 
carried out on lyophilized fractions which were reconstituted m  
about 200pl of growth medium without FCS (Section 2 20)
7 1
2 19 3H-Thymidine incorporation Assay
Cell growth was measured by the extent of 3H-thymidine (Amersham , 
AD438D) incorporation into DNA by various treatments NRK cells 
were used in a standard assay to determine the elution profile of 
RPMI-2650 CM mitogenic activity from Bio-Gel P-30
Method
Cells were set up at 104 cells per 16mm well in 24 well plates 
(Costar 3524) m  1ml growth medium with 5% foetal calf serum 
Plates were incubated at 37°C and 5% CC>2 for 3 days Waste 
medium was then removed and the cells rinsed with 1ml growth medium 
without foetal calf serum Cells were then refed with 1ml growth 
medium without foetal calf serum and incubated for 2 days at 37°C 
and 5% CC>2 lOOjjl of test samples or controls and 20pl of 
3H-thymidine (6 6 Ci ml'-*-) was added to each well and incubated 
for a further 24 hours at 37°C and 5% CC>2
Method of Counting .
Waste medium was removed and stored for radioactive waste disposal 
Wells were rinsed with 1ml cold PBS and 4 rinses with 1ml cold 5% 
trichloroacetic acid, followed by two rinses with 1ml EtOH 
(absolute alcohol) Plates were then dried at 37°C 1ml of 0 3N 
NaOH was added to each well and the plates were incubated at 37°C 
for 30 m m s  0 5ml of this solution was removed from each well and 
transferred to a scintillation vial (Beckmann 158715) containing 
100 1 of 1 5N HC1 6mls of scintillation cocktail [Toluene Triton 
X-100, 2 1 v/v, containing 0 4% 2,5-diphenyloxazole (PPO) (BDH 
14615)] was then added to the vials which were shaken well before 
counting on a Beckmann Scintillation Counter (69 3409Y)
2 20 ^-^I-EGF Radioreceptor Assay
EGF and TGF-a bind to the EGF receptor on a mole per mole basis 
(Todaro et al , 1980) Concentrated samples of CM from RPMI-2650 
and 663+N (a known TGF-a producer) were compared m  this assay
Method
105 A431 cells were inoculated m  16mm wells m  24 well plates 
(Costar 3524) m  1ml DME + 10% FCS and incubated overnight at 
37°C in an atmosphere of 5% CO2
Waste medium was removed and the cells rinsed twice with cold 
binding buffer (DME) + 1% BSA (Sigma A7030)
Standards and test samples were prepared m  cold binding buffer and 
kept on ice until required l^I-EGF (Amersham 1M 124) was 
prepared to give a final activity of 0 OIjjCi per IOOjjI of binding 
buffer The concentrations of EGF (Sigma E1257) for the standards 
were as follows lOjjg ml*^f 500 ng ml'^ -, 100 ng ml*^, 50ng 
m l l O n g  ml'l, 5ng ml"^, lng ml'^
100 1 of each standard was added to triplicate wells with 100 1 of 
■*-2^l-EGF Total volume of medium per well was 200jjl All 
samples were mixed well by swirling and incubated at 20°C for 1 
hour 100m1 of test samples were also set up as for standards with 
IOOjjI ^^I-EGF an(j incubated at 20°C for 1 hour
The supernatant was removed and the cells rinsed three times with 
lml cold binding buffer The cells were then dissolved with 1ml 
0 5N NaOH and transferred to counting vials (Rohren tubes 55 44 
Starsted) The wells were rinsed out twice with 0 5ml of 0 5N NaOH 
which were also transferred to counting vials
The samples were then counted for 1 min on a mini gamma counter 
(LKB 1275)
A standard curve was drawn up of counts versus concentration of 
EGF Unknowns were then read from this curve
Note
(1) Stocks of EGF were prepared m  450jjl quantities m  PBS at 10 g 
ml'^and stored at -20°C A freshly thawed stock was used 
m  each experiment.
(2) Results were estimated as percentage inhibition of each sample 
over total -^2^I-EGF bound in the absence of a competitor
« . , < rCPM bound per sample - non-specific CPM 1An,% inhibition = 1 r------ ---- s-------------------x 100JTotal CPM - non-specific CPM
2 21 Hormones and growth factors used m  ^^I-EGF ra(j10- 
receptor assay
Three hormones, Progesterone, Dexamethasone and g-estradiol were 
obtained from Dr Denis Headon from University College Galway , 
were incorporated m  the 12^1-EGF radioreceptor assay They were 
examined for their effect on EGF receptors on A431 and T47D cells
Method
A431 cells and T47D cells were set up at 10^ cells per 16mm well 
(Costar 3524) m  1ml DME with 10% foetal calf serum The following 
concentrations of hormones were set up for each cell type
Progesterone** (stock 20jjg rnl"^ - EtOH) 3 lng ml'^
Dexamethasone (stock lOOjjg ml"-*- EtOH) lOOng ml"^
g-Estradiol (stock 20*jg ml EtOH) 2 7ng ml'^
The plates were incubated for 24 hours at 37°C and 5% CO2
Waste medium was removed and all cells were rinsed twice with 1ml 
cold binding buffer (DME) with 1% BSA IOOjjI IjjCi ml'^
125I-EGF (370 kilo BQ) was added to each well IOOjjI  of DME was 
added to each well Non-specific binding of ^2^I-EGF was 
determined m  the presence of excess unlabelled EGF where IOOjjI  of 
10pg ml"I EGF was added to the well The assay was completed 
as described m  Section 2 20
Dept of Biochemistry, University College, Galway
Stocks were reconstituted m  a small amount of EtOH and growth
medium to 20^g ml'l Progesterone, lOOjjg rnl'^ - Dexamethasone,
-120jjgjnl B-Estradiol 
See Plate 10 and 11 for photographs of A431 and T47D m  monolayer 
culture
Plate 10 : A431 monolayer culture
Ph. 1 (150X) magnification.
Plate 11 : T47D monolayer culture
Ph. 1 (150X) magnification.
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2 22 Reverse Phase HPLC
Concentrated CM from RPMI-2650 and 663+N cells were dialysed, 
lyophilized and reconstituted m  0 1% tnfluoro acetic acid (TFA) . 
Insoluble particulate matter was removed by centrifugation at 4000 
rpm for 15 mins
Method
Samples filtered through"0 45 m filters (Millipore SJ HV LOLNS) 
were injected onto a C^gjJ-Bondapak column (30cm x 3 mm, Waters 
Associates) The column was equilibrated with 20% acetonitnle/
0 1% TFA and run at a flow rate of 0 8ml/min A gradient of CH3 
CN from 20-40% for 100 mms, was followed by a 15 min linear 
gradient to 60%, then to 80% for over 5 m m s  Fractions of 1 6ml 
were collected, lyophilized and reconstituted in growth medium 
All fractions were assayed for activity (use of solvent
trap during lyophilization) Fig 2 5 shows gradient profile of 
acetonitrile
Bio-Gel P-30 fractionation of RPMI-2650 CM showed two peaks of 
activity m  the TGF-3 assay These two pools of activity were 
lyophilized and independently run on HPLC Every third fraction 
from each run was then reconstituted m  growth medium and assayed 
for autocrine, TGF-g and ^2^I-EGF competition activity
Note All solvents were analar HPLC grade and were filtered and 
degassed before use (Organic solvents through sartorious SM 1107 
and aqueous through Sartorious SM 11106 filters)
A number of known growth factors were incorporated into the TGF, 
TGF-3 and autocrine assays, at the concentrations shown m  Table 
2 3 800mls of concentrated RPMI-2650 CM was fractionated on 
Bio-Gel P-30
Fractions 10-18 were pooled, lyophilized and reconstituted m  5mls 
DME + lmg % BSA (100%) [X] , [1/5X] and [ 1 / 1 0 X ] dilutions were also 
prepared and tested m  the assays Combinations of growth factors 
and RPMI-2650 CM were assayed, using the following concentrations
2 23 Known growth factors m  TGF, TGF-ft and autocrine assays
TGF-a 5ng ml'l
TGF- 3 0 2ng ml'l
EGF 2 Ong ml*-*-
PDGF 1 Ong ml*l-
RPMI-2650 1/5
Table 2 3 Known Growth Factors m  TGF, TGF - 8 and autocrine
assays
Growth Factor Reconstitution Working Concentration
Buffer* m  Assays
TGF-aGenentech 50^g ml"1 DME 50, 5 and 0 5ng ml ^
55 1 g
TGF-g R & D Research 10yg ml'^-4mM HC1 2 , 0 2 , 0 02ng ml“ 1
(PD-1)
EGF Sigma E4127) lOyg ml'lpBS 2ng ml ^
PDGF (Sigma P8147) 200ng ml_1DME lng ml
Bombesin (Sigma B5508) 308ng ml'^-DME lOnM
FGF (Sigma F1881) lOOjjg ml^DME 100, lOng, ml-1
* Reconstitution buffer contained lmg % BSA Controls contained 
lmg % BSA,
2 24 Colony Counting
2 24 1 Monolayer
Monolayer assays stained with Leishmann's stain as in Section 2 8 
were counted by hand or by image analysis
The image analysis system consisted of placing the stained plate on 
a light source The image of the plate was then relayed to a 
television screen by camera The image analyser (AMS 40-10) was 
calibrated to pick up those colonies with more than 20 cells The 
conditions used for counting were stored m  a memory recall bank 
for subsequent assays All counts were collected on a print-out
2 24 3 Agar Colonies
Colonies were counted on an inverted microscope (CK Olympus Tokyo) 
at 100X or 40X All colonies greater than 50jjm in diameter after 
at least 8 days m  culture were counted An eye-piece graticule 
was graduated using a stage micrometer and was then used to size 
colonies
All agar plates were viewed, superimposed upon a transparent 
gndded disc with 4mm2 grids An average of 30 grids were viewed 
for each 30mm plate The total number of colonies per plate was 
then estimated and percentage of the colony forming efficiency 
determined
CFE « )  - g° colonies per plate 
No. cells plated
The mean CFE (%) for each sample, which was usually set up m  
triplicate, was determined and the standard error calculated
I 2 (Ei )2
I E x  - n
V n-1SEM = ± — ------— ---------
f r
Where n = number of replicates per sample 
x — CFE of each replicate per sample 
E = sum of the samples from 0 to n 
SEM = standard error of the mean
% 
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Because of the long assay period involved and the many parameters 
which had to be examined, most experiments were performed only in 
triplicate. Standard error of the mean is recorded to give an idea 
of variability; because only triplicate cultures were examined, 
some of the results would not be significant in students t test, 
but they provided valuable information on trends, which allowed 
further progress.
M i n u t e s
Flg- 2- Graph of Acetonitnle gradient used in HPLC 
Analysis
Flow rate 0.8ml/min. 
Collected 1.6ml fractions
SECTION 3
RESULTS
3. Results
3 1 Effect of RMPI-2650 feeder layers on growth of RPMI-2650 
cells
A double layer agar assay system as described m  Section 2 10 1 was 
set up m  which one population of RPMI-2650 cells - feeder cells, 
formed the feeder layer and a second population of RPMI-2650 cells 
was suspended in the upper layer
The data in Fig 3 1 and Table 3.1 show that the presence of a
feeder layer of RPMI-2650 cells influences the CFE of similar cells 
in the double layer assay system At low feeder cell 
concentrations, no enhancement is found although a slight 
inhibition over the control showed up a number of times At 5 x 
103 to 5 x 104 cells a stimulation of cell growth is observed 
m  the upper layer At higher feeder concentration, the level of 
stimulation decreases Since the upper cell layer is physically 
separated from the feeder layer, these results imply that a 
diffusible autostimulatory substance was produced m  proportion to 
the number of cells present m  the feeder layer Removal of an
inhibitory substance by the feeder cells could also be an
explanation for the stimulation of RPMI-2650 colony formation
Table 3 1 RPMI-2650, double layer agar feeder assay
RPMI-2650 feeder CFE (%) RPMI-2650*
layer concentration 3 x 104** 2 x 104**
0 1 02 ± 0 18 1 36 ± 0 39
102 0 42 ± 0 12 0 56 ± 0 22
103 0 76 ± 0 08 1 0  ± 0 48
5 x 103 2 19 ± 0 12 2 46 ± 0 42
104 2 71 ± 0 12 3 6 ± 0 26
5 x 104 2 5 ± 0 60 3 7 ± 0 89
105 1 1  ± 0 32 4 17 ± 0 72
5 x 105 0 96 ± 0 73 3 27 ± 0 27
* ± S E M , (n - 3)
* * Cone cells plated m  the upper layer per 35mm plate
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Fig. 3.1 RPMI-2650, double layer agar feeder assay
a  2 x 104 , □  3 x 104 cells plated m  the 
upper layer.
Before we could eliminate the possibility that RPMI-2650 cells were 
removing an inhibitory substance from the assay system described m  
Section 3 1, it was necessary to show that the feeder effect could 
be transmitted via a cell-free conditioned medium (CM) collected 
from RPMI-2650 cells RPMI-2650 cells were grown m  monolayer for 
up to 4 days m  25cm2 flasks Waste medium was removed when the 
flasks were 90% confluent and replaced with growth medium This 
conditioned medium was collected from these cultures at 18, 22 and 
26 hours Unconditioned medium was used as a control at time 0 
These samples were tested m  the double layer assay system as 
m  Section 2 10 4 and the results of this experiment are shown m  
Table 3 2
3 2 Effect of RPMI-2650 conditioned medium on RPMI-2650 cells
m  a double layer agar assay system
Table 3 2 Effect of RPMI-2650 conditioned medium on RPMI-2650 
cells m  a double layer agar assay system
RPMI-2650 CM CFE (%) RPMI-2650*
Conditioning time 4 x 103** 1 5 x 103**
0 0 0
18 hrs 9 35 ± 1 87 6 94 ± 2 32
22 hrs 13 71 ± 3 31 9 61 ± 3 67
26 hrs 10 15 ± 0 96 11 48 ± 1 22
* ± S E M (n = 3)
* * Cell concentration (per 35mm plate) m  upper layer
These results confirmed that RPMI-2650 cells were secreting a 
stimulatory factor into their extracellular environment, and that 
the physical presence of feeder cells was not necessary for the 
feeder effect The slight reduction m  CFE found m  26 hr CM 
compared to 22 hr CM have been due to nutrient depletion found at 
higher cell concentrations or to production of inhibitors This 
assay was termed the RPMI-2650 "autocrine" assay
A serial dilution of RPMI-2650 cells was set up in the double layer 
agar assay system to determine a suitable indicator cell 
concentration as described m  Section 2 10 4 The results of this 
experiment are shown in Table 3 3
Table 3 3 The effect of RPMI-2650 indicator cell concentration 
m  the double layer agar assay
3 3 The effect of RPMI-2650 indicator cell concentration m
the double layer agar assay
Cone RPMI-2650 cells 
per plate
CFE (%) RPMI-2650*
105 TNTC**
3 x 104 2 38 ± 0 40
104 1 80 ± 0 40
3 x 103 0 90 ± 1 20
103 0
0 0
* ±S E M (n=3)
* * Too numerous to count
The above results show that at concentrations above 10  ^ cells per 
plate, it becomes difficult to make accurate colony counts The 
colonies are too numerous with many merging to form clumps of 3 and 
4 colonies At 103 cells per plate no colonies grew For 
subsequent autostimulatory assays, we decided that the most 
suitable indicator concentration for RPMI-2650 cells was 104 - 3 
x 104 cells per plate This gave a low background which should 
not mask the autocrine activity of RPMI-2650 CM
3 4 The effect of Agar and Agarose on the CFE of RPMI-2650
cells m  the double layer assay system
A series of concentrations of RPMI-2650 cells were set up m  the 
double layer assay using two anchorage independent support 
matrices^ The assays were set up using agar (Bacto Difco) and 
Agarose Type II (Sigma A677) using the procedure described m  
Section 2 10 4 The results from this experiment are shown m  
Table 3 4 1
Table 3 4 1 Clonal growth of RPMI-2650 cells m  Agar and Agarose
Cone RPMI-2650 cells CFE (%) RPMI-2650*
per plate Agar Agarose
3 x 104 1 93 ± 0 5 3 7 ± 0  3
104 2 20 ± 0  3 3 3 ± 1 1
3 x 103 2 50 ± 0  8 3 2 ± 0 8
0 0 0
* ± S E M  (n = 3)
These results showed that RPMI-2650 cells grew more efficiently m  
agarose than in agar This was an important finding which showed 
that the use of agar m  the autostimulatory assay would provide a 
reduced background CFE of RPMI-2650 cells in comparison with 
agarose We also found that high concentrations of colonies in 
agarose tended ( m  a random manner, m  some assays) to 
disintegrate, thus making accurate counting difficult We 
therefore concluded that agar was a more suitable matrix than 
agarose for the autostimulatory assay
Collection and ultrafiltration of RPMI-2650 CM m
serum-free media
RPMI-2650 CM was initially collected m  MEM with 5% foetal calf 
serum However, for the purpose of purification of the autocrine 
factor, it was necessary to collect serum-free CM from RPMI-2650 
cells In this experiment, RPMI-2650 CM was concentrated to [10X] 
by ultrafiltration in Section 2 12 The retentate and filtrate 
were assayed in the autocrine assay and the results are as shown m  
Table 3 5 1
Table 3 5 1 RPMI-2650 autocrine assay
Test Sample CFE % RPMI-2650*
RPMI-2650 CM control 
RPMI-2650 30,000 retentate [10X] 
RPMI-2650 30,000 filtrate 
Unconditioned MEM-FCS
,1
0 68 ± 0 44 
2 80 ± 0 09 
0 64 ± 0 20 
0 42 ± 0 20
* ± S E M (n = 3) of 104 cells per 35mm plate
This experiment was important because it demonstrated that 
RPMI-2650 CM could be collected m  serum-free media thus 
facilitating further purification. It also illustrated that the 
autostimulatory substance(s) had a molecular weight m  excess of 30 
kDa and excluded trivial explanations of the CM effect, such as 
removal of the conditioning cells of toxic substances
3 6 Effect of growth conditions and passage level of indicator
cells on RPMI-2650 autocrine assay
RPMI-2650 CM collected from roller bottle cultures as described m  
Section 2 11 1 was ultrafiltered to [10X] through YM 30 and YM 2 
Amicon membranes as described m  Section 2 12 Samples of the 
retentates and filtrates were collected The remaining YM 30 
filtrate was passed through the YM 2 membrane to give a [10X] 
retentate with all those molecules ranging m  sizes between 1 and 
30 kDa The samples were filter sterilized and the retentates 1R, 
30R and 1-30R were then diltued m  growth medium All the samples 
were subsequently assayed m  the autocrine assay using two passage 
levels of RPMI-2650 cells In Table 3 6 1 the RPMI-2650 indicator 
cells were taken from 3-day log-phase cultures and in Table 3 6 2 
the RPMI-2650 indicator cells were taken from confluent cultures
The results as shown m  these experiments indicate that the growth 
phase at which the indicator cells are used is very important The 
cells taken from the log phase of growth as shown m  Table 3 6 1 
showed the dilution effect of RPMI-2650 CM, while the cells taken 
from confluent cultures m  the stationary phase gave mixed 
stimulation results with the dilution curves of RPMI-2650 cells 
It seems therefore, that the growth phase from which the indicator 
cells are taken is more important than the passage level of the 
cells The careful pretreatment of RPMI-2650 autocrine indicator 
stocks is very important m  this assay-
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Table 3 6 1 The effect of RPMI-2650 CM on different passage
levels of log phase RPMI-2650 cells
RPMI-2650 CM CFE (%) RPMI-2650
Test sample
i
P 40** P 58**
30,000 retentate [10X] 1 41 ± 0 09 1 85 + 0 24
f i  II [ 5X] 1 49 ± o 37 1 51 + 0 08
I f  If [ X] 0 56 ± 0 05 0 94 + 0 08
30,000 filtrate 0 18 ± 0 01 0 31 ± 0 12
1,000 retentate [10X] 2 14 ± 0 13 1 64 + 0 24
I I  I t [ 5X] 1 74 ± 0 07 1 42 + 0 25
f f  I t t X] 0 31 ± 0 08 0 77 + 0 17
1,000 filtrate 0 10 ± 0 04 0 21 + 0 03
1,000-30,000 retentate [10X] 0 16 ± 0 06 0 19 + 0 01
f t  f t f t [ 5X] 0 21 ± 0 03 0 37 + 0 06
f f  f t f t [ X] 0 25 ± 0 09 0 39 ± 0 04
Control CM untreated 0 53 ± D 0 65 + 0 05
Control medium 0 15 ± 0 02 0 37 + 0 01
* ± S E M (n = 3) of 3 x 104 cells per 30mm plate
* * Passage level of indicator cells
Table 3 6 2 The effect of RPMI-2650 CM on different passage
levels of confluent indicator RPMI-2650 cells
RPMI-2650 CM
Test sample CFE (%) RPMI-2650*
104 2 x 104 4 x 104
Passage No - 36
1,000 retentate [8X] 0 06 ± 0 02 0 10 ± 0 04 0 05 ± 0 02
[4X] 0 20 ± 0 00 0 28 ± 0 10 0 02 ± 0 10
[ X] 0 16 ± 0 02 0 20 ± 0 05 0 56 ± 0 05
Control CM untreated 0 01 ± 0 02 0 02 ± 0 00 0
Control medium ND** ND 0
Passage No 56
1,000 retentate [8X] 0 15 ± 0 05 0 38 ± 0 10 0 38 ± 0 09
[4X] 0 43 ± 0 05 0 33 ± 0 11 0 34 ± 0 09
[ X] 0 58 ± 0 02 0 04 ± 0 02 0 30 ± 0 05
Control CM untreated 0 11 ± 0 02 0 01 ± 0 02 0 17 ± 0 02
Control medium ND ND 0
* ± S E M  ( n = 3 ) o f  the concentration of indicator cells shown
* * Not determined
3 7 1 Effect of serum on RPMI-2650 cell growth m  monolayer
The ability of RPMI-2650 cells to detect differences in foetal calf 
serum concentration was determined with monolayer cultures of 
RPMI-2650 cells The cells were grown m  35mm plates in growth 
medium with 5% and 10% foetal calf serum Various cell 
concentrations were set up The results for 3 x 103 and 103 
cells per plate are shown m  Table 3 7 1
Table 3 7 1 Effect of serum concentration on the growth of 
RPMI-2650 cells in monolayer
Cone RPMI-2650 Number of colonies per plate (X102)
cells per plate 5% PCS 10% FCS
3 x 103 15 72 ± 1 4 18 4 ± 1 8
103 9 60 ± 1 9 10 9 ± 1 5
0 0 0
These results show that RPMI-2650 cells grow well m  medium 
supplemented with 10% foetal calf serum Cell growth is in 5% 
foetal calf serum is almost as good as growth m  10% serum. This 
indicated that for routine cell maintenance it was more economical 
to use 5% foetal calf serum, thus halving the cost of serum while 
only reducing cell growth by about 10%
3 7 2 Serum batch testing with RPMI-2650 cells m  monolayer
Foetal calf serum is an important component of growth medium in 
cell culture Batches of serum differ greatly in their basic 
components so it is important to work with a batch which has been 
proven to work well for the particular cell line and assay system 
involved
We received several batches of foetal calf serum One of these 
batches was tested m  the TGF-assay (See 3 8 4) and found to be 
suitable for work with RPMI-2650 cells and the TGF assay Table 
2 7 2 shows the difference m  growth of RPMI-2650 cells, between a 
good working batch - 30Q, and a new batch B6 7, at 5% serum 
concentration
Table 3 7 2 Serum batch testing with RPMI-2650 cells m  
monolayer
Cone RPMI-2650 cells RPMI-2650 cell growth*
per 16mm well
B7 6 30Q
104 94 00 ± 15 7 161 20 ± 64 67
103 1 50 ± 0 9 10 37 ± 0 98
102 1 02 ± 1 4 2 26 ± 1 53
* Cells were stained with Leishmann's stain 2, and counted by image 
analysis 2 Counts are expressed as area m  "picture cells'
These results show that the new batch B6 7 is not as effective as 
the working batch 30Q m  stimulating cell growth
3 8 1 Development of the TGF assay
Since there has been much recent interest m  the so-called 
"transforming growth factors" as autocrine regulators, it was of 
interest to determine if RPMI-2650 CM with autocrine activity 
contained such factors Three normal fibroblast cell lines as 
described m  Table 2 2 were examined for their suitability in the 
TGF assay which was set up as described in Section 2 10 2 
Positive TGF samples were prepared in CM collected from a known TGF 
producer cell line, 663+N. This CM was collected m  two media 
types DME and SLM (see Table 2 1) The results of this experiment 
are shown m  Table 3 8 1.
Table 3 8 1 Different CM collection media and different
cell lines m  the TGF assay
Test sample CFE (%) 
NRK
of indicator ce 
NRK-49F
11 line* 
AKR-2B
663+N CM (SLM + 5% FCS) 
" (DME + 5% FCS) 
Control (SLM + 5% FCS) 
(DME + 5% FCS)
47 0 ± 8 3 
6 3 ± 2 2 
21 3 ± 0 7 
0
1 20 ± 0 05 
0 83 ± 0 04 
0 28 ± 0 09 
0 36 ± 0 10
3 16 ± 0 29 
1 26 + 0 36
0 98 ± 0 10
1 83 ± 0 28
* S E M (n = 3) of 1 2 x 103 NRK, 5 x 104 NRK-49F and 
10^ AKR-2B indicator cell concentrations
These results indicated that NRK cells responded better to the 
presence of TGF activity than NRK-49F and AKR-2B indicator cells 
These results also showed that SLM gave an undesirably high 
background m  comparison to DME when examined in the NRK assay
NRK was chosen as the indicator for routine TGF assays since it was 
felt that the low background (in the case of DME) would provide a 
more reliable assay
3 8 2 Agar versus Agarose as a semi-solid matrix m  the
TGF-Assay
The TGF assay was prepared as described in 2 10 2 using two 
semi-solid matrix types agar (Bacto Difco) and agarose type II 
(Sigma-A6877). The effect of CM prepared from 663+N cells m  DME 
was determined for TGF activity as shown m  Table 3 8 2
Table 3 8 2 Agar versus agarose m  the TGF assay
Test Sample CFE (
Agar
%) NRK*
Agarose
663 + N CM (DME) 
Control medium (DME)
13 66 ± 8 5 
0
11 01 ± 7 06 
4 83 ± 0 58
* ± S E M (n = 3) of 1 2 x 103 cells per plate
In this experiment, the most significant finding was that the 
background m  agar is non-existent, while m  agarose the background 
is quite high Here again as in 3 4 1, we found that colonies m  
agarose tended to disintegrate and become very diffuse The reason 
for this is not understood
3 8 3 The effect of passage level of NRK indicator cells in the
TGF assay
Various passage levels of NRK cells were examined in the TGF assay 
663+N CM was used as a positive indicator m  the assay as shown 
in Table 3 8.3
Table 3 8 3 Effect of NRK passage level m  the TGF assay
Test sample
Passage 21
CFE (%) R 
24
RK*
26 32
663+N CM 
Control medium
20 62 ± 0 60 
0 02 ± 0 04
9 43 ± 0 29 
0
9 32 ± 1 00 
0 02 ± 0 04
4 11 ± 0 88 
0
* ± S E M (n => 3) of 6 x 103 cells per 30mm plate
This experiment showed that the passage level of NRK used in the 
TGF assay can be very important We found m  general that NRK 
between passage 17 and 23 was most suitable for the TGF assay 
Also, use of stocks, freshly thawed from liquid nitrogen ensured 
relative freedom from contaminants such as mycoplasma
3 8 4 Serum batch testing m  the TGF assay
Two batches of foetal calf serum were examined m  the TGF assay A 
sample of 663+N CM and RPMI-2650 CM were compared for TGF activity 
as described in 2 10 1 The results are shown m  Table 3 8 4
Table 3 8 4 Serum batch testing in the TGF assay
Test Sample CFE (%) 
2 OF**
NRK*
30Q**
663+N CM 
RPMI-2650 CM 
Control medium
1 00 ± 0 7 
0 53 ± 0 3 
0
5 2 ± 0.0 
2 0 ± 0 7 
0
* ± S E M (n = 3)
** Batch number
These results showed that the batch of serum used in the TGF assay 
was extremely important All batches of serum differ m  their 
basic components It is, therefore, important to test a number of 
batches of serum and to use the most suitable batch for all 
subsequent work In this experiment, it was noted at the time of 
counting that the colony size formed in the presence of serum batch 
30Q was far greater than those formed in 20F serum All subsequent 
TGF work and autocrine work was carried out using 30Q serum Other 
batches of serum were used for general cell maintenance
3 8.5 Estimation of a suitable,NRK indicator cell concentration
m  the TGF assay
Many of the TGF assays using NRK as the indicator were set up using 
1 2 x 103 NRK cells per plate However, it became obvious later 
that CM from RPMI-2650 cells was far less effective than 663+N CM 
in the TGF assay At 1 2 x 103 cells per plate, the background 
CFE (%) was 0 This meant that the presence of very low levels of 
TGF activity would not be seen Some batches of RPMI-2650 CM were 
not active m  the TGF assay and this may have been the reason It 
was, therefore, necessary to use concentrated samples of CM. This 
was not practical when testing many batches of RPMI-2650 CM, so we
decided to try to increase the background CFE (%) of NRK m  the
assay and in this way to attempt to detect low TGF activity in 
RPMI-2650 CM. Table 3 8 5 shows the general background CFE of 
various concentrations of NRK cells m  the TGF assay
Table 3 8 5 Effect of plating density on NRK colony formation m
the TGF assay
Number of cells 
plated
CFE (%) NRK*
6 x 103 0 36 ± 0 10
5 x 103 0 21 ± 0 06
4 x 103 0 38 ± 0 23
3 x 103 0
2 x 103 0 11 ± 0 15
* ± S E M (n = 3)
These results show that below 4 x 103 cells per plate the 
concentration of NRK cells is at a critical level (low number of 
colonies or no colonies form) Unless the activity of the CM used 
is more than borderline, it may not always be detected 6 x 103 
cells per plate was subsequently chosen as the cell concentration 
m  the TGF assay.
3 8 6 Effect of duration of conditioning on TGF activity of 
663+N CM
CM was collected from two passage levels of 663+N cells grown m  
25cm2 flasks at 48, 72, 96 and 120 hours These batches of CM 
were then assayed for TGF activity as described in Section 2 10.2 
The results of this experiment are shown m  Fig 3 8 6 and Table 
3 8.6
Table 3 8 6 Effect of duration of conditioning on TGF activity 
of 663 + N CM
Test Sample CFE (%) NRK*
Passage 31 Passage 60
663+N 0 hrs 0 0
I t 48 hrs 0 80 ± 0 30 1 0 ± 0 4
I t 72 hrs 2 20 ± 1 10 3 5 + 0 6
I t 96 hrs 0 60 ± 0 34 2 7 + 1 0
I t 120 hrs 0 06 ± 0 10 1 9 + 1 0
* + S E.M (n = 3) of 3 x 103 NRK cells per 35mm plate
The results described m  Fig 3 8 6 and Table 3 8 6 , shows that 
663+N CM secretes optimum TGF activity up to 72 hours after setting 
up From then on, the production of TGF decreases rapidly in P 31 
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Fig. 3.8.6. TCF activity of CM collected frori 663+N cells 
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3 9 1 Effect of serum m  RPMI-2650 CM m  the TGF assay
Stocks of RPMI-2650 cells were grown to 90% confluency for 48 hours 
in 25cm2 flasks in MEM with 10% foetal calf serum Waste medium 
was removed and the cells were set up with MEM with 5% foetal calf 
serum This medium was conditioned for 48 hours Control MEM with 
5% foetal calf serum was incubated at 37°C for 48 hours These 
two batches of medium were ultrafiltered through YM2 membranes to 
give the following concentrates CM - [5 16X] and unconditioned 
MEM to [ 6 6X] A control of sample of MEM with 10% foetal calf 
serum was also ultrafiltered to [4 14X] Samples of retentâtes, 
filtrates and non-ultrafiltered CM and medium were assayed for TGF 
activity as shown m  Fig 3 9
Table 3 9 1 Effect of serum m  RPMI-2650 CM in the TGF assay
Test Sample
Control MEM 
+ 5% FCS
CFE (%) NRK* 
Control MEM 
+ 10% FCS
CM
+ 5% FCS
Control
5.000 retentate
5.000 filtrate
0
0 5 ± 0 5 
0
0 83 ± 1 04 
2 50 ± 0 00 
0
0 33 ± 0 28 
18 03 ± 0 50 
0
* ± S E.M (n = 3) of 1 2 x 103 cells per plate
These results showed that serum influenced activity in the TGF 
assay The stimulatory effect caused by foetal calf serum m  the
5,000 retentate was small when compared to the effect caused by CM 
from RPMI-2650 cells The presence of even a small amount of 
concentrated serum factors m  CM during purification could cause 
misinterpretation of some of the results
3 9 2 Absorption to membrane filters of RPMI-2650 CM TGF
activity during filter-sterilization
Samples of RPMI-2650 CM concentrated by ultrafiltration were 
examined m  one TGF assay after sterilization Two sterile 
disposable filters were examined It was found that Millex-GS 
filters (Millipore-SLGS 0250S) absorbed up to 80% of the TGF 
activity from the sample while Millex-GV filters (Millipore-SLGV 
025 BS) absorbed 28% of the TGF activity Results are shown m  
Table 3 9 2 The GS filters are composed of cellulose acetate 
while the GV filters are composed of Polyvinylidene difluoride 
Because of the low levels of growth factor secreted into CM, it is 
important to avoid undue loss of activity caused by binding to 
filter membranes as shown here
Table 3 9 2 Absorption of RPMI-2650 CM TGF activity to membrane 
filters during filter sterilization
Test Sample CFE % NRK*
Millex-GV 5 50
Millex-GS 1 56
Control CM 7 70
Control Medium 0 2 0
* 3 x 103 NRK cells per 35mm plate
3 10 Comparison of 663+N and RPMI-2650 CM m  the TGF assay
Samples of CM was prepared from 663+N cells in SLM and from 
RPMI-2650 cells m  MEM The CM was ultrafiltered through either 
the YM5 or YM30 membranes as described m  Section 2 12 and assayed 
in the TGF assay, as shown m  Table 3 10 1 Samples of the 663+N 
YM5 filtrate were taken at three stages during ultrafiltrations, 
after 70mls (i), 170mls (2), and 195mls (3) of filtrate had passed 
through the membrane The 5,000 retentates were diluted to half 
their concentrated form with 5,000 filtrate The 30,000 retentate 
as shown m  Table 3 9 2 was ultrafiltered through the YM5 
membrane(5-30R) The retentates m  this experiment were 
concentrated approximately [10X]
The results m  Table 3 10 1 show that 663+N cells secrete more TGF 
activity than RPMI-2650 cells The dilution effect of 663+N CM
does not appear to be linear This may mean that the upper
sensitivity limits of the assay have been reached The most 
concentrated sample of RPMI-2650 CM m  this case is well within the 
limits of the assay Table 3 10 2 indicates that 663+N CM and 
RPMI-2650 CM contain different proportions of transforming growth 
factors of different molecular weights The 663+N TGF activity is 
primarily in the 5-30 retentate, while the RPMI-2650 TGF activity 
is in the 30 retentate The results m  Table 3 9 1 also show that 
the YM5 membrane is not absolute The efficiency of this membrane 
to retain molecules greater than 5 kDa decreases as the sample is 
concentrated
Experiment 1 as shown m  Table 3 10 1 was repeated one week later 
(Expt 2) and showed that the activities obtained m  this assay can 
vary considerably from assay to assay, but that the profile of 
results are generally similar This underlines the importance of 
including control unconditioned and conditioned media m  each 
experiment, and the desirability m  future work, when stable 
purified forms of the growth factors have been obtained of 
including a standard of known activity m  each experiment
Table 3 10 1 Comparison of 663 + N CM and RPMI-2650 CM m  the
the TGF assay
Test Sample 
663+N CM Control
CFE (%) 
Expt 1 
11 6 8 ± 1 25
NRK*
Expt 2 
15 3 ± 1 92
5F (1) 0 .. _  .. . 0  .
5F (2) 0 33 ± 0 28 0 16 ± 0 28
5F (3) 0 6 6 + 0 76 1 16 ± 0 28
5R [5 6X] 30 22 ± 2 36 48 43 ± 5 80
5R [2 8X] 24 04 ± 3 78 40 91 ± 4 94
Control medium (SIM) 0 0
RPMI-2650 CM Control 0 6 6 ± 0 28 0
5F 0 0
5R [5 3X] 2 16 ± 0 57 3 6 6 ± 0 76
5R [2 6X] 1 00 ± 0 50 1 33 ± 0 76
Control Medium (MEM) 0 0
* ± S E M (n - 3) of 1 2 x 103 cells per 35mm plate
Table 3 10 2 Comparison of 663+N CM and RPMI-2650 CM m  the 
TGF assay
Test Sample CFE (%) 
663+N CM
NRK*
RPMI-2650 CM
5R 0 75 ± 0 36 0 44 ± 0 21
5F 0 08 ± 0 0
3 OR 0 27 ± 0  04 0 69 ± 0 04
30F 0 64 ± 0 19 0 10 ± 0 04
5-30R 0 47 +0 12 0 1 1  ± 0 1 2
CM Control 0 33 ± 0 0 38 ± 0 19
Medium Control 0 0
* + S E M, (n = 3) of 6 x 103 NRK cells per plate
3 11 1 Examination of NRK-49F as an indicator for the TGF-B assay 
In order to specifically detect the presence of TGF-B in 
conditioned media, we used NRK-49F cells m  a TGF assay with 2ng 
ml'l EGF as described m  Section 2 10 3 (NRK cells are 
sensitive to TGF-a and to TGF-a and TGF- 6 together, but not to TGF- 8  
NRK-49F cells are sensitive to TGF- 8  m  the presence of EGF)
Table 3 11 1 shows the effect of various batches of CM on NRK-49F
cells with and without EGF
Table 3 11 1 Examination of NRK-49F as an indicator for the TGF- 8
3 11 Development of the TGF-8 assay
assay
Test Sample CFE (%) 
+ EGF**
NRK-49F*
-EGF
RPMI-2650 CM 5R [6X] 9 40 ± 0 70 0 6 6 ± 0 15
5R [10X] 20 50 ± 0 70 3 40 ± 0 26
663+N CM 0 96 ± 0 10 1 6 6 ± 0 05
NRK-49F CM 5R [10X] 8 1 0  ± 0 60 0 63 ± 0 15
" Control 0 50 ± 0.00 0
Control Medium 0 43 ± 0 05 0
* ± S E M (n = 3) of 2 x 104  cells per 30mm plate
* *  2 ng ml'l
These results show that RPMI-2650 CM contains a TGF- 8 like growth 
factor which is strongly potentiated by EGF 663+N CM activity 
is inhibited by the addition of EGF A sample of NRK-49F CM 
ultrafiltered through YM5 to [10X] was also tested m  this assay 
and shown to be potentiated by the presence by EGF
NRK cells (± EGF) may also be used to detect TGF-8 , but CFE m  
the presence of CM without added EGF is often so high that it 
becomes difficult to reliably detect EGF induced stimulation 
NRK-49F (± EGF) is therefore the indicator system of choice for 
detection of TGF-8 , while NRK is more sensitive m  the detection of 
TGF (a + B)
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3 11 2 Effect of EGF on the RPMI-2650 autostimulatory assay
RPMI-2650 cells were set up for an autocrine assay as described m  
Section 2 10 4 2ng ml"^ EGF was added and samples of CM were 
assayed. A control experiment without EGF was 'also set up The 
results from this experiment are shown m  Table 3 11 2
Table 3 11 2 Effect of EGF on the RPMI-2650 autostimulatory 
assay
Test Sample CFE (%) 
+ EGF**
RPMI-2650*
-EGF
RPMI-2650 CM 30R (MEM) 
” 30F (MEM) 
CM (MEM) 
Control MEM 
663+N CM (SLM)
Control SLM
1 74 ± 0 12 
1 18 ± 0 63 
0.33 + 0 57
0 28 + 0 09
1 83 + 0 04 
1 92 + 0 42
2 8 0 ± 0 09 
0.64 ± 0 20 
0 6 8 ± 0 44 
0 42 ± 0 25 
3 . 0 0  ± 0 06 
2 44 ± 0 96
* ± S E M (n = 3)
** 2 ng ml'l »
This experiment clearly shows that EGF does not stimulate the 
growth of RPMI-2650 cells m  agar, m  fact, there is an indication 
of a possible inhibitory effect, although more data would be needed 
to establish statistical significance
This experiment also shows that SLM medium gives a very high 
background m  the presence of RPMI-2650 cells. This masks the 
stimulatory activity of CM prepared m  it; MEM was therefore used 
routinely for RPMI-2650 CM preparation m  subsequent experiments.
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3 12 Mitogenic activity of RPMI-2650 CM prepared from 
suspension culture
Samples of RPMI-2650 CM collected from a 100ml suspension culture 
system at 24 hour intervals over a 7 day period (see Section
2 1 1  2 ) were assayed for their ability to influence incorporation 
of 3 H-Thymidine into NRK cells as described m  Section 2 19 The 
remaining CM was pooled and ultraflltered to [28X] through a YM5 
amicon membrane and was also tested m  this assay Control medium 
(MEM) and control medium with 10% foetal calf serum were included 
m  the assay The results of this experiment are shown m  Table
3 12
Table 3 12 NRK Mitogenic activity of RPMI-2650 CM collected from 
suspension culture
Test Sample 3 H-Thymidine incorporation (CPM)*
**
RPMI-2650 CM 24 hr 4,520 ± 522 8 8
48 4,937 ± 149 1 0 1
72 4,403 ± 620 83
96 4,514 ± 670 8 8
1 2 0 6,065 ± 990 153
144 7,045 ± 1,800 194
168 5,085 ± 692 1 1 2
[28X] 12,154 ± 1,853 407
Control MEM 2,396 ± 361 0
Control MEM + 10% FCS 8,576 ± 135 257
* ± S E M (n = 3)
** % increase of CPM over control MEM
These results indicated that RPMI-2650 cells contained a mitogen 
active on NRK cells m  monolayer and was concentrated by 
ultrafiltration through a YM5 amicon membrane It is not clear if 
the factor(s) involved are identical to, or different from, the 
factor(s) which stimulate NRK growth in agar
3 13 1 125j.£gp competition activity in RPMI-2650 and 663+N CM
The 125j _£qf radioreceptor assay was set up to detect for EGF 
like molecules m  CM collected from RPMI-2650 cells A lengthy 
method was used m  the initial experiments This method was later 
shortened to the method described m  Section 2 20 663+N CM had
been reported to contain TGF-ct (Dr Ian Pragnall, personal 
communication) A concentrated sample of 663+N CM was incorporated 
into the ■*-25l-EGF radioreceptor assay and was found to compete 
with 12^1-EGF for EGF receptor sites Batches of CM from 
RPMI-2650 cells were ultrafiltered through different cut-off 
membranes to [10X] concentrates, as described m  2 12 These were 
shown to have no effect in the 12^1-EGF radioreceptor assay 
Subsequent experiments were set up with 663+N CM at a top 
concentration of [15X] with 50%, 25% and 10% dilutions, and 
RPMI-2650 CM with a top concentration of [300X] with similar 
dilutions, and were assayed m  the ^25j.gQp radioreceptor assay 
Fig 3 13 1 and Table 3 13 1 shows the results of this experiment
These results show that RPMI-2650 CM and 663+N CM contain 
1 9 SI-EGF competing activity However, it would appear from these 
results that 663+N CM contains up to 20 times more 125j_gQp 
competing activity than an equivalent sample of RPMI-2650 CM For 
example, the results m  Table 3 13 1 show that for a [300X] 
concentrate of 663+N CM, a similar dilution curve is given At 25%
dilution of both 663+N CM and RPMI-2650, they both inhibit about 
62% 125j_£qp binding. This is converted to pg from the standard 
curve i e 3162 pg approx When the concentration factors are 
taken into consideration, it would appear that m  this particular 
case 663+N cells secreted approximately 8 4ng equivalent EGF 
binding factor per ml of growth medium and RPMI-2650 cells secreted 
0 42ng equivalent EGF binding factor per ml of growth medium 
Figure 3 13 2 shows the standard curve of inhibition of binding of 
1 2 5 I-EGF by EGF
Table 3.13 1 Effect of RPMI-2650 and 663+N CM in the 125I-EGF
radioreceptor assay
Cone CM (%) % inhibition of 
RPMI-2650 CM *
L2 5 I-EGF binding* 
* 663+N CM
1 0 0 8 6 27 84 10
50 78 27 74 27
25 62 29 63 99
1 0 45 08 57 94
0 0 0  0 0 0 0  0 0
* All S E M were less than 10%
** Cone RPMI-2650 CM [300x] and 663+N CM [15X]
% Cone. CM
125Fig. 3.13.1 I-EGF binding competition by CM from
RPMI-2650 C3 , and 663+N cellsS.
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Fig. 3.13.2 Standard curve of inhibition of binding 
of 125I-EGF by EGF.
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3 13 2 Presence of EGF receptors on some cell lines
An 12^1-EGF radioreceptor assay was set up as described m  
Section 2 20 A431 cells and 3 other cell lines (NRK, RPMI-2650
and SCC9) were compared for their ability to bind l^i-EGF Non­
specific binding was determined m  the presence of excess 
unlabelled EGF (lOjjg ml*^) The results from this experiment are 
shown m  Table 3 13 2 These results show that A431 cells have the 
most EGF receptor sites NRK and SCC9 cells have less and 
RPMI-2650 cells have a relatively small number of EGF receptor 
sites
Table 3 13 2 l^j-EGF binding to various cell lines
Cell line* Relative counts per m m  
Adjusted to allow for non-specific binding
A431 2759 37
RPMI-2650 45 33
NRK 984 66
SCC9** 642 97
* 10^ cells per 16mm well were plated for each cell line
At this concentration virtually all the cells attached
** Squamous carcinoma cell line (Tongue)
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3 14 1 Dialysis of 663+N and RPMI-2650 conditioned media
It was necessary to dialyse CM prior to fractionation by Bio-Gel 
P 60 m  order to change the medium to acetic acid for column 
chromatography 663+N CM was dialysed against acetic acid and PBS 
as described m  Section 2.14 Table 3 14 1 shows the results from 
this experiment
Table 3 14 1 Effect of dialysis on TGF activity of 663+N CM
Test Sample CFE (%) NRK*
Dialysis 663+N CM 1% Acetic Acid 4°C 10 5***
t ti i it 11 R T ** 4 2
i i i. pBS 4 0 C 2 9
Control CM untreated 6 5
Control medium 0  0
*, 3 x 103 cells per 35mm plate
** Room temperature
* * *  Raw data mislaid, S E M s not available
Some TGF activity is lost by dialysis against PBS at 4°C and by 
dialysis against acetic acid at room temperature A slight 
activation of TGF activity occured during dialysis of 663+N CM at 
4°C It would appear therefore, that dialysis of 663+N CM 
against acetic acid at 4°C is the method of choice
The autocrine TGF and TGF-3 activities of RPMI-2650 CM were shown 
to be stable to dialysis and this procedure was widely used m  the 
preparation of RPMI-2650 CM before fractionation by column 
chromatography
3 14 2 Dilution curve of 663+N conditioned medium
Since column chromatography involves dilution of applied samples, 
it was necessary to establish that the activity detected m  the TGF 
assay was not lost through excessive dilution A sample of 663+N 
CM was diluted m  growth medium and assayed for TGF activity as 
shown m  Fig 3 14 1
These results show that 663+N CM TGF activity dilutes m  a linear 
manner This assay shows however, that at high concentrations of 
663+N CM, a saturation level is reached and above this 
concentration, a mildly inhibitory effect is seen
% Cone 6 6 3  +  N CM ( n ea t  ) 
Q 6 6 3  +  N TGF Activity
Fig 3 14.1 : Dilution curve of 663+N CM TGF activity 
(1 2 x 1Q3 NRK cells)
3 14 3 Dilution effect of RPMI-2650 conditioned medium m  the TGF
and TGF- B assays
A sample of RPMI-2650 was concentrated to [10X] by ultrafiltration 
through a YM2 cut-off membrane as described m  Section 2 12 This
sample of CM was then assayed for TGF and TGF-B activity as shown
m  Fig 3 14 2 and Table 3 14 2
Table 3 14 2 Dilution effect of RPMI-2650 CM in the TGF and TGF- 8
assays
Cone RPMI-2650 
CM
TGF
CFE (%) NRK*
TGF- 8  
CFE(%) NRK-49F*
■** ■**
[10X] 7 45 ± 0 99 1 0 0 1 92 ± 0 3 1 0 0 %
[4X] 7 09 + 1 33 95 1 1 2  + 0 2 62 5
[2X] 4 41 + 1 98 59 1 0 51 + 0 06 26 5
[1 33X] 0 58 + 0 55 7 7 0 23 + 0 06 11 9
Control medium 0 0 0 02 + 0 04 1 04
* ± S E M (n = 3) of 6 x 103 NRK cells per 30mm plate and 2 x
104  NRK-49F cells per plate
** Results shown as % change over 100% control
These results show that RPMI-2650 CM is sensitive to dilution m  
growth medium when assayed for TGF and TGF- 8 activity The TGF 
assay shows that RPMI-2650 CM has reached saturation levels at its 
highest concentrations m  the TGF assay The TGF- 8  activity is 
represented by a linear dilution curve
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Fig. 3.14.2 : Dilution effect of RPMI-2650 CM on NRK □  
and NRK49F a  cells.
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3 14 4 Dilution curve of RPMI-2650 CM m  the autocrine assay
A [10X] concentrated sample of RPMI-2650 CM by ultrafiltration 
through a YM2 amicon membrane was diluted m  growth medium and 
assayed for autocrine activity The dilution curve results are 
shown m  Fig 3 14 3 and Table 3 14 3 These results show that the 
autocrine activity of RPMI-2650 CM is sensitive to dilution m  
growth medium
Table 3 14 3 Dilution effect of RPMI-2650 CM on RPMI-2650 cells
Test Sample CFE (%) RPMI- 2650*
**
RPMI-2650 CM [10X] 2 14 ± 0 13 1 0 0 . —
[ 5X] 1 74 ± 0 07 81 3
[ X ] 0 31 ± 0 08 14 48
Control medium 0 0 15 ± 0 02 0 07
* ± S E M (n = 3) of 3 x 103 cells per 30mm plate
* *  Growth expressed as percentage of [10X] control
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Fig. 3.14.3. Dilution curve of RPMI-2650 CM on 
RPHI-2650 cells
115
3 14 5 Dilution effect of RPMI-2650 CM collected from suspension
culture m  the TGF and autocrine assays
A sample of RPMI-2650 CM collected from suspension culture as 
described in Section 2 11 2 was ultrafiltered through a YM2 amicon 
membrane to [21X] This sample of retentate was diluted m  growth 
medium and assayed for TGF and autocrine activity The dilution 
curve of TGF activity is shown in Fig 3 14 4 and Table 3 14 4 
The autocrine activity is shown in Table 3 14 5
Table 3 14 4 Dilution curve of TGF activity of RPMI-2650 CM 
[IPX] from suspension culture
Test Sample
■■ ■ ■ — ....... — —  ■
CFE (%) NRK*
RPMI-2650 CM [21X] 100 19 5 ± 4.0
90 18 5 ± 1 7
80 14 2 ± 5 6
70 18 8 ± 3 7
60 1 0  8 ± 5 9
50 9 0 ± 5 5
40 4 9 ± 2 5
30 4 8 ± 1 0
2 0 2 18 ± 0  08
1 0 0 95 ± 0 3
Control Medium MEM 0
* ± S E M (n = 3) of 6 x 103 NRK cells per 30mm plate
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Table 3 14 5 Dilution curve of autocrine activity of RPMI-2650
CM f 21X1 from suspension culture
Test Sample CFE (%) RPMI-2650*
RPMI-2650 CM [21X] 100 0 24 ± 0 20
90 0 21 ± 0 09
80 0 15 ± 0 04
70 0 14 ± 0 02
60 0 02 ± 0 03
50 0 04 ± 0 01
40 0 09 ± 0 07
, 30 0 05 ± 0 02
2 0 0 10 ± 0 04
1 0 0 05 ±0.04
Control Medium MEM 0
* ± S E M (n = 3) of 5 x 104  cells per 30mm plate
The dilution curve results of RPMI-2650 CM m  the TGF assay show 
poor stimulation at low CM concentrations The stimulatory effect 
of RPMI-2650 CM is very obvious up to 70% where it peaks Above 
this concentration, the optimum sensitivity of the TGF assay has 
been reached The autocrine dilution curve shows that RPMI-2650 
cells are less sensitive to stimulation by RPMI-2650 CM than NRK 
cells RPMI-2650 cells are insensitive to the presence of low 
concentrations of RPMI-2650 CM Colonies form in some plates and 
very few colonies in other plates A definite stimulatory effect 
is seen only above 70% of a 21X concentrate
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Fig. 3.14.4 Dilution curve of RPMI-2650 CM from 
suspension cultures m  the TGF assay.
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3 15 1 Large scale production of RPMI-2650 CM
It was necessary to culture RPMI-2650 cells on a larger scale than 
with 25cm2 flasks (lOmls per flask) if the large volumes of CM 
(>500mls) needed for purification/fractionation were to be obtained 
routinely m  a reasonable length of time
The trend of TGF activity of conditioned media was shown to be
dependent on cell concentration (see Table 3 15 1, experiment using
25cm2 flasks for collection of RPMI-2650 CM) and time of
conditioning (see Table 3 15 3, CM from roller bottles)
Roller bottles, microcarrier cultures and suspension cultures were 
set up as described m  Sections 2 11 1, 2 11 2, and 2.11 3 Tables 
3.15 2 and 3 15 3 compare activities of CM produced by RPMI-2650 
cells grown m  25cm2 flasks, roller bottles, suspension and 
microcarrier cultures Suspension cultures seem to provide the 
best results, roller bottles are also a very simple and convenient 
method for scale-up The microcarrier method is long and tedious 
to carry out, and the data presented indicate that it has no 
special advantage for this particular application Subsequently, 
large scale production of CM was performed exclusively with roller 
and suspension cultures
Table 3 15 1 TGF activity of RPMI-2650 produced from 25cm2 
flasks
Concentration of RPMI-2650 
cells per 25cm2 flask
CFE (%) NRK *
CM collection after 48 hours
3 x 105 0 53 ± 0 50
1 x 1 0 6 0 6 6 ± 0 75
1 5 x 106 1 0  ± 0 50
2 x 1 0 6 1 6 6 ± 0 28
6 x 1 0 6 1 16 ± 1 60
9 x 106 1 83 ± 0 57
* ± S E M  (n = 3) of 1.2 x 103 cells per 35mm plate
Table 3 15 2 TGF activity of RPMI-2650 CM from large scale cell
culture methods
r
Test Sample CFE (%) NRK*
RPMI-2650 CM Suspension culture
" Microcarrier Cytodex 1 
" Roller bottle 
Control Medium
2 48 ± 0 12 
1 8 6 ± 0 1 2  
1 62 ± 0 56 
0
* + S E M (n - 3) of x 103 cells per 35mm plate
Table 3 15 3 TGF activity of RPMI-2650 CM produced by various 
culture methods
Test Sample CFE (%) NRK*
RPMI-2650 CM roller bottle 24hr 0 26
t t  t t  i t 48hr 1 40
I t  t t  II 72hr 1 6 0
Microcarrier Cytodex 1 1 2 hr 0 26
I t  I t 24hr 0 13
25cm2 flask 1 2 hr 0 06
t t  I t 24hr 0 06
I t  If 48hr 0 26
Control medium (SLM) 0
* 3 3 x 103 cells per 35mm plate
3 15 2 RPMI-2650 CM production by suspension culture
RPMI-2650 cells were set up in suspension culture as described m  
Section 2 11 2 Initial experiments were set up to determine the 
parameters of RPMI-2650 cells in suspension culture Inoculation 
density, spinner speed, feeding and counting methods were examined 
It was found that RPMI-2650 cells grew well m  suspension culture 
The growth curve showed an initial lag period of 24-48 hrs which 
was followed by a period of rapid growth Feeding at 4hr intervals 
was necessary to maintain steady growth, which was greatly reduced 
by nutrient depletion Fig 3 15 1 shows a flow chart of RPMI-2650 
suspension culture systems. A 100ml suspension culture was used as 
a starting culture (S^) , which was subcultured after 8 days into 
two more 100ml suspension cultures (S2 and S3 ), these were used 
to inoculate a 2 0 0 ml suspension culture L^) using half the total 
cell number from S^ and S2 S2 was subsequently used for CM 
preparation which was collected for 7 days at 24 hour intervals 
S3 was used to set up 200ml suspension cultures L2 and L3  
L^, L2 and L3 were used for CM preparation collected for 8  
days at 4 hour intervals
In 100ml suspension culture system 4 x 10^ cells/ml were 
inoculated and grew to about 1 4 x 10^ cells/ml by day 10 
Thereafter, some decrease m  cell numbers occurred In a 200ml 
suspension culture system, 3 0 x 106 cells/ml were inoculated and 
grew to about 2 x 1 0  ^cells per ml after 1 0  days m  culture and 
thereafter some decrease in cell numbers occurred
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Fig. 3.15.1. Growth of RPMI-2650 cells in suspension 
culture
Log conc. cells per culture system 0 
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^ - feed, ^ - collection of CM
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3 15 3 TGF activity of RPMI-2650 CM prepared from suspension
culture
Table 3 15.4 shows the TGF activity of RPMI-2650 CM collected from 
a 100ml suspension culture S3 , as shown m  Fig 3 15 1 100ml
batches of CM were collected at 24hr intervals for 7 days Table 
3 15 5 shows the TGF activity of RPMI-2650 CM collected from 3 
200ml suspension cultures L]_, L2 and L3 200ml batches of CM 
were collected at 48hr intervals for 4 days Samples of each of 
these batches of CM were assayed for TGF activity and the remaining 
CM pooled and ultraflltered through YM5 to [28X] for the 24 hour 
batches and [21X] for the 48 hour batches
These results show that RPMI-2650 cells produce a steady flow of 
TGF activity The [21X] and [28X] concentrates gave very high 
activity as expected These concentrates were used for dilution 
curves (Table 3 14 4 and 3 14 5) and for 3 H-Thymidme assay
Table 3 15 4 TGF Activity of RPMI-2650 CM batches from a 100ml 
suspension culture system at 24hr intervals
(3 1 2  )
Test Sample CFE (%) NRK*
RMPI-2650 CM(S2)** 24hrs 0 78 ± 0 09
48hrs
72hrs
96hrs
1 2 0 hrs
0 55 ± 0 17 
0 47 ± 0 09
0 55 ± 0 04 
0 69 ± 0 17
144hrs 0 75 ± 0 14
168hrs 0 69 ± 0 21
[28X] CM concentrate 
(5,000 retentate) 
Control medium (MEM)
27 48 ± 3 12
0 24 ± 0 15
* ± S E M (n = 3) of 6 x 103 cells per 30mm plate
* *  S3 as m  Fig 3 15 1
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Table 3 15 5 TGF activity of RPMI-2650 CM prepared from 200ml 
suspension cultures
Test Sample CFE (%) NRK*
RPMI-2650 CM Lj** 48 hrs 0 92 ± 0 34
96 hrs 0 61 ± 0 25
" 144 hrs 0 36 ± 0 05
" L2 48 hrs 0 38 ± 0 17
" 96 hrs 1 25 ± 0 33
" 144 hrs 0 92 ± 0 08
" L3 48 hrs 0 78 ± 0 09
" 96 hrs 0 83 ± 0 23
" 144 hrs 1 08 ± 0 43
[21X] CM concentrate 25 99 ± 2 29
(5,000 retentate)
Control Medium (MEM) 0 24 ± 0 15
* ± S E M (n - 3)
* *  L^, L2 and L3 200mls cultures as m  Fig 3 15 1
3 16 1 Bio-Gel P-60 Chromatography of 663+N CM
A sample of 663+N CM was ultrafiltered to [50X] through a YM5 
Amicon membrane as described m  2 12 The [50X] sample was 
dialysed against 1 % acetic acid and lyophilized as described m
2 15 The sample was reconstituted m  1M acetic acid and clarified 
by centrifugation at 5 , 0 0 0  rpm for 1 0  m m s  and manually applied to 
a Bio-Gel P-60 column 28 x 6ml fractions were collected 1 5ml 
lots of each fraction were lyophilized and reconstituted in 1ml 
growth medium, filter sterilized and assayed for TGF activity 0 8  
ml samples of each fraction were assayed for protein content by the 
Bio-Rad Microassay method as described m  2 16 The protein 
profile of 663+N CM eluted from Bio-Gel P-30 is shown m  Fig
3 16 1 and the TGF profile is shown m  Fig 3 16 2
These results show that 663+N CM TGF activity elutes into two peaks 
of activity Pool II is completely separated from bulk protein 
while Pool I is not fully separated from bulk protein Pool I is 
found mainly m  fractions [10-12] and Pool II mainly m  fractions 
15-18
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Fig. 3.16.1 Protein analysis of Bio-Gel P-60 
Chromatography of 663+N CM
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3 16 2 Bio-Gel P-60 Chromatography of RPMI-2650 CM
A sample of RPMI-2650 CM was ultrafiltered to [300X] through a YM5 
Amicon membrane This [300X] 5,000 retentate was dialysed against 
1% acetic acid, lyophilized, reconstituted m  1ml 1M acetic acid 
and clanfed by centrifugation at 5 , 0 0 0  rpm for 1 0  mins as 
described m  Sections 2 12 and 2 15
This sample was then applied to a Bio-Gel P-60 column 30 x 8ml 
fractions were collected 1 5ml samples were removed from each 
fraction, lyophilized and reconstituted m  growth medium These 
samples were filter sterilized and assayed for TGF activity 
Samples were also assayed for TGF activity in the presence of 2ng 
ml'l EGF Protein determination was by the Bio-Rad Micro-assay 
(2 16) The protein profile is shown in Fig. 3 16 3 and the TGF 
and TGF + EGF assays are shown m  Fig 3 16 4 and Fig 3.16 5
These results show that RPMI-2650 CM contains TGF activity which is 
eluted by Bio-Gel P-60 chromatography A distinct peak of activity 
was located around fractions 9 and 10 A calibration curve for
approximate molecular weight determination showed that this 
activity was approximately 7 8 kDa and on analysis of the 663+N TGF 
activity profile, this peak appeared to elute m  a similar 
molecular weight range (differences in fraction volume were taken 
into consideration) The broad band of TGF activity for RPMI-2650 
CM m  the presence of EGF may imply that RPMI-2650 CM contains a 
strongly potentiated EGF factor(s) which is present m  high amounts 
in RPMI-2650 CM The TGF and TGF + EGF activity may be different 
An alternative chromatography gel with a narrower fractionation 
range than Bio-Gel P-60 separated the RMPI-2650 TGF factor(s) more 
clearly Bio-Gel P-30 was subsequently set up This gel has a
fractionation range from 40 kDa to 2 5 kDa Bio-Gel P-60 has a 
fractionation range of 60 kDa to 3 kDa
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3 17 1 Bio-Gel P-30 Chromatography of RPMI-2650 CM
A [550X] sample was prepared as described m  Secion 2 18 and 
applied to a Bio-Gel P-30 column (2 2mg protein) 8ml fractions 
were collected and 0 8ml samples were assayed for protein content 
as described m  Section 2 16 The protein profile is shown m  Fig 
3 17 1 The remaining fractions were lyophilized and reconstituted 
m  3 5mls growth medium and filter sterilized Various bioassay 
activity profiles were then determined The TGF profile of 
RPMI-2650 CM fractionated by Bio-Gel P-30 is shown m  Fig 3 17 2 
The TGF- 8 profile is shown m  Fig 3 17 3 (-EGF), (+EGF) Fig 
3 17 4 and the autocrine activity profile is shown m  Fig 3 17 5
These results show that major peaks of growth activity elute around 
fraction [16] m  these bioassays A second smaller peak of 
autostimulatory activity elutes at a lower molecular weight peak
Samples of each fraction (lOOpl of fractions reconstituted m  3 5ml 
volumes) were also tested m  the ^25j - E G F  radioreceptor assay but 
no activity was detected, possibly because the samples were 
insufficiently concentrated for this assay (in a later column run - 
3 17 2 - this assay was successfully carried out)
m
ic
ro
 
grm
 
pr
ot
ei
n 
pe
r
Fraction  no
Fig. 3.17.1 Protein Profile of RPMI-2650 CM 
fractionated by Bio-Gel P-30 
Chromatography
133
CF
E 
(%
) 
NR
K 
TG
F
F r a c t i o n  n o
Fig. 3.17.2 TGF Activity of RPMI-2650 CM
from Bio-Gel P-30 Chromatography
C
F
E
(%
) 
N
R
K
-4
9
F
 
(+
)E
G
F
 
C
F
E
(%
) 
N
R
K
-4
9
F
 
(-
)E
G
F
Fig. 3.17.3 TGF-g (-EGF) activity of RPMI-2650 CM 
from Bio-Gel P-30 Chromatography
Fig. 3.17.4 TGF-g activity of RPMI-2650 CM from Bio-Gel P-30
Chromatography (NRK-49F-EGF activity of RPMI-2650
i  c  a  1 c  e V i r t r . t n  i i 'v
CF
E 
( 
% 
) 
R
P
M
I-
2
6
5
0
F ra c t io n  no
Fig. 3.17.5 Autocrine activity of RPMI-2650 CM 
from Bio-Gel P~30 Chromatography
3 17 2 inhibition and 3H-Thymidine incorporation of
Bio-Gel P-30 Chromatography of RPMI-2650 CM
A (600X) concentrated sample of RPMI-2650 CM was prepared as 
described in 3 18 1 and eluted from a Bio-Gel P-30 chromatography 
column 8ml fractions were collected 0 8ml samples were assayed 
for protein content as described in Section 2 16 The protein 
profile is shown m  Fig 3 17 6 The remaining sample was 
lyophilized and reconstituted m  2 0 0 p l growth medium lO O P l  
samples were assayed for competition as described m
Section 2 20 The remaining 100 pi samples were brought to 1 3mls 
with growth medium, filter sterilized and assayed for autocrine 
activity and 3 H-Thymidine incorporation into NRK cells as 
described in 2 10 4 and 2 19 Fig 3 17 2 shows the 12^1-EGF 
inhibition profile of RPMI-1650 CM eluted by Bio-Gel P-30 
chromatography and Fig 3 17 8 shows the 3H-Thymidine 
incorporation profile into NRK cells by RPMI-2650 CM from Bio-Gel 
P-30 chromatography
The results m  Fig 3 17 7 and Fig 3 17 8 , show that RPMI-2650 CM 
contains an EGF like molecule which is also mitogenic for NRK 
cells m  monolayer The autocrine assay set up at the same time as 
these assays did not work It would appear from these results that 
the TGF activity seen in Fig 3 17 2 is not necessarily due to TGF-a 
as was the general impression from that experiment, but to a 
separate molecule or molecules distinct from TGF-a Further 
purification was necessary to determine whether the TGF activity 
shown m  Fig 3 17 2 was due to one or more molecules Further 
purification of RPMI-2650 CM was subsequently carried out by HPLC 
as m  Section 3 18 1
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3 18 1 Fractionation of ^S^.ggp competing activity from 663+N 
CM by HPLC
In order to check the feasability of HPLC separation of TGFs m  
RPMI-2650 CM, we first tested the system using CM from the high 
level TGF producer 663+N A 150ml concentrated sample of 663+N CM 
was prepared as described in Section 2 22 and applied to a C18 
yBondapak column m  0 5ml of 0 1% TFA 1 6ml fractions were 
collected, lyophilized reconstituted in 500)j1 growth medium lOOyl
samples were assayed for ^^5j - E G F  competion activity No 
activity was detected A second run using a [300X] sample of 
pretreated CM, as described in Section 2 22, was dissolved m  1ml 
of 0 1% TFA This 1ml sample was run on the column 1 6ml 
fractions were lyophilized and reconstituted in 300pl of growth 
medium KDjul samples were assayed for 125j_pQp competition 
activity A definite peak of activity was detected in fractions 
[16-20] as shown in Fig 3 18 1 Since only fractions 9-54 were 
assayed, the possibility that further activity would have been 
eluted outside these fractions cannot be excluded
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3 18 2 Fractionation of ^-25j_gQp competing and TGF-B activities
from RPMI-2650 CM by HPLC
Bio-Gel P-30 chromatography had separated the TGF activity (of 
RPMI-2650 CM) into two major peaks (Fig 3 17 2) A [700X] sample
of RPMI-2650 CM was subsequently eluted on a Bio-Gel P-30 column
and these two peaks were pooled as follows and applied to a C18
pBondapak column as described m  2 21
Pool I - High molecular weight fractions [8 , 7, 10] at 
approximately 24mls This sample was lyophilized and reconstituted 
m  1ml 0 1% TFA and applied to the HPLC column for the first run
Pool II - Lower molecular weight fractions, [11-20] at 
approximately 80mls, were lyophilized and reconstituted in 1ml 0 1 % 
TFA, was applied to the HPLC column in a second run
Up to 72 x 1 6 ml fractions were collected from each run These 
were lyophilized using a solvent trap Every third fraction was 
reconstituted in 200yl growth medium IOOjjI of this was assayed 
for 12^1-EGF competing activity The results from these assays 
are shown m  Fig 3 18 2 and Fig 3 18 3
The remaining fractions were reconstituted m  1ml growth medium, 
filter sterilized and every alternative fraction was assayed for 
TGF- 8 or autocrine activity Fig 3 18 4 shows the results for the 
TGF- 8 assays No peak of activity was detected m  the autocrine 
assay for either pool I or pool II
The failure to detect autocrine activity could be due to a number 
of factors
(1) Dilution on the HPLC below detectable limits
(2) Irreversible binding to the HPLC column
(3) Instability during the HPLC run
(4) Separation of two or more fractions on the HPLC, which 
need to act m  combination m  order to stimulate 
proliferation of RPMI-2650 cells
Explanations (2), (3) and (4) would imply non-identity of the 
RPMI-2650 autocrine activity with TGF-oi or TGF-3 , since the latter 
activities survived the HPLC procedure Explanation (1) seems 
unlikely, m  the control RPMI-2650 conditioned media used, the TGF-B 
activity was 1 73 CFE units, and the autocrine activity was 0 11 
CFE units This gave a ratio of approximately 17 0 1 (variations 
m  this did occur) The highest peak of TGF-3 activity from the 
HPLC gave a value of 1 36 units, on this basis, a peak of about 
0 085 CFE units for autostimulatory activity would have been 
expected
The conclusion from the results are as follows
(a) Pool I from Bio-Gel P-30 chromatography of RPMI-2650 CM 
contains the majority of the TGF-B activity,
(b) Pool II contains the bulk of TGF-Cl activity, but also a 
significant amount of TGF-B activity
(c) No autocrine activity was detected m  the HPLC fractions
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3 19 1 Ultrafiltration of RPMI-2650 CM
Batches of RPMI-2650 CM were collected from roller bottle cultures 
as described in Section 2 11 1. One large batch of CM was acid 
neutalized as described in Section 2 11 (on a scale-up basis)
Both batches of CM non-acid treated and acid treated, were 
separated into 130ml lots and ultrafiltrered through a series of 
molecular weight cut-off membranes as described in Section 2 12 
Samples from these ultrafiltered fractions were analysed for 
protein content as m  Section 2 16.Fig 3 19 1 compares the protein 
content of each ultrafiltered fraction from the non-acid treated 
and the acid treated batches Table 3 19 1 shows the protein 
values
These results show that the retentates contain most of the protein 
while the filtrates have very little protein Both the non-acid 
treated and acid-treated samples have very similar profiles Some 
of the results are difficult to explain, m  particular, the protein 
values m  the 1000-5000 fraction are very high, while they are much 
lower m  the < 5,000 fraction Some technical problem must have 
arisen m  the preparation of one of these fractions
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Table 3 19 1 Protein analysis of 2 RPMI-2650 CM batches.
untreated and acid neutralized and concentrated by 
ultrafiltration
Test Sample * ;ug protein per ml
untreated acid neutralized
RPMI-2650 1,000 retentate 40 0 0 41 75
I! 1 , 0 0 0  filtrate 0 0 1 0
I 1,000-5,000 retentate 29 30 26.50
I 5,000 retentate 25 75 21 50
I 5,000 filtrate 0 25 0
I 5,000-10,000 retentate 0 75 0 25
I 1 0 , 0 0 0  retentate 35 0 0 39 00
I 1 0 , 0 0 0  filtrate 0 1 2 0 0 1
I 10,000-30,000 retentate 1 1 0 0 17 50
I 30,000 retentate 27 50 35 75
I 30,000 filtrate 62 3 80
Control CM untreated 15 OC 14 56
Control CM acid neutralized ND** 11 50
Control medium (MEM) 0 0
* All retentâtes were concentrated to [10X] 
* *  ND - not done
•1 /  n
3 19 2 TGF, TGF-B and autocrine activity of RPMI-2650 acid
neutralized and ultrafiltered CM
The acid neutralized and ultrafiltered samples of RPMI-2650 CM as 
assayed for protein content in 3 19 1,were assayed for TGF, TGF- 8  
and autocrine activity Fig 3 19 2 and Table 3 19 2 show the TGF 
activity of RPMI-2650 CM m  the various ultrafiltered fractions 
The TGF activity m  RPMI-2650 CM appears to be greater than 30kDa, 
with a small amount of activity escaping into the 30,000 filtrate 
Fig 3 19 3 and Table 3 19 3 show the autocrine activity of 
RPMI-2650 CM Some autocrine activity appears to be lost on acid 
neutralization as shown by the control untreated CM and the control 
acid neutralized CM However, the remaining autocrine activity is 
concentrated by ultrafiltration and appears to be greater than 
30kDa See also Table 3 6 1 for autocrine activity of non-acid 
treated RPMI-2650 CM
Fig 3 19 4 and Table 3 19 4 show the TGF-3 activity of RPMI-2650 
CM after acid neutralization and ultrafiltration These results 
show that without EGF, RPMI-2650 CM contains very little NRK-49F 
stimulatory activity in the retentâtes In the presence of EGF 
however, the TGF- 8 activity of RPMI-2650 CM was strongly 
potentiated Acid neutralization of RPMI-2650 CM appears to 
stimulate TGF- 8 activity m  RPMI-2650 CM as shown in the control 
acid neutralized and untreated CM samples
The overall conclusion from these experiments indicate the TGF,
TGF- 8 like and autocrine activities of RPMI-2650 CM are relatively 
acid stable and of high molecular weight. The fact that they can 
be concentrated by ultrafiltration also establishes that the 
activity of CM m  the autocrine assay is due to production of a 
stimulator rather than removal by the conditioning cells of 
inhibitory factors The loss of TGF activity through the 5,000 
membrane m  the TGF assay is puzzling since the 30,000 and 10,000 
membranes appear to have retained most of this activity even though 
they have larger molecular weight cut-off values In the TGF-3 
assay, the reduction m  activity between the 30,000 fraction to the
1 , 0 0 0  fraction in that order, may imply the interaction of two 
molecules One molecule greater than 30kDa is being inhibited or 
is m  competition with EGF for the stimulation of RPMI-2650 CM TGF-3 
activity by a molecule which is increasingly found m  the lower
molecular weight fractions Analysis of the retentate data m  the 
RPMI-2650 autocrine assay in the student t test showed that the 1 
kDa retentate was significantly different to the 30kDa retentate 
at the 5% significance level.
Table 3 19 2 TGF activity of RPMI-2650 CM, acid neutralized and 
ultrafiltered
¿4
Test Sample* CFE (%) NRK**
RPMI-2650 CM 1R 15 54 ± 1.00
IF 0
1-5R 8 07 ± 0 75
5R 2 10 ± 0 56
5F 0.08 ± 0 . 0 0
5-10R 0
10R 20 89 + 1 20
10F 0 08 ± 0 08
10-30R 9 23 ± 1 20
30R 16 15 ± 0 06
30F 0 41 + 0 14
Control CM untreated 4 53 + 0 70
Control CM acid neutralized 3 83 + 0 50
Control medium (MEM) 0
* All retentâtes and filtrates are X(103) fractionation range
and all retentâtes [10X] concentrates
** S E M (n = 3) of x 103 cells per 30mm plate
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Fig. 3.19.2 TCF Activity of acid neutralized RPflI-2650 
CM after ultraflltration
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Table 3 19 3 Autocrine activity of RPMI-2650 CM acid neutralized
and ultrafiltered
Test Sample* CFE &) RPMI-2650**
RPMI-2650 CM 1R i 0 44 ± 0 04
IF 0 26 ± 0 03
1-5R 0 28 ± 0 06
5R 0 53 ± 0 08
5F 0 18 ± 0 02
5-10R 0 11 ± 0 03
10R 0 60 ± 0 14
10F 0 18 ± 0 06
10-30R 0 28 ± 0 13
3 OR 0 69 ± 0 10
30F 0 24 ± 0 16
Control CM untreated 0 37 ± 0 05
Control CM acid neutralized 0 1 ± 0 01
Control medium (MEM) 0 06 ± 0.00
All retentâtes and filtrates are X(103) fractionation range 
and all retentâtes are [10X] concentrates 
** S E M (n = 3) of 1 8 x 10]4 cexis per 30mm plate
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Table 3 19 4 TGF-S activity of RPMI-2650 CM acid neutralized and
u l t  r a f i l t e r e d .
Test Sample * CFE % NRK- 
2ng ml'1 EGF
49F**
-EGF
RPMI-2650 CM 1R 3 15 ± 0.00 0 31 ± 0 12
IF 0 03 ± 0 01 ‘ 0
1-5R 1 83 ± 0 15 0 13 + 0 03
5R 3 09 ± 0 76 0 07 ± 0.00
5F 0 13 ± 0 03 0
5-10F 0 08 ± 0 02 0
10R 5 77 ± 0 45 0 17 ± 0 12
10F 0 12 + 0.00 0
10-30R 0 34 ± 0 06 0 03 + 0 02
30R 7 26 ± 0 43 0 15 + 0 00
30F 0 13 + 0 04 0
Control CM untreated 1 51 + 0.00 0
Control Cm acid neutralized 2 73 + 0 36 0 01 + 0 01
Control medium (MEM) 0 13 + 0 01 0
* Ail retentâtes and filtrates are X(103) fractionation range 
and retentâtes are [10X] concentrates
** ± S E M (n = 3)
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3 20 Effect of Hormone treatment on EGF receptor levels m  A431
and T47D cells
Progesterone, Dexamethasone and ¡3-estradiol were incubated with 
T47D and A431 cells for 24 hours and examined m  the 125l-EGF 
radioreceptor assay as described m  Section 2 21 Table 3 20 1 
shows the result from three experiments These results show that 
the receptor levels for EGF on A431 and T47D cells are influenced 
by the presence of certain hormones 12^I-EGF binding by T47D 
cells is greatly influenced by progesterone while the binding by 
A431 cells is influenced by Dexamethasone Possible mechanisms and 
biological significance of these results are considered m  the 
discussion
Table 3 20 1 Effect of hormone treatment on the EGF receptor on 
A431 and T47D cells
Test Sample CPM 125I-EGF binding
T47D * A431 'k
Progesterone Expt 1 286 34 ± 46.0 64 2 1012 6 ± 158 5 -13 3
2 260 75 ± 26.0 92 1 1009 7 ± 111 9 4 6
3 191 70 ± 44.0 24 8 ND -
Dexamethasone Expt 1 200 00 ± 23 9 14 7 1709 0 ± 88 8 46 4
2 104 00 ± 35 6 -23 4 1476 ± 109 0 53 0
3 170 20 ± 9 5 10 8 2317 8 ± 54 6 42 4
ß-Eastradiol Expt 1 151 30 ± 25.0 -13 1058 3 ± 191 0 -9 4
2 191 70 ± 40 9 41 2 1040 7 ± 197 1 7 8
3 168 50 ± 28.0 9 7 1593 2 ± 34 4 -2 3
No Hormone Expt 1 174 30 ± 52 0 0 1167 0 ± 73 4 0
2 135 70 ± 11 9 0 964 7 ± 38 4 0
!________  3 153 60 ± 47 6 0 1627 0 ± 117 0 0
* Percentage change over control - no hormone treatment
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3 21 TGF Activity m  normal and tumor bearing rats
In spite of their suggestive nomenclature, little definitive data 
is available on the connection between transforming growth factors 
and cancer In collaboration with Dr Veronique Preat of the
a ,University of Louvain (Belgium) , who provided the serum samples, 
we examined TGF serum levels m  normal, tumour bearing, and 
partially hepatectomised rats, available as part of a programme on 
liver chemical carcinogenesis Samples of lyophilized serum from 
rats were reconstituted m  1ml ultrapure water, filter sterilized, 
diluted to 50%, 25%, 12 5% and 10% and assayed for TGF activity 
The results are shown m  Fig 3 21 1 Results of colony size 
distribution m  the 25% dilution samples are shown m  Table 3 21 1
These results show that rat serum contains TGF activity which is 
sensitive to dilution The cancer and nodule samples contain a lot 
of TGF activity However, size distribution analysis of colonies 
m  these samples m  the TGF assay show that the tumour sample 
contains a higher percentage of large colonies than the nodule 
sample The cancer sample, therefore, contains a more potent 
growth stimulatory activity than any of the other samples The 
partial hepatectomy sample has a reduced level of TGF activity 
indicating that the high levels seen m  serum from pre-malignant 
and malignant livers are unlikely to be merely proliferation 
related Control serum showed little activity and all colonies 
were small as shown m  the size distribution information Control 
medium showed no activity
* Laboratory de Biochimie, Toxicologique et Cancerologique, 
Universite Catholique de Louvain, Bruxelles, Belgium
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T a b l e  3 21  1 E f f e c t  o f  r a t  s e r u m  s a m p l e s  o n  c o l o n y  s i z e
distribution m  the TGF assay
Test Sample Diameter of NRK colonies (in jam)*
120-124 240-365 365-490 490-610 610-730 >730
Control 1 0 0% _ - _ _
Nodule 91 1 6 6 2 2 - - -
Cancer 45 7 25 7 11 4 11 4 4 2 1 4
Partial
hepatectomy
43 2 31 3 25 3 - -
* Results expressed as % of total number of colonies counted m  5
fields of view
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3 22  E f f e c t  o f  p u r e  g r o w t h  f a c t o r s  a n d  R P M I - 2 6 5 0  CM m  t h e  TGF,
TGF-3 and autocrine assays
Samples of known growth factors were prepard as described m  
Section 2 23 All growth factors including a concentrated sample 
of RPMI-2650 CM from Bio-Gel P-30 were prepared with a carrier 
protein (B S A lmg%) Preliminary analysis of various 
concentrations of B S A m  the TGF and TGF-3 assays showed no 
effect at this concentration
The purified sample of RPMI-2650 CM assayed with the pure growth 
factors was purified by Bio-Gel P—30 chromatography and was 
concentrated by 800 times from the original CM Fractions [10-18] 
were pooled, lyophilized and reconstituted m  5mls growth medium
Table 3 22 1 and Table 3 22 2 show the results of these growth 
factors m  the TGF, TGF- 8 and autocrine assays
In the TGF assay, TGF is active on its own (presumably m  
co-operation with TGF- 8 present m  the serum in the assay system) 
TGF- 8 alone is inactive At the concentrations used, TGF-ct does 
not show a linear dose response curve EGF is active m  the TGF 
assay and FGF also shows a slight stimulatory effect RPMI-2650 CM 
also shows a dilution effect The results from the combined growth 
factors show that RPMI-2650 CM with TGF or EGF shows a stimulatory 
effect significantly greater than most of the other combined growth 
factors An interesting finding was the lack of extra stimulation 
when TGF-3 and RPMI-2650 and RPMI-2650 CM were combined, however, 
TGF-a , TGF-3 plus RPMI-2650 CM were stimulatory to approximately 
the same level as TGF-a plus RPMI-2650 CM
The TGF-3 assay shows an lhnhibitory effect with increasing 
concentrations of TGF-a As expected, TGF- 8 is stimulatory m  this 
assay and RPMI-2650 CM is very active in this assay, supporting our 
earlier results which suggest tht RPMI-2650 cells secrete a TGF-3 
like factor
The autocrine assay shows a saturation stimulation effect with TGF- 
and TGF-a All growth factors appear to be stimulatory for 
RPMI-2650 cells including RPMI-2650 CM It would appear from these 
results that RPMI-2650 cells are extremely sensitive to high 
concentrations of growth factors which cause inhibition as shown by 
the effect caused by the combined effect of TGF-a and TGF- 8 The 
addition of RPMI-2650 CM to these growth factors inhibits the 
growth of RPMI-2650 cells further
It would appear, therefore, from these results that RPMI-2650 CM 
contains TGF-3 and a lesser amount of TGF-Ot From the TGF- 8 assay, 
it was estimated that the original sample of RPMI-2650 contained 
2 5 pM TGF- 8 High levels of growth factors m  the autocrine assay 
are inhibitory The stimulatory effect of FGF m  this assay is 
interesting The possibility that the B S A included with the 
growth factors during preparation contains low levels of 
contaminating growth factors, which could act m  co-operation with 
the added growth factors, cannot be excluded
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TABLE 3 . 2 2  1 C o m p a r i s o n  o f  k n o w n  g r o w t h  f a c t o r s  a n d  R P M I - 2 6 5 0  CM i n  t h e  TG F, T G F-ft  a n d  a u t o c r i n e  a s s a y s
Tes t  Sample
CFE (%) NRK* 
Colony d i a m e t e r  s i z e
CFE (%) NRK-49F CFE (%) RPMI-2650
> 120jjm > 50jjm
TCF-a 50ng ml 5 57 ± 0 .22 14.82 ± 2 .6 7 0 .0 5 9 + 0 .0 0 6 0 .2 5 ± 0 .0 4
TGF-a 5ng m l " 1 3 .38 ± 0 .62 15.75  ± 1.45 0 .1 0 9 + 0 .02 0 .2 9 ± 0 .0 3
TGF-a 0 . 5ng m l " 1 2 5 ± 0 11.75 ± 1.2 0 .1 72 + 0 .0 2 0 .3 3 ± 0 .0 9
TGF-& 2ng ml” 1 0 0 1 .46 + 0 .7 9 0 . 1 3 ± 0 .0 5
TGF-6 0 2ng m l ' 1 0 0 0 .197 + 0 .0 2 8 0.21 ± 0 .0 2
TGF-B 0 02ng ml“ 1 0 0 0 .  105 + 0 .0 2 0 . 1 9 ± 0 . 0 8
EGF 2ng m l " 1 3 04 ± 0 .4 4 15.1 ± 1.55 0 .0 8 + 0.01 0 .2 5 ± 0 .0 5
PDGF 1ng m l_1 c** C 0 .0 8 4 + 0.01 0 .2 7 ± 0 .0 3
Bombesin lOnM (16 2ng ml
r
0 0 0 .0 9 6 ± 0 .0 2 6 0 .2 3 ± 0 .0 2
FGF 100ng ml""1 0 4 ± 0 .0 8 1 .76  ± 0 .7 8 0 109 + 0 .012 0 .3 5 ± 0 . 0 4
FGF 10ng m l " 1 0 0 0 .1 0 9 + 0 .0 1 6 0.  19 ± 0.01
RPMI-2650 CM [X] 3 67 ± 0 .2 9 11 58 ± 1.45 6 .1 1 6 + 0 .1 9 0 .1 3 ± 0 .0 5
RPMI-2650 CM [4- X] 5 0 1 .37 ± 0 .4 4 3 .0 23
+ 0 .3 2 4 0 .078±  0 .0 3
RPMT-2650 CM [ | Q x ] 0 0 29 ± 0 .2 9 1 .89 + 0.271 0 .091±  0.01
C o n t r o l  Medium 0 0 0 .0 6 7 + 0 .0 1 5 0 .0 7 8  ± 0 .0 2
* ± S E M (n = 3) o f  6 x 10* NRK c e l l s ,  3 x 104 RPMI-2650 c e l l s  and 2 x 104 NRK-49F c e l l s  p e r  30mm p l a t e
A C C on tam ina ted
TABLE 3 22 2 . C o m p a r i s o n  o f  k n o w n  g r o w t h  f a c t o r s  a n d  R P M I-2  6 5 0  CM m  t h e  TG F, T G F - g  a n d  a u t o c r i n e  a s s a y
Test Sample *
CFE (% 
Colony di 
> 1 2 0jjm
) NRK** 
ameter size 
> 50jjm
CFE (%) NRK-49F** CFE (%) RPMI-2650**
PDGr/EGF/TGF-3 2 69 ± 0.34 13.24 ± 3.07 0.206 ± 0.016 0.019 ± 0
PDGF/FGF/TGF-a 4 02 ± 0.51 14.72 ± 0.88 0.097 ± 0.021 0.012 ± 0.04
PDGF/EGF/RPMI-2650 CM 5 95 ± 0.72 20.28 ± 3.28 2.195 ± 0 159 0.088 ± 0.014
TGF-a/TGF-3 3.61 ± 0.99 13.25 ± 1.79 0 1 2 2 ± 0.026 0.13 ± 0.04
TGF-a/RPMI-2 650 CM 9.86 ± 0.89 23.85 ± 0.59 2.037 ± 0.176 0.052 ± 0.02
TGF-3/RPMI-2650 CM 0 04 ± 0.08 1.37 ± 0 44 2.25 ± 0.27 0.029 ± 0.01
TGF-a/TGF-B/RPMI-2650 CM 8 9  ± 1.77 24.14 ± 0.14 2. 169 ± 0.064 0.025 ± 0.01
EGF/1GF-3 3.53 ± 0.21 14.34 ± 1.37 0. 105 ± 0.016 0.046 ± 0.01
Control Medium 0 0 0.067 ± 0.015 0 078 ± 0.02
PDGF Ing ml \  EGI 2ng ml \  TCF-a 5ng ml \  TGF-8 0 . 2 n g  ml 1 ; RPMI-2650 CM [^ ]
o  /  t  J
* ± S E M (n = 3) o f  6 x 10 NRK c e l l s ,  3 x 10 RPMI-2650 c e l l s  and 2 x 10 NRK-49F c e l l s  p e r  30mm p l a t e
SECTION 4
DISCUSSION
4  DISCUSSION
Current research in the area of growth factors is providing new 
insights into the control of animal cell growth The malfunction 
of cellular control mechanisms can lead to different types of 
disease Tumour cell growth is of particular interest due to the 
high incidence of death to young and old from the various forms of 
cancer The development of in vitro methods to establish and grow 
tumour cells on a routine basis is an important area of cancer 
research, but for many tumour cell types it is not very successful 
Tumours contain a heterogenous population of normal and malignant 
cells (Hart et al , 1981) and a small population of stem cells may 
be responsible for tumour growth Because of the presence of 
mesodermal tissue which grows profusely it is difficult to 
routinely culture tumour cell lines which could be used to 
determine chematherapeutic measures for individual patients and to 
study a range of biochemical immunological and other parameters 
which may be important m  tumour growth and progression
The failure of tumour cells, which grow so readily in vitro, to 
grow progressively m  culture, could be due to many factors 
including lack of a perfusion system or absence of cellular 
interactions Another possibility, discussed m  more detail m  
Section 1 14, is that tumour cell growth requires high local 
concentrations of locally produced growth factors The results 
presented here relate to the investigation of production of the 
autocrine and other growth factors by the human carcinoma line 
RPMI-2650 (Moore and Sandberg, 1963) These cells originated m  a 
pleural effusion from a patient with carcinoma of the nasal septum 
Extensive growth of human cells m  culture generally leads to 
changes m  the cells karyotype and after many passages, the cells 
may not be representative of the cell population m  the original 
tumour RPMI-2650 cells are however, available at a low passage 
level which is important if experimental results from this cell 
line are to be relevant for comparison to tumour cell growth This 
cell line is quasi diploid and does not have the extensive 
karyotypic abnormalities of many widely used human cell lines like 
Hela
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The aberations m  control mechanisms which are responsible for 
aberrant growth of tumour cells are not understood fully How do 
tumour cells escape from normal control systems7 Why are some 
cells responsive to certain growth regulators while others are not’ 
How many mechanisms are involved7 These are some of the questions 
often asked of how cancer occurs and continues to progress and 
becomes malignant or benign
Preliminary experiments were set up with serially diluted RPMI-2650 
cells m  monolayer It was found that at low cell concentrations 
no colonies formed, but as the concentration of cells plated 
increased the number of colonies formed increased exponentially 
The concentration-dependent nature of RPMI-2650 cells at low 
concentrations was examined m  a double layer agar assay system 
(see Section 2 10 1) A low concentration of RPMI-2650 cells 
suspended m  a semi-solid agar matrix supplemented with growth 
medium was set up with increasing concentrations of RPMI-2650 cells 
physically separated from these cells as a "feeder" monolayer, on 
the base of the tissue culture dish The interesting finding from 
this experiment was that the cells m  the feeder layer stimulated 
those m  the upper layer m  a concentration dependent manner 
However, at the higher feeder concentrations the amount of 
stimulation decreased This could have been due to nutrient 
depletion or build up of waste products, since these cultures were 
part of a closed system, which was capable of supplying a limited 
amount of nutrients Alternatively, a cell-produced auto-inhibitor 
could be involved
The work described here concentrated on an explanation of the 
autostimulatory effect m  RPMI-2650 cells Medium was collected 
from cultures of RPMI-2650 cells ("conditioned medium", CM) and was 
incorporated with RPMI-2650 cells m  the upper layer of the double 
layer assay This medium was found to stimulate RPMI-2650 cells 
This finding proved that the physical presence of feeder cells was 
not necessary to stimulate cell growth It also opened the way to 
biochemical investigation of the CM effect The samples of CM 
tested m  the assay indicated that it was altered m  some 
fundamental way by the growth of RPMI-2650 cells The 
possibilities that removal of an inhibitor or production of an 
autocrine growth factor were the reasons for this stimulatory 
effect were examined However, before this could be achieved, the 
RPMI-2650 autocrine assay had to be developed to a reliable stage
Various parameters of the RPMI-2650 autocrine assay were examined 
The sensitivity of the assay varied from experiment to experiment 
but the activity profiles were generally the same One of the 
major problems m  the assay was a high background At first all CM 
samples were collected m  medium with 10% foetal calf serum It 
was shown, however, that 5% foetal calf serum, while halving the 
cost of this expensive medium supplement, reduced the cell growth 
yields by only 10% All cell lines were cultured with 5% foetal 
calf serum, while CM was prepared m  medium without foetal calf 
serum which facilitates later purification We found that 
concentrated (ultrafiltered) CM prepared without foetal calf serum 
stimulated RPMI-2650 cells to grow This confirmed that 
cell-derived rather than serum-derived factors were being examined 
Other parameters like indicator cell concentration and type of 
collection medium for CM were also examined To allow for 
variation m  sensitivity m  the assay, a cell concentration well 
above the cut-off point was taken and used m  most of the assays 
RPMI-2650 CM was prepared m  the two media types, SLM and MEM MEM 
is a basic medium while SLM contains extra vitamins and ammo acids 
and a carbon source m  the form of sodium pyruvate which unlike the 
glucose m  MEM is shunted metabolically towards the TCA cycle 
rather than to lactic acid production (lactic acid is responsible 
for lowering the pH of the medium which may prevent cell growth) 
While SLM is superior for growth of RPMI-2650 cells, the background 
m  SLM was usually much higher and may have masked autocrine 
activity The semi-solid matrix m  the assay (agar) was also 
examined and compared with agarose Background CFE was greater m  
agarose than m  agar The assay could have been alternatively 
adjusted (cell number, serum concentration) to reduce the agarose 
background CFE as agarose is a purer form of agar Agar may 
contain toxic impurities at a greater concentration than m  
agarose It was found that m  many of the agarose assays,
RPMI-2650 colonies disintegrated and became difficult to count 
The reason for this is not understood
We found that the autocrine assay was very sensitive to assay 
conditions Careful pretreatment was essential if the assay was to 
be successful Indicator RPMI-2650 cells taken from exponential 
log phase cultures gave good results while cells from confluent 
cultures often gave less predictable results It was also found 
that while m  culture, cell lines sometimes became progressively
granular and growth slowed down Work with these cells generally 
gave no results or very poor results Analysis of medium samples 
from these cultures m  a modified mycoplasma test developed m  our 
laboratory showed that such cells were often contaminated with 
mycoplasma Despite regular screening for mycoplasma the problem 
continued to arise occasionally
Other experimental variables such as the presence of high levels of 
foetal calf serum m  the assay (and experimental error) may be 
responsible for the variability often found m  this assay 
Rizzino, (1984) has shown that a serum-free agar assay has proved 
very useful m  detecting growth factors Future work with the 
autocrine assay would benefit greatly from the development of a 
serum-free based method
Further analysis of the autocrine activity of RPMI-2650 cells was 
difficult due to the small amounts of growth factor secreted into 
the medium Large scale cell culture was the next step However 
the presence of autocrine growth factors m  other cell lines led us 
to examine the relationship between our autocrine growth factor and 
those m  the literature Halper and Moses, (1983) showed the 
presence of an autocrine factor m  CM from SW-13 cells, derived 
from a human adenocarcinoma of the adrenal cortex This autocrine 
factor was found to separate from other known growth factors by 
HPLC An autocrine factor for human small cell lung cancers 
(Bombesin) is also known (Carney et al , 1970) The most widely 
known but not well understood transforming growth factors also 
function m  an autocrine manner (Sporn and Todaro, 1980, Sporn and 
Roberts, 1985b) The autocrine hypothesis as discussed m  the 
Introduction has become a concept m  the link between growth 
factors and cancer research Transforming growth factors have been 
found m  many tissue types both normal and tumour, m  many cell 
types m  culture and m  body fluids (Childs et al , 1982, Roberts 
et al , 1983, Sherwm et al , 1983 Cooper et al , 1984, Hamburger 
et al , 1985, Zwiebel et al , 1986) We looked at the possibility 
that RPMI-2650 CM contained a transforming growth factor
Transforming growth factors (TGFs) are a family of growth factors 
which are generally identified by their ability to induce normal 
fibroblasts to grow m  a semi-solid matrix (De Larco and Todaro, 
1978) The ability of TGFs to render cells anchorage-independent
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is not absolutely unique to TGFs, however it is used widely as a 
basic detection assay (anchorage-independent growth is a function 
of the total growth factor concentration m  the medium (Kaplan and 
Ozanne, 1983)
Anchorage independent assays were examined for their ability to 
detect TGFs A positive TGF control was prepared from a -”-irus 
transformed cell line, 663+N This cell line is a 
myeloproliferative sarcoma virus (MPSV) transformed NRK line which 
was known to produce TGFs It was kindly supplied by Dr Ian 
Pragnall, Beatson Institute for Cancer Research, Glasgow (Koury and 
Pragnall, 1982) Pilot studies on optimised production of TGFs was 
undertaken with this line
Three normal fibroblast cell lines were examined as indicators m  
the TGF assay NRK cells appeared to be the most sensitive 
NRK-49F and AKR-2B cells showed very little response NRK cells 
differed from NRK-49F and AKR-2B cells m  that besides responding 
with a higher CFE m  the presence of TGF, the colonies were much 
larger and easy to count (De Larco et al , 1981, Nickell et al , 
1983, Richmond et al, 1985, Fernandez-Pol et al , 1986) Once a 
suitable indicator cell line was located we set about optimizing 
the assay (Dooley and Clynes, 1986) The assay was first set up 
with 1 2 x 103 cells per plate A change of foetal calf serum 
batch caused some difficulties since then the assay system was 
optimized using one particular batch of foetal calf serum Foetal 
calf serum variation meant that the optimum conditions with one 
batch were different for another batch We subsequently selected 
an alternative batch of foetal calf serum which was used m  all 
other growth factor work
A range of NRK indicator cell concentrations were examined m  the 
TGF assay, we found that below 4 x 103 cells per dish, NRK cells 
responded m  a random manner At 6 x 103 cells per dish a low 
background or no background CFE was observed, The importance of 
borderline background was important for analysis of many batches of 
CM with low levels of TGF activity (RPMI-2650 CM) Our positive 
control, 63+N CM, contained a lot of TGF activity and became 
inhibitory at high concentrations We found that RPMI-2650 CM 
contained low levels of TGF activity Samples of RPMI-2650 CM
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which were concentrated by ultraflltration showed increased TGF 
activity with increased concentration
The passage number of NRK cells were examined for their response to 
TGF factors as the indicator cell line aged We found that as 
these cells aged, they responded less efficiently to TGF factors 
In an effort to standardize the assay, NRK cells were regularly 
thawed from liquid nitrogen stocks and strictly used between 
passages 17-22 Once the cells aged beyond this passage level they 
were discarded
The basic anchorage independent matrix m  the assay was also 
examined It was found here again that like RPMI-2650, NRK cell 
growth was greater in agarose than m  agar and the colonies which 
formed m  agarose became very diffuse A low background was more 
useful so agar was chosen as the anchorage independent support m  
this assay Agarose may have a more important role to play m  
clonogenic assays where cells from human tumours are grown m  a 
semi-solid nutrient media and used as models for examining the 
biology of human tumours and the response of patients to drug 
therapy In these assays, encouragement of clonal growth rather 
than low background is required (Hayes et al , 1985) Enderson et 
al , (1985), showed that the conditions employed m  setting up 
soft agar assays greatly influenced the sensitivity of primary 
human clonogenic assays
The production of TGF activity by two passsage levels of 663+N 
cells was examined over a period of time It was found that 
production of TGF activity increased for up to three days m  
culture The limitation of the collection method was that 663+N 
cells continued to grow and secrete growth factors for this 
period of time m  a serum free medium but due to basic nutrient 
depletion or accumulation of waste products and pH change the cells 
were unable to continue growing These results also showed that 
663+N cells appeared to secrete more TGF activity as they aged 
(increasing passage number) This occurrence may be explained by 
adaption of cells to growth m  culture It is known that in vivo 
tumours consist of a heterogenous population of cells (Hart and 
Fiddler, 1981), subpopulations of cell lines may arise m  culture 
and faster growing cells may overgrow the other cells m  culture
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Preliminary experiments showed that while 663+N cells secrete a lot 
of TGF activity, these growth factors were inefficient m  
stimulating RPMI-2650 cells RPMI-2650 cells differ from NRK and 
663+N cells m  that RPMI-2650 cells are epithelial and NRK and 
663+N cells are fibroblastic cells The essential control 
mechanisms of these cells are basically different It seemed 
however, that RPMI-265 cells were producing some growth factors 
similar to 663+N growth factors, since CM from both these cell 
types were active m  the TGF assay Preliminary purification by 
ultrafiltration of CM from these two cell lines showed that 663+N 
cells were producing TGF activity which was predominantly m  the 
5-30 kDa range and activity from RPMI-2650 was predominantly m  the 
greater than 30 kDa range However, it also seemed likely that 
each cell line had a small amount of activity m  the predominant 
molecular weight range of the growth factor of the other cell line 
The two known TGFs have molecular weights of 6 kDa and 25 kDa The
possibility that RPMI-2650 cells were producing predominantly the 
25 kDa molecule (TGF- (3) and 663+N cells were producing 
predominantly the 6 kDa molecule (TGF-a) seemed likely (Derynck et 
al , 1985, Roberts et al , 1985, Hanauske et al , 1987) Given 
that TGF-Ot and TGF- 8 may interact m  solution, and that the 
fractionation cut-off limit of ultrafiltration membranes is very 
approximate and depends on shape as well as size, this seems to be 
a reasonable working hypothesis
RPMI-2650 CM was examined for dilution effects m  a number of 
assays The response of RPMI-2650 CM to dilution was important if 
the growth factor activity were to be detected following 
purification procedures like column chromatography Samples of 
RPMI-2650 CM were concentrated by ultrafiltration and serial 
dilutions tested m  the autocrine assay RPMI-2650 cells responded 
m  a linear manner to dilution of CM from RPMI-2650 cells This 
pattern emerged repeatedly and also that the cells responded to a 
narrow range of concentrations On dilution RPMI-2650 cells 
responded to the CM and at higher concentrations saturation 
occurred
All other dilution curves involving 663+N CM m  the TGF assay and 
RPMI-2650 CM m  the TGF and TGF-3 assay showed a linear 
relationship at low dilution, with a saturation effect at high 
concentration Sufficient data were not available to generate and
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analyse the exact shape of the curves However, there was some 
suggestion of a sigmoidal shape m  some cases, this was 
particularly pronounced m  the case of RPMI-2650 CM m  the TGF 
assay, but not for 663+N m  the same assay A sigmoidal effect 
could suggest the cooperative action of 2 factors, one of them 
being present at limiting concentrations TGF-Ot and TGF-3 are 
known to act m  combination m  stimulation of NRK cell growth m  
the TGF assay (Anzano et al , 1983) From the results presented 
here, it is evident that 663+N produced considerably more (perhaps 
by a factor of 20 times) TGF- than RPMI-2650, and the sigmoidal 
curve for the latter may indicate dilution of TGF-a below a 
critical level m  the presence of excess TGF- 8 The limited data 
presented here do not allow fuller speculation on this or other 
possibilities (such as inhibitory molecules or effects on receptor 
activity)
Concentration of CM from RPMI-2650 and 663+N cells by 
ultraflltration caused a large increase m  TGF, TGF-6 , 1 2 5j.gQp 
binding and autocrine activity, showing that both of these cell 
types were secreting growth factors into their extracellular 
environment This was an important finding which dismissed the 
possibility that removal of inhibitors was responsible for growth 
stimulation by conditioned medium Initial experiments m  whch 
RPMI-2650 and 663+N CM were concentrated by ultraflltration showed 
that RPMI-2650 TGF activity was predominantly m  the 30 kDa range 
while 663+N growth factor activity was predominantly m  the greater 
than 5 kDa retentate, but not m  the greater than 30 kDa retentate, 
indicating a TGF size range of 5-30 kDa for the 663+N TGF factor
Results of the autocrine activity of ultrafiltered RPMI-2650 CM 
were difficult to interpret However, acetic acid treatment and 
neutralization, although lowering the autocrine activity m  the 
unconcentrated CM, allowed successful ultrafiltration of autocrine 
activity Acid treatment results m  some loss of protein, and may 
remove competing factors or activate other growth factors 
(Lawrence et al , 1984, Pircher et al , 1984)
These results suggest that there are at least two components m  the 
autocrine activity of RPMI-2650 cells One of these components is 
of low molecular weight (as seen m  the activity of the less than 1  
kDa retentate) and one of high molecular weight (greater than 30
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kDa) There is some indication also from the results of an 
inhibitory activity m  the greater than 1 kDa retentate There is 
an indication that this may be a TGF-a-like factor since CM from 
663+N cells which contains a substantial amount of TGF-a, is also 
slightly inhibitory m  the RPMI-2650 autocrine assay Further work 
would be necessary to establish this The fact that the retentate 
activities are m  the order 30 kDa > 10 kDa > 5 kDa > 1 kDa is not 
readily explicable
Ultraflltered RPMI-2650 CM tested m  TGF assay showed enhancement 
of activity m  all retentates, whether acid-neutralized or 
untreated The 5 kDa retentate gave considerably lower activity 
than the 1 kDa, 10 kDa or 30 kDa retentates The substantial loss 
of TGF activity m  the 5 kDa retentate was a recurring feature of 
this ultrafiltration membrane (or of the batch used) We came to 
the conclusion that this membrane was faulty since the activity 
lost through this membrane was again concentrated m  the 1-5 kDa 
retentate This batch of membranes may have been "leaky" to 
protein, as evidenced by the high protein level m  the 5 kDa 
filtrate when subsequently concentrated over a 1 kDa cut-off 
membrane
In the TGF- 8 assay, acid-neutralization of RPMI-2650 CM was shown 
to stimulate TGF- 8 activity The presence of EGF m  this assay 
potentiates TGF- 8 like activity in RPMI-2650 CM which is retained 
m  the 30 kDa retentate TGF- 8 activity is significantly decreased 
m  the 2 kDa retentate and this may be caused by an inhibitor of 
TGF- 8 activity m  this retentate The loss of TGF-B m  the 5 kDa 
retentate may as mentioned above, be a feature of this batch of 
membranes
Purification of RPMI-2650 CM was hampered by the low levels of 
growth factors secreted into conditioned growth medium Cells were 
routinely grown m  25cm2 flasks which yielded 30mls of 1-day CM 
over a 3 day period Ths meant a very long preparative time and/or 
flask number before up to 500mls of CM could be obtained In 
general, large scale animal cell culture methods are an important 
source of substantial amounts of complex proteins (including 
antibodies and enzymes) produced by mammalian cells which cannot be 
produced m  bacteria because of their inability to correctly 
process or modify these molecules (Arathoon and Birch, 1986)
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We examined a number of large scale methods of cell culture and 
compared the differences m  handling and CM production The 
methods examined were roller bottle, microcarrier and suspension 
culture We found that microcarriers, which are ideal for growth 
of anchorage dependent cells, since the growth of these cells on 
dextran beads increases the ratio of surface area to volume of 
medium as compared to monolayer cultures (e g roller bottle 
systems), are somewhat cumbersome m  practice Roller bottles 
were easy to handle and gave a reasonable yield of CM (300mls of 
1-day CM m  3 days) This method was used for CM production 
Suspension culture systems were found to be very suitable for 
culturing RPMI-2650 cells While the subculture of these systems 
was simple, suspension cultures tended to require more handling 
than roller bottle cultures In this system RPMI-2650 cells were 
grown m  suspension and grew into clumps after a few days m  
culture This culture method yielded 300mls of 1-day CM m  3 days 
from a 100ml culture or 600mls of 1-day CM m  3 days from a 200ml 
culture On a comparative basis a 25cm2 flask could yield up to 
4 x 10^ RPMI-2650 cells A roller bottle could yield over 108 
RPMI-2650 cells (670 cm2) and a 100ml suspension culture could 
yield 2 x 108 RPMI-2650 cells This makes suspension cultures 
more economical m  terms of medium costs and space
TGF and autocrine activity m  RPMI-2650 CM appeared to be 
relatively stable to acid treatment Concentration by 
ultraflltration followed by dialysis and lyophilization did not 
appear to decrease activity An early experiment showed that a lot 
of TGF activity was lost after CM samples were filter sterilized 
using an ordinary millipore filter (Millex GS), so a special low 
protein binding millipore filter was used m  all subsequent 
experiments
The major purification step attempted, was the use of gel 
filtration m  acetic acid which has been shown (De Larco and 
Todaro, 1980) to separate TGFs from the bulk of protein m  CM, thus 
providing a purer TGF preparation for subsequent assays or for 
futher purification by HPLC Initial runs were undertaken using 
Bio-Gel P-60, because of its wide fractionation range (3-60 kDa)
CM from 663+N, a high-level TGF producer, was fractionated 
initially Analysis of the resulting fractions showed that the TGF 
activity m  this CM was separated from the bulk of protein into one
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major and one small peak These results were similar to those of 
De Larco and Todaro (1980) who partially purified sarcoma growth 
factors from Moloney MSV-transformed 3T3 cells
A sample of RPMI-2650 CM was then fractionated by Bio-Gel P-60 and 
showed a small trace of TGF activity When EGF was incorporated 
into the assay a broad peak of activity resulted Since the 
initial runs with Bio-Gel P-60 indicated that the TGFs size range 
was 5-30 kDa, subsequent work was with Bio-Gel P-30 which had a 
fractionating range of 2 5-40 kDa Samples of RPMI-2650 CM 
fractionated by this column were assayed for TGF, TGF-8 , autocrine, 
1 2 5i_egF binding inhibition and thymidine incorporation 
These reults showed that RPMI-2650 CM contained growth factors 
which were active m  all these assays We found that the TGF 
activity consisted of two peaks of activity A small peak of 
activity m  the 20-30 kDa range and a second larger peak m  the 
smaller molecular weight range 5-15 kDa The TGF- 6 assay also 
showed two peaks A minor peak m  the high molecular weight area 
and a very broad peak m  the lower molecular weight range 
approximately similar to those of the TGF assay peaks The 
autocrine assay showed one definite peak m  the lower size range 
5-15 kDa Both the 1 2 ^I-EGF radioreceptor and the ^H-thymidine 
assays showed one m a m  peak of activity m  the low molecular weight 
range
This work led the way to further purification of RPMI-2650 CM, by 
removing bulk protein from the active protein molecules and 
presented a relatively pure sample of growth factors for HPLC, and 
which we were to subsequently assay m  comparison to other known 
growth factors Accurate molecular weight determination of these 
active molecules was difficult due to the broad bands of activity 
which resulted Smaller fraction sizes might be advisable for 
future work
Fractionation of the RPMI-2650 growth factor activity by HPLC was 
the next step This system was set up with 663+N CM as a positive 
TGF-a control, and using a method described by Anzano e_t al ,
(1983) We fractionated 663+i'J CM and lyophilized the fractions 
before analysing them m  the radioreceptor assay The
results from this experiment showed that the 1 2 5j.gQp competition 
binding activity m  663+N CM eluted at about 28-30% acetonitnle
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Anzano et al , found that their 1 2 5j.£Qp competing activity 
eluted at 31-32% acetonitnle
Based on these findings, we prepared a batch of RPMI-2650 CM and 
partially purified it by Bio-Gel P-30 We lyophilized two pools of 
fractions which corresponded to the main peaks of activity detected 
m  the TGF assay of a preliminary Bio-Gel P-30 run These pools of 
activity were eluted separately from the HPLC column Every third
fraction from each run was then assayed m  the
radioreceptor assay, the autocrine assay and m  the TGF- 6 assay 
Activity was detected m  the ^2^1-EGF radioreceptor assay and m  
the TGF- 6 assay but not m  the autocrine assay
Pool I which contained the larger molecular weight molecules from 
the Bio-Gel P-30 run showed very little 125j_gQp competitive 
activity Pool II, however, showed two small peaks, one of which 
eluted around 28-30% acetonitnle and the second major peak eluted 
around 58-60% acetonitnle The results from the TGF- 8 assay 
showed two m a m  peaks of activity m  Pool I which were eluting 
around 38-40% acetonitnle, with a range of 58-80% acetonitnle for 
the second peak Pool II showed a small early peak which eluted 
around 28-30% acetonitnle and two other peaks m  the same position 
as the two peaks eluted m  Pool I at 38-40% acetonitnle and 50-80% 
acetonitnle
These results showed that Pool I contained no significant levels of
- I O C I-EGF activity but contained most of the TGF- 6 like activity, 
while pool II contained 1 2 ^I-EGF activity and some TGF- 8 like 
activity The TGF- 8 like peaks of activity from RPMI-2650 CM which 
showed up after HPLC are similar m  position to those detected by 
Anzano et al , (1983) using CM from virally transformed cells
These results would midcate that the high molecular weight Pool I 
samples, contained a TGF- 6 like molecule The lower molecular 
weight Pool II, contained all the TGF-a like activity but also 
contained a substantial level of TGF-g like activity This finding 
shows that gel filtration chromatography does not separate TGF-a 
and TGF- 8 like molecules effectively, whereas HPLC purification 
does, m  agreement with other published work (Anzano et al ,
1985)
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Loss of autocrine activity m  the HPLC fractions could be due to a 
number of factors Since control samples of CM did show activity, 
it is possible that the autocrine factor may have been unstable 
during the run or was irreversibly bound to the column matrix If 
this was the case, then the autocrine activity of RPMI-2650 is 
dissimilar to other known TGFs The possibility of a third 
distinct group of growth factors separate from the known growth 
factors has been discussed by Halper and Moses (1983) and Richmond 
et al , (1985) Another possibility may be separation of two 
molecules which must act m  concert to stimulate activity
The discrepancy between the identity of the TGF-g like molecule 
found m  Pool II (lower sized factors) and its proposed molecular 
weight has been discussed by Massague (1983) who found that a high 
molecular weight molecule interacted with the chromatography matrix 
of Bio-Gel P-60 and, therefore, eluted at a later fraction 
However, it is also possible that the TGF-8 -like molecule secreted 
by RPMI-2650 cells may interact with the TGF-alike molecule since 
they co-elute
The effect of known purified growth factors was examined and 
compared to a partially purified sample of the active fractions of 
RPMI-2650 CM eluted from Bio-Gel P-30 m  the TGF, TGF-8 and 
autocrine assays The TGF assay showed that TGF-a and EGF were 
stimulatory In the case of TGF-a, where different concentrations 
were examined, the response was dose dependent The effect of 
combined growth factors showed that the TGF activity of 
RPMI-2650 CM was potentiated by the addition of TGF-ctor EGF No 
potentiation was observed on addition of TGF-8 These results 
suggest that RPMI-2650 CM contains a TGF-8 like molecule In the 
TGF assay NRK indicator cells will grow when EGF or TGF-a are 
present but growth is limited The presence of TGF-8 stimulates 
the formation of large NRK colonies (Brown and Blakely, 1984) The 
lack of increased stimulation found when TGF-a and TGF-8 were added 
is difficult to explain Growth stimulation was expected It is 
likely that our range of TGF- 8 concentrations was too dilute to be 
detected m  this assay Sipes et al , (1985) found that 5ng 
ml ' 1 TGF- 8 with 5ng ml' 1 TGF-a showed stimulation m  the TGF 
assay We used a 25 times less concentrated sample TGF-8 is 
present m  the serum m  the TGF assay, and the amount added here 
(0 2ng ml'1) may be insufficient to cause additional stimulation
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RPMI-2650 CM would add TGF-a and TGF-B to the system so that 
stimulation could be expected
The TGF-B assay showed stimulation by TGF-a and RPMI-2650 CM The 
stimulatory effect by RPMI-2650 CM was far greater than that by 
TGF-B We estimated from this data that our original RPMI-2650 
contained 2 5pM TGF-B TGF-a caused increased activity with a 
decrease m  concentration This was not surprising since it was 
previously shown that the TGF-a activity m  a sample of 663+N CM , 
high m  TGF-a like growth factor, was inhibited by the presence of 
EGF m  the TGF-B assay TGF-a and EGF are very similar growth 
factors and compete equally for binding to the EGF receptor (Lee 
et al , 1985) This situation appears to have arisen here EGF 
is an inherent additive to the TGF-B assay, and the negative 
response observed at high concentrations of TGF-a may be caused by 
down-regulation of EGF receptor binding sites m  the presence of 
excess EGF-like molecules (Cuatrecasas, 1982) The combined growth 
factors showed no obvious changes in growth The response of cells 
m  culture is very obviously a function of the growth factors 
present (van Zoelen et al , 1986)
The results from the autocrine assay showed that all the purified 
growth factors stimulated the growth of RPMI-2650 cells Dilution 
effects were not obvious with TGF-a or TGF-B The most significant 
growth effect was observed for lOOng ml' 1  FGF (fibroblast growth 
factor) which was an interesting finding FGF, like TGF-a, EGF and 
TGF-B (Lee et al , 1985, Roberts et al , 1986) is a stimulator of 
angiogenesis and is involved m  wound healing, tissue repair and 
also m  promoting vascular tissue growth (Baird et al , 1985)
FGF has also been reported to stimulate anchorage-independent 
growth of AKR-2B and NR - 6 cells (Rizzmo and Ruff, 1986) Almost 
all combinations of tne purified growth factors tested appear to be 
inhibitory for RPMI-2650 cell growth We had shown previously that 
RPMI-2650 cells responded to a very narrow growth factor 
concentration range
These results show that of all the combined growth factors, TGF-a 
+ TGF- B, and TGF-a + EGF are less inhibitory than other growth 
factor combinations than RPMI-2650 CM These results would suggest 
that RPMI-2650 cells are very sensitive to the overall growth
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factor content m  the medium and are inhibited by high 
concentrations of growth factors
The fact that the assay systems upon which the TGF, TGF- 8 and 
autocrine assays are based, include a high serum concentration 
(8 6%), may complicate the results and their interpretation The 
cells are normally grown m  medium supplemented with 5% foetal 
calf serum, and transfer to a higher serum concentration may 
introduce a stress factor It has been shown that serum contains 
transforming growth factors (Childs et al , 1982) and that the 
transformation of NRK cells is caused by the interaction of three 
growth factors TGF-a, TGF-3 and PDGF (platelet-derived growth 
factor) (Assoian et al , 1984) which have been isolated from human 
platelets Since serum contains high levels of PDGF (released from 
platelets during clotting) it is possible for this assay to detect 
the presence of added TGF-Ot and TGF- 8
In the growth factor assays which we set up, BSA (lmg/lOOml) was 
also included as a carrier protein for the purified growth factors 
(and RPMI-2650 partially purified CM) Although this had no effect 
when added as a control m  the various assays, it is possible that 
BSA may contain trace levels of growth factors or inhibitors which 
on their own show no marked effect but could be activated m  the 
presence of high concentrations of specific growth factors
As a possible means of explaining the inhibitory effect of high 
concentrations of TGF-a on RPMI-2650 cells, we examined the EGF 
receptor content of these cells relative to NRK cells and to A431 
cells which are known to have an unusually high number of EGF 
receptor binding sites (Haigler et al , 1978) NRK cells bound up 
to 18 times more 1 2 ^I-EGF than RPMI-2650 cells and A431 cells 
bound about 3 times more 1 2 5j.gQp than nrk cells The difference 
m  the ability to bind 1 2 5j.gGp may re]_ate t 0 ability to respond 
to TGF-a The response of the cells to TGF-a is however, 
influenced by other growth factors, like TGF-g which has a biphasic 
effect on EGF receptors m  NRK cells (monolayer) (Assoian, 1985)
Low affinity EGF binding sites increase m  number, whereas the high 
affinity sites undergo a transient decrease m  affinity followed by 
a prolonged increase m  number This alteration m  the affinity of 
EGF receptors causes the cells to respond differently to the same 
amount of TGF-a m  the presence of TGF-g The response of
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RPMI-2650 cells and NRK cells is most likely modulated through a 
complex interaction of growth factors and their receptors in our 
assay system
We examined the relationship between EGF receptor levels and 
hormones using A431 cells and a human breast cancer cell line T47D 
We found that A431 cells had the capacity to bind up to 8 times 
more 125j.gQp than T47D cells and that the receptor binding 
capacity was increased m  these cells by different hormones 
Dexamethasone caused a significant increase m  the capacity to 
bind 1 2 ^I-EGF m  A431 cells and progesterone caused a 
significant increase m  the capacity to bind in X47D
cells Growth factors or hormones can influence the EGF receptor 
binding ability m  different cell types (Murphy et al , 1985,
Newman et al , 1986) We also prepared hormone treated and control 
cultures for analysis of EGF receptor mRNA levels and types by Dr 
D Headon, University College, Galway, but final results are not 
yet available It would be of interest to determine whether or not 
hormonal control is at a transcriptional or other level
We also carried out some collaborative work with Dr V Preat, m  
the University of Louvain m  Belgium Various samples of rat sera 
were examined for their ability to stimulate NRK colony formation 
m  the TGF assay We found that samples of serum from rats with 
carcinogen-induced malignant hepatomas caused a massive stimulation 
of NRK colony growth while serum from rats bearing pre-malignant 
liver nodules gave a lesser, but still high activity The 
non-treated controls gave background levels of activity Samples 
of serum from partially hepatectomised rats stimulated NRK colony 
formation but not to the extent seen m  the tumour and nodule 
samples These results show that it may be possible to use assays 
like the TGF assay to detect raised levels of growth factors m
serum samples from patients with cancer It may be possible to
monitor the levels of growth factor activity before and after
chemotherapy The isolation of increased levels of a high
molecular weight TGF-a from the urine of patients with disseminated 
adenocarcinoma of breast has now been shown by Stromberg e_t al 
(1987) They suggest that their urinary TGF-a assay may m  some 
cases assist mammography as a useful method for early detection of 
breast cancer
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The purpose of the work described here was to determine the nature 
of the cut-off effect m  RPMI-2650 cells The data presented 
established the involvement of autocrine factor(s) Analysis of 
RPMI-2650 conditioned medium led us to the conclusion that 
RPMI-2650 cells secrete both TGF-a-like and TGF-g-like growth 
factors into their exracellular environment Whether the autocrine 
growth activity m  RPMI-2650 cells is due to TGF-a or TGF-B or 
other known growth factors or to a novel autocrine growth factor is 
still uncertain HPLC analysis of a partially purified sample of 
RPMI-2650 autocrine activity showed complete loss of autocrine 
activity, while both the TGF-a-like and TGF-S-like growth factors 
survived this purification step like other known TGFs (Halper and 
Moses, 1983) There is a possibility that the autocrine factor was 
diluted below its active level, since it is particularly sensitive 
to dilution however, given the usual ratio of TGF-B t 0 autocrine 
activities m  CM and the amount of TGF-a eluted from HPLC, this 
explanation is unlikely Possible explanations for the loss of 
RPMI-2650 autocrine activity on HPLC (including instability of 
separation of two components) have been discussed earlier In the 
ultraflltration experiments it was shown that a large autocrine 
factor > 30 kDa and an acid-activated autocrine factor < 1 kDa are 
present m  RPMI-2650 CM
The ultrafiltered retentates contain the concentrated factors of 
higher molecular weight than that of the cut-off filtration 
membrane used, but it is important to remember that the 
non-concentrated factors of lower molecular weight than the cut-off 
membrane used are also present The 30 kDa retentate, for 
instance, may therefore contain both growth factors m  a different 
ratio from that m  the original CM, while the 1,000 filtrate may 
contain the smaller of the autocrine factors on its own
In the retentates used for gel filtration, the lower molecular 
weight form would be present at a much lesser concentration and is 
therefore, not detected after column chromatography or HPLC The 
data presented here do not allow us to say with certainty that 
the activity m  the 1 , 0 0 0 filtrate is due to a secreted factor, as 
opposed to removal of toxic or inhibitory substances by the 
conditioning cells The autocrine activity m  the larger molecular 
weight range could possibly be caused by the interaction of 
specific concentrations of TGF-a-like and TGF-g-like growth factors
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which could act m  concert to stimulate RPMI-2650 growth The 
combined effect of TGF-a and TGF- 8 is an accepted mechanism of 
autocrine activity m  NRK cells (Anzano et al , 1983)
It was hoped that an examination of pure growth factors in the 
autocrine assay would help to determine the identity of the 
autocrine factors The effect of the purified known growth factors 
may, however, have been influenced by the presence of foetal calf 
serum m  the assay which provided low levels of various mitogens 
The inhibitory effect seen with the combined growth factors is 
difficult to explain, but may be due to the presence of excess 
levels of growth factors Inhibitory effects have been observed 
with many growth factors (Feng et al , 1986) In different 
systems, TGF-$ may act as an inhibitor, a stimulator and a potent 
inducer of differentiation (Roberts et al , 1985, Like and 
Massague, 1986, Massague, 1987) Since the autocrine assay 
developed for RPMI-2650 involved anchorage-independent growth m  
agar, the autocrine activity detected could relate to growth 
stimulation per se, or to specific stimulation of anchorage- 
independent growth A possible link between the accumulation of an 
abundant extracellular matrix and anchorage-independent growth has 
been suggested by Ignot and Massague (1986) A mitogenic effect of 
TGF-(3 may be due to the increase of EGF receptor number or affinity 
(Assoian, 1985) RPMI-2650 cells contain low numbers of EGF
receptors, so that an autocrine mechanism involving TGF-a alone 
seems unlikely
In order to establish the identity of the autocrine growth 
factor(s) produced by RPMI-2650 cells, further purification and 
characterization work is necessary High level producer clones, if 
available, would be helpful An important step would be scale-up 
of suspension or microcarrier culture of the cells, to provide a 
more concentrated sample for HPLC analysis HPLC involving a more 
concentrated sample should resolve the question of whether the 
disappearance of autocrine activity on HPLC reported here was due 
to dilution, inactivation or separation of synergistic factors 
Collecting smaller fraction volumes might also enhance resolution 
m  gel filtration, and thus assist m  discrimination between TGFs 
and autocrine factors A repeat of the experiment using known 
purified growth factors (especially FGF) combined with a range of 
stability tests (e,g heat, pH, sulphydryl reducing agents etc)
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should narrow the range of possible candidate growth factors 
However, it may be difficult to devise a method for concentration 
of the hypothesised low moleclar weight autorcnne factor, thus 
making purification difficult Our studies showed that RPMI-2650 
cells possess low levels of EGF receptors on their surfaces 
Binding studies with other lodmated purified growth factors (eg 
TGF-B)(Frolik £t al , 1984, Fanger et al , 1986) and quantative 
determination of receptor numbers and affinity by Scatchard 
analysis would be valuable m  assessing possible autocrine 
mechanisms Growth blockage by treatment with antibodies to a 
specific growth factor receptor would provide the best evidence for 
involvement of that growth factor m  growth control m  the cell 
system being examined This has been used by Cuttitta et al ,
(1985) to confirm an autocrine role for bombesin m  human small 
cell lung cancer cells It must be remembered, however, that 
growth factors may act m  stimulatory or inhibitory fashion 
depending on their concentration and on combinations of other 
growth factors present Development of a serum-free autocrine 
assay might simplify interpretation of the results Given the 
day-to-day variation m  results m  the autocrine assay, use of a 
standard active CM in a range of experiments would be useful, and 
would allow quantitative data on yield and purification factor to 
be recorded
Further research along the lines suggested would appear to be worth 
considering Only by dissecting the molecular details of growth 
control m  a range of human tumour lines, will the mechanisms by 
which cells grow and differentiate m  normal developing and adult 
tissues and m  malignant cells m  vivo become clear Such 
knowledge is needed m  order to develop the rational therapy for 
cancer which is urgently needed
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ABBREVIATIONS
A T C C American Tissue Culture Collection
B S A Bovine serum albumin
C F E Colony forming efficiency
C M Conditioned medium
C P M Counts per minute
D M E Dulbeccos Modified Eagles Medium
E D T A Ethylene diamino tetraacetic acid
E G F Epidermal growth factor
F C S Foetal calf serum
F G F Fibroblast growth factor
HC1 Hydrochloric acid
HEPES 4-(2-hydroxyethyl) + piperazmeethansulphonic acid
HPLC High performance liquid chromatography
12-^ I-EGF Iodine labelled Epidermal growth factor
MEM Minimum essential medium
n Number of replicates
NaOH Sodium hydroxide
A gm agar growth medium
NEAA Non-essential ammo acids
228
NRK Normal rat kidney cells
PBS Phosphate buffered saline
PDGF Platelet derived growth factor
P/S Penicillin/streptomycin
r p m revolutions per minute
S E M Standard error of the mean
TGF Transforming growth factor
Ve Column elution volume
Vo Column void volume
NGF Nerve growth factor
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